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CHAPTER ONE -  INTRODUCTION
1.1 Coronary Heart Disease
1.1.1 Historical Review
(a) The Heart and Cardiovascular System
Man’s understanding o f the heart and the mechanisms of its diseases are 
increasing at an exponential rate, with much of our knowledge being attained in 
the last few decades. However, each period in history has provided new insights 
and added to the collective understanding of the heart, its functions and afflictions.
Cave paintings drawn more than 10,000 years ago illustrate that even primitive 
man recognised the importance of the heart as a life sustaining force. One such 
mural, drawn by Aurignacian Man in Northern Spain, depicts an outline of a 
mammoth with a heart shaped spot in the middle of the body and is generally 
assumed to depict where a hunter should aim (Poliak and Ashworth, 1968). The 
first recorded rudimentary description of the circulation can be found in ancient 
Chinese texts, dating from around 2,600 BC, where the Physician Huang Ti 
declared “the blood current flows continuously in a circle without a beginning or 
end and never stops”. However, Huang Ti lived in a quasi-religious and 
superstitious time and this theory was never accepted, with traditional belief that 
the heart was the seat of happiness and a witness to the body’s behaviour reigning 
supreme.
Two millennia later, the Classical Period of the Greek philosophical movement 
brought major advances in the medical arts. The advent of animal dissection 
allowed direct observation of the heart and vasculature. However, although these 
observations were more empirical and rational than previous times, they were still 
tainted by the religious and semi-spiritual beliefs of the period. For example, 
Alcmaeon of Greece noted empty arteries after death in 600 BC and deduced that 
they normally contained air. A few centuries later, Eransistratus of Egypt, claimed 
that in life a substance called Pneuma (air or spirit) circulated in the arteries, 
replaced with every breath, and that when an artery was cut, blood rushed in to fill 
the void left by escaping Pneuma. Therefore, it was loss of the life sustaining 
Pneuma rather than exsanguination that was the cause of death when arterial injury 
was sustained (Osier, 1921). However, this theory was disproved by direct 
observational evidence by Claudius Galenus of Alexandria (131 -  201 AD) who 
described the heart and movement of blood in the arteries. However, he did not 
realise that blood was circulated and taught of two distinct types of blood -  
“nutritive” which was made by the liver and carried by veins to the organs where 
it was consumed and “vital” which contained the spirit and was made by the heart 
and carried by arteries (Osier, 1921). These teachings remained largely 
unchallenged until the European Renaissance period of the 15^ ’^ and 16^  ^centuries.
The anatomical drawings, based on human dissection, of Leonardo da Vinci from 
the 15^ ’’ century are famous for their detail and illustrate a greater understanding of 
the circulation than was evident previously. However, he still described the liver 
as the centre of circulation and drew holes in the interventricular septum. The
English court physician, William Harvey (1578 -  1657 AD) is often regarded as 
the father of cardiovascular medicine and is credited with the first accurate 
description of the circulation as a closed system in 1628 (Harvey, 1628). He even 
hypothesised the presence of tiny vessels which linked the arterial and venous 
systems. The advent of the microscope allowed the likes of Marcello Malpighi 
(1628 -  1694 AD) and Antoni van Leeuwenhoek (1632 -  1723 AD) to confirm the 
presence of capillaries, and the teachings of Harvey became widely accepted.
(b) Coronary Artery Disease
Although the coronary circulation had been described many years previously, it 
was not until 1768 that the term angina pectoris was coined by the English 
Physician, William Heberden in a lecture to the College of Physicians of London, 
posthumously published in 1802 (Heberden, 1802) -
‘'There is a disorder o f the breast marked with strong and peculiar 
symptoms, considerable for the kind of danger belonging to it, and 
not extremely rare, which deserves to be mentioned more at length.
The seat o f it, and sense o f strangling, and anxiety with which is 
attended, may make it not improperly be called angina pectoris. They 
who are afflicted with it, are seized while they are walking, more 
especially if  it be uphill, and soon after eating, with a painful and 
most disagreeable sensation in the breast, which seems as if  it would 
extinguish life, if  it were to increase or to continue; but the moment 
they stand still, all this uneasiness vanishes In all other
respects, patients are, at the beginning o f this disorder, perfectly
well Males are most liable to this disease, especially such as
have past their fiftieth year. ”
Greater understanding of the pathophysiology of coronaiy artery disease and 
coronaiy death was provided over the next few decades. In 1793 the Scottish 
pathologist John Hunter described the presence of disease of the coronary arteries 
at autopsy in a man who had died following a fit of anger. A few years later, 
another Scot, Edward Jenner described changes in the coronary arteries which he 
described as “bony canals”. In 1808, Matthew Baillie concluded that “ossification 
of the coronary arteries would seem to produce, or to be intimately connected 
with, the symptoms which could constitute angina pectoris (Baillie, 1808).” 
However, it was not until 1867 that the first drug for the symptomatic relief of 
angina was introduced by T. Lauder Brunton in 1867. This drug was amyl nitrate 
and its related compounds remain a cornerstone in the modern management of 
angina.
Diagnostic cardiology was revolutionised by the invention of the 
electrocardiogram by Willem Binthoven in the early 20^ '^  century. The first 
description of the electrocardiographical changes associated with myocardial 
infarction came from the American physician James Bryan Herrick (1861 -  1954 
AD). In a presentation to the American Association of Physicians in 1912 he 
postulated that myocardial infarction was caused by coronary thrombosis (Herrick, 
1912) and following publication of the ECG changes occurring in dogs after 
coronary arteiy ligation by his colleague Fred Smith in 1918 (Smith, 1918), he
demonstrated the ability of the ECG to diagnose the presence of acute myocardial 
infarction in a living patient (Herrick, 1918). In the same year, Bousfield described 
the ECG changes during angina (Bousfield, 1918), ushering in the era of 
diagnostic electrocardiography.
In the last 80 years, there have been great advances in all aspects of cardiology. 
New diagnostic methods for the detection of coronary arteiy disease have been 
developed and refined, notably the introduction of staged exercise testing by Bruce 
and colleagues in 1963, the advent of cardiac catheterisation first reported by 
Forssmann in 1929, refined and popularised by Judkins and Sones in the 1970s, 
the development of nuclear and ultrasonic imaging and the recent explosion in 
magnetic resonance angiography. Increased understanding of the 
pathophysiological processes involved in coronary disease and resultant changes 
to the heart have widened our therapeutic targets and improved our ability to 
modulate the process and further advances are occurring in an exponential fashion.
1.1.2 Epidemioloev
In the 19‘*^ century, heart disease was the fourth leading cause of death, with 
infectious diseases accounting for the majority of mortality (Anonymous 1993). 
Improvement in sanitation and the advent of antibiotic therapy has markedly 
reduced the incidence of many infections and their related mortality, especially in 
the Western world. This, coupled with a longer lifespan, along with environmental 
and dietary changes, has lead to the emergence of ischaemic heart disease (IHD) 
as the leading cause of death in the modern world. The Global Burden of Diseases
Study showed that ischaemic heart disease was directly responsible for 6.26 
million deaths of the 50.6 million deaths worldwide in 1990, and that 29% of all 
deaths could be attributable to a cardiovascular cause (Murray and Lopez, 1997b). 
This figure is set to increase to 36% of all deaths by 2020 with IHD also being 
projected as the leading cause of disability (Murray and Lopez, 1997a).
These statistics are mirrored in the UK, with an overall prevalence of treated 
coronary heart disease (CHD) of around 3% of the population (Office for National 
Statistics, 2000; Ghandi, 1997). This figure is an underestimate, as those with 
asymptomatic or never treated disease are not included, and the true prevalence 
must therefore be much higher. Age, sex and socio-economic status are all 
powerful predictors of CHD. There is a marked incremental rise in CHD 
prevalence with advancing age, rising from 0.5% in men aged 35-44 to 9.3% aged 
55-64 and 21.7% at age 75 and older. Overall, men are 2 to 3 times more likely to 
develop coronary disease than women but this age related increase in prevalence is 
mirrored (figm*e 1.1). Increasing life expectancy and reduced birth rate has meant 
that the population is ageing and the burden of disease will increase in the next 
few decades. Socio-economic deprivation is also associated with increasing 
frequency of CHD (table 1.1).
Figure 1.1
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Legend - Prevalence of CHD by age and sex in the UK 1994/8. 
Adapted from data obtained from the Office of National Statistics (Office for 
National Statistics, 2000).
Table 1.1
Deprivation Category Men 
(all ages)
Women 
(all ages)
Ql: least deprived 3.13% 1.74%
Q2 3.38 1.90
Q3 3.56 2.13
Q4 3.63 2.17
Q5: most deprived 4.09 2.60
Legend - Prevalence of CHD by deprivation category 1986/92. 
Adapted from data obtained from the Office of National Statistics (Office for 
National Statistics, 1997).
The WHO MONICA Project has provided information on the geographical 
differences in prevalence of CHD over a 10 year period, starting in the mid-1980s 
(Tunstall-Pedoe et al. 1999). Scotland has the unenviable record for the highest 
incidence of coronary events per 100,000 population in women and the second 
highest event rate for men out of the 35 populations studied in 21 countries (table 
1.2). The event rates (standardised for age) were 111 per 100,000 population for 
men and 265 per 100,000 for women, compared to 431 and 134 respectively in the 
USA and 233 and 36 in Toulouse, France. Some of these regional variations may 
be attributable to differing genetic predisposition in the populations studied, but 
dietary factors and other risk factors must play a role.
It is therefore clear that CHD is a common disease process and is the leading cause 
of death in the UK. In Scotland, there were 12,500 deaths from coronary heart 
disease in the year 2000 (data from Scottish Executive website). The sequelae of 
angina and myocardial infarction cause disability and premature death and are 
undoubtedly a major public health problem.
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Figure 1.2
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Legend Coronary event rates per country from the WHO MONICA 
Project for (a) men and (b) women. Adapted from data 
obtained from Tunstall-Pedoe et al 1999 (Tunstall-Pedoe et 
al. 1999).
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1.2 Acute Coronary Syndromes
1.2.1 Classification
Over the last few year's, the classification of presentation with ischaemic heart 
disease has shifted from an ECG and enzyme-centric standpoint to a risk 
stratification and treatment orientated approach. The traditional classification of 
ischaemic coronary syndromes of unstable angina, non-Q wave and Q wave 
myocardial infarction was developed in the pre-thrombolytic era and was based on 
the progression of ECG changes and rise in standard cardiac enzymes (creatine 
kinase, lactate dehydrogenase and aspartate transaminase). However, improved 
treatment and better diagnostic tools have made this classification obsolete. For 
example, a patient presenting with chest pain and ST elevation on an ECG would 
be expected to develop a Q wave MI, but reperfusion, be it spontaneous or by 
intervention with thrombolytic therapy or primary angioplasty, can prevent the 
development of Q waves on the ECG. Similarly, patients without ST elevation on 
ECG can develop subsequent Q waves (figure 1.3) (Zaacks et al. 1999). In 
addition, more sensitive biochemical markers such as the troponin complexes can 
detect evidence of myocardial damage when traditional cardiac enzymes are 
negative.
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Figure 1.3
NON ST ELEVATION ACS SX ELEVATION MI
Troponin-v e  Dynamic ECG changes Troponin+ve ST elevation
UNSTABLE ANGINA NON-Q MI QMI
Enzymes negative Enzymes positive/no Q waves Q waves
INCREASING RISK
Legend Modem classification of Acute Coronary Syndromes and 
how they relate to the traditional classification
These observations, coupled with an increased understanding of the 
pathophysiology of acute ischaemia have lead to the development of a new 
classification under the broad umbrella term of acute coronary syndromes (ACS) 
(figure 1.3) (Joint European Society of Cardiology/American College of 
Cardiology Committee, 2000; Braunwald E et al. 2000). It is now recognised that 
acute ischaemic syndromes represent a continuum from the traditional diagnostic 
categories of unstable angina through to acute myocardial infarction. The key to 
the new classification is risk stratification and treatment approach. Occlusive
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thi'ombus causing ST elevation on the ECG presents with the highest risk and is 
usually associated with cardiac enzyme rise. The treatment is with reperfusion 
therapy, pharmacological or catheter based, and is therefore classified 
independently -  ST elevation MI. The term non-ST elevation acute coronary 
syndrome is applied to the remainder of unstable cardiac ischaemic syndromes -  
pain occurring at rest or on minimal exertion. These patients are risk stratified 
according to clinical, ECG and enzyme (including troponin) criteria which 
influence prognosis and allow targeting of therapy dependent on risk. They range 
from low risk with normal ECG and negative troponin to high risk with dynamic 
ECG changes and enzyme rise (figure 1.3). The terms ST elevation MI and non- 
ST elevation ACS will be employed in the rest of this thesis.
1.2.2 Epidemiology
As discussed in section 1.1.2, coronary heart disease is widespread in Scotland and 
the rest of the UK. There are 274,000 new myocardial infarctions per year in the 
UK. There are currently more than 1.3 million people in the UK who have had a 
heart attack, two thirds of whom are men (Office for National Statistics, 2000). 
The number hospitalised per annum with non-ST elevation acute coronary 
syndrome is more difficult to ascertain due to the changing diagnostic 
classification and the overlap with non-cardiac chest pain, but the number is 
conservatively estimated at more than 500,000. There are more than 2.1 million 
people in the UK with a diagnosis of angina pectoris (Office for National 
Statistics, 2000).
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1.2.3 Pathophysiology
Stable angina is caused by fixed, flow-limiting, slowly developing, plaque 
stenoses of one or more of the epicardial arteries. Acute coronary syndromes are 
characterised by rupture of an unstable plaque with resultant thrombus formation 
(Davies, 2000). There are many factors which may be responsible for the 
transformation from stable to unstable plaque and this is an area of intense 
research (Davies, 2000; Davies, 1996; Lee and Libby, 1997; Fuster et al. 1999).
Fissuring of the vulnerable unstable plaque exposes the lipid rich core, promoting 
thrombin formation, fibrin generation and platelet activation and aggregation, 
further rupturing the plaque. Triggers for fissuring include recruitment of 
inflammatory mediators and influx of macrophages, activation of matrix 
metalloproteinases, haemodynamic sheer stress and increased blood viscosity 
(Ross, 1999; Ardissino et al. 1997; Davies, 1996; Malek et al. 1999; Rosenberg 
and Aird, 1999). This pathophysiology is common to both ST elevation MI and 
non-ST elevation ACS. The key difference is in whether there the resultant 
platelet, thrombin and fibrin rich thrombus is occlusive or non-occlusive. 
Occlusive tlirombus tends to occur suddenly, producing pain, ST segment 
elevation on the ECG and myocardial necrosis with resultant enzyme rise due to 
complete absence of antegrade flow in an epicardial coronary artery. Partial or 
complete antegrade flow occurs in non-occlusive thrombi and patients present 
with a more stuttering course and have no ST elevation on ECG. The thrombus 
composition is also a little different, being platelet rich rather than fibrin rich, like 
the tlirombi of ST elevation MI. Myocardial necrosis can occur due to distal
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embolisation of platelet rich thrombi, occluding the microcirculation. Often this is 
at a level undetectable by standard cardiac enzymes, but the advent of troponin 
assays has allo’wed identification of minor degrees of myocardial damage. This 
forms the basis o f the different therapeutic strategies employed in the two groups -  
reperfusion therapy in ST elevation MI and anti-thrombotic and anti-platelet 
therapy in non-ST elevation ACS.
1.2.4 Non-ST Elevation Acute Coronary Syndromes
(a) Prognosis
As previously discussed, non-ST elevation acute coronary syndrome is an 
umbrella term for presentations with cardiac chest pain but without ST elevation 
on the ECG. There is therefore a wide range of risk within this population and 
consequently, risk stratification is paramount. High-risk groups can have mortality 
rates as high as 9% (Antman et al. 1996) and combined rate of death, MI or 
urgent revascularisation of 40.9% (Antman et al. 2000). Table 1.2 outlines 
indicators of higher risk, and there are published scoring systems (Antman et al. 
2000). Historical factors such as older age, diabetes, previous MI, and other 
vascular disease increase absolute mortality by up to 50% (Boersma et al. 2000). 
Clinical features such as presence of heart failure or hypotension also confer a 
higher risk (Boersma et al. 2000) as does prior use of aspirin (Alexander et al. 
1999).
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According to registry data, the presence of ST depression on the admission 12 lead 
ECG is a powerful adverse prognostic indicator (Nyman et al. 1993). ST segment 
depression of >0.05mm in two or more contiguous leads is associated with more 
than a two-fold risk of death at 1 year (Cannon et al. 1997), and depression >2mm 
with a 6 fold increase (Kaul et al. 2001), compared to those with no ST segment 
deviation. Sequential ECG changes are also important with new T wave inversion 
also increasing risk (Cannon et al. 1997).
More recently, the development of sensitive assays for the troponin complexes, 
has allowed further risk stratification. The troponin complex is formed by three 
proteins -  troponin I, C and T. It regulates calcium dependent myosin-actin 
interaction and is present in both skeletal and cardiac muscle. The cardiac 
isoforms of troponin T and I are exclusively expressed in cardiomyocytes. 
Troponin should normally be undetectable in the blood, and therefore, the 
presence of cardiac troponin T or I in blood is specific for myocardial muscle 
damage. In the last decade or so, numerous clinical trials have clearly 
demonstrated the powerful predictive value of a positive troponin (T and I) with 
respect to predicting mortality and recurrent events in patients presenting with 
unstable angina (Hamm et al. 1992; Ohman et al. 1996; Antman et al, 1996; 
Lindahl et al. 1996; Galvani et al. 1997). In the TIMI IIA  trial, Troponin 
positivity was associated with an early mortality of 4.7% compared to 0.4% in the 
troponin negative group (Antman et al. 1996). These data are supported by other 
trials and have clearly shown that troponin T and I predict events at 30 days. 
However, data from the FRISC trial show that admission troponin continues to 
predict events even at 5 months (Lindahl et al. 1996). Furthermore, it is not just
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positivity for troponin that is predictive of outcome, the absolute level of troponin 
is also important, with higher levels associated with increased mortality rates 
(Antman et al. 1996).
Table 1.2
• Historical Characteristics
Age >65 years 
Diabetes Mellitus 
Previous Myocardial Infarction 
Other Vascular Disease 
Previous aspirin therapy
• Clinical Characteristics
Pulmonary crepitations 
Pulmonaiy oedema on CXR 
Hypotension 
Recurrent pain
• ECG
ST depression 
T inversion
• Biochemistry
Positive troponin 
Raised CK-MB
Legend - High risk features in Non-ST elevation ACS
18
(b) Overview of Acute Treatment
As discussed previously, acute coronary syndromes are characterised by the 
unstable plaque with associated non-occlusive, platelet rich thrombus and distal 
embolisation of micro-thrombi. The cornerstone of treatment is therefore anti­
platelet and anti-thrombotic therapy. Vasodilators such as nitrates and anti- 
ischaemics such as beta-blockers aie often used to ameliorate symptoms, but have 
little or no effect on outcome. There has also been considerable debate in the 
literature regarding whether an early interventional approach in the catheterisation 
laboratory or an early conservative approach is optimal, and this is discussed 
briefly later. Most studies have used a combined endpoint of death and myocardial 
infarction, or death, myocardial infarction and urgent revascularistaion (MACE -  
Myocardial Adverse Clinical Events), and this terminology will be employed in 
the next few paragraphs.
There are thi'ee principle groups of antiplatelet agents currently available -  aspirin 
(a cyclo-oxygenase inhibitor), clopidogrel (a thienopyridine inhibitor of the 
platelet ADP receptor) and the glycoprotein Ilbllla inhibitors. Aspirin has been 
extensively investigated in the setting of non-ST elevation ACS and has been 
shown to reduce MACE by up to 70% (Lewis et al. 1983; Theroux et al. 1988; 
The RISC Group, 1990). The other classes of anti-platelet therapy have been 
studied against placebo in addition to aspirin. There are no head to head 
randomised control trials comparing classes in this population. The recent CURE 
study compared the early addition of clopidogrel to standard aspirin therapy vs. 
aspirin alone in patients presenting with ACS and demonstrated a relative risk
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reduction of the primary endpoint of death/MI/stroke of 20% (9.3% vs. 11.4%) 
(Yusuf et al. 2001). Glycoprotein Ilbllla inliibitors have been extensively studied 
in this patient population, both as medical management, and as an adjunct to early 
intervention. The results of medical management with these agents are conflicting. 
A meta-analysis of data from three large trials (PURSUIT, PRISM-PLUS and 
CAPTURE) shows an early 34% reduction in death or MI (predominantly MI) 
using these agents (Boersma et al. 1999), but the GUSTO-V ACS trial showed no 
benefit (Simoons ML and GUSTO V-ACS investigators, 2001). However, this 
trial recruited a low risk group, and the benefit seen in CAPTURE and PRISM- 
PLUS were all limited to the group who were troponin positive. These key 
differences may explain the apparent disparity.
Anti-thrombotic therapy with unfractionated heparin (UFH), in addition to aspirin, 
reduces death and MI by 33% compared to aspirin alone (Oler et al. 1996). More 
recently, there is evidence that low molecular weight heparin may be more 
beneficial in reducing events than UFH. Enoxaparin reduces MACE rates to 
15.6% compared with 18.7% for UFFI (Antman et al. 1999a). Again, benefit 
seems to be greatest in those at higher risk. For example, patients with positive 
troponin achieved the greatest benefit with enoxaparin in the TIMI 1 IB trial.
A large proportion of the cardiovascular literature in recent years has concerned 
the merits of both the early invasive and early conservative approaches to the 
treatment o f non-ST elevation ACS (Table 1.3). Early studies such as TIMI IIIB 
and VANQWISH showed no benefit of an invasive strategy (The TIMI IIIB 
Investigators, 1994; Boden et al. 1998), and indeed, there were more early deaths
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and myocardial infarctions in the invasive arm in the VANQWISH study (24% vs, 
19%, p=0.05) (Boden et al. 1998). However, TACTICS-TIMI 18 and FRISC II 
have both demonstrated greater than 20% reduction in MACE in the invasive 
strategy compared to conservative (Cannon et al. 2001; Fragmin and Fast 
Revascularisation during Instability in Coronaiy artery disease Investigators., 
1999), especially in high risk groups with dynamic ECG changes or positive 
troponin. The key differences in these studies were the concomitant use of 
glycoprotein Ilbllla inliibition in TACTICS and prolonged treatment with low 
molecular weight heparin in FRISC II.
There are many therapeutic options in the treatment of ACS, and the key lies in 
defining risk so as best enable us to choose our strategy and to make best use of 
resources.
Table 1.3
TRIAL Follow up
Invasive
arm
MACE
Conservative
arm
MACE
OR P value
TIMI IIIB 6 weeks 16.2% 18.1% 0.90 0.33
VANQWISH 1 yeai' 24.0% 18.5% 1.3 0.05
FRISC II 6 months 9.4% 12.1% 0.78 0.03
TACTICS 30 days 7.4% 10.5% 0.71 0.009
TACTICS 6 months 15.9% 19.4% 0.82 0.025
Legend - Rates of Myocardial Adverse Clinical Events (MACE) and 
Odds Ratio in trials of early invasive versus early conservative 
strategy in non-ST elevation ACS
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1.2.5 ST Elevation Myocardial Infarction
(a) Prognosis
The early mortality associated with acute myocardial infarction (AMI) has been 
falling over the last two or three decades, primarily due to better acute treatment 
and secondary prevention (De Vreede et al. 1991; McGovern et al. 1996). 
Mortality rates in clinical trials can be as low as 2.5% (Grines et al. 1993), but 
these populations are highly selected, and probably do not reflect the true extent of 
case-fatality rates. Data from the American National Centre for Health Statistics 
show a fall in case-fatality rate from 37% in 1975 to 13% in patients aged 45-64 
years (Levy, 1998). Further registry data suggest the current figure for in-hospital 
mortality may be higher, at around 18%, if all age groups are included (Mahon et 
al. 1999). However, it is important to remember that this figure represents the 
mortality rate for those reaching hospital, and if those dying prior to admission are 
included, the true fatality rate for AMI may be closer to 40-50%. Again, historical 
factors such as older age, diabetes, previous MI, and other vascular disease 
increase mortality. Clinical features such as presence of heart failure or 
hypotension also confer a higher risk (Hammermeister KE et al. 1979). 
Echocardiographic features of LV dilatation, degree of wall motion abnormality 
and ejection fraction are powerful adverse prognostic indicators (White HD et al. 
1987; Sutton et al. 1997; Dujai*din et al. 1997).
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(b) Overview of Acute Treatment
The last 20 years have brought great advances in the treatment of ST elevation MI. 
Therapies in the acute phase shown to confer a survival benefit include antiplatelet 
therapy, reperfusion therapy (thrombolytic and mechanical), beta-blockers and 
ACE inhibitors.
With regard to antiplatelet therapy, aspirin has been studied in a huge cohort of 
patients, reducing mortality by more than 20% when used alone, increasing to 
53% when given in combination with tlirombolysis (Antiplatelet Trialists' 
Collaboration, 1994; ISIS 2 (Second international Study of Infarct Survival), 
1988). There is some evidence that more powerful antiplatelet agents, such as the 
glycoprotein Ilbllla receptor antagonists may also have a role in the treatment of 
AMI (Antman et al. 1999b).
The underlying pathophysiology of ST elevation MI is occlusive thrombus. 
Intravenous thrombolytic therapy has also been extensively studied, and coupled 
with aspirin, is the cornerstone of treatment of ST elevation MI in most countries, 
including the UK. There are no data to support the use of thrombolysis in patients 
without ST elevation (Fibrinolytic Therapy Trialists, 1994). Angiographic studies 
have clearly shown the importance of achieving patency and restoring blood flow 
in occluded infarct related arteries both in short and long term reduction of 
mortality (Lendeiiink et al. 1995). Patency rates at 90 minutes vary from 50-75% 
depending on the thrombolytic agent used (The GUSTO Angiographic 
Investigators, 1993). The effect on mortality is striking, with a meta-analysis of
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nearly 60,000 patients from 9 studies showing an 18% overall reduction in fatality 
rate, at the expense of a 1% stroke risk (Fibrinolytic Therapy Trialists, 1994). The 
benefits are time dependent with a larger survival benefit if given early (Boersma 
et al. 1996). However, there is still some benefit up to 12 hours from the onset of 
symptoms (LATE (Late Assessment of Thi'ombolytic Efficacy) Study Group, 
1993). This benefit continues long after the acute event (Franzosi et al. 1998). It is 
important to remember that the largest gains are to be found in those patients who 
are at highest risk -  anterior myocardial infarction, concomitant heart failure, older 
age and diabetics (Fibrinolytic Therapy Trialists, 1994).
The same is true of mechanical reperfusion strategies, and there is increasing 
evidence of its superiority to thrombolytic therapy, especially in high risk patients 
(Grines et al. 1999b). Patency rates of >90% can be achieved with primary 
angioplasty (Grines, 1996; Grines et al, 1993) and improvements in balloon and 
stent design, coupled with the newer antiplatelet agents may improve this figure 
further. This translates into a superior survival benefit and does not seem to be so 
temporally dependent as thrombolysis (Weaver et al. 1997; Grines et al. 1999a).
Other, non-reperfusion based, interventions include beta-blockers and ACE 
inliibitors. Acute administration of beta-blockade have been shown to reduce early 
and long term mortality in ST elevation MI, but their effects on mortality are 
probably not additive to thrombolytic therapy (Roberts et al. 1991). However, 
their use in secondary prevention is well established. There is a wealth of evidence 
to support the use of ACE inliibitors in the early phase of AMI (24-48 hours) and 
as secondaiy prevention and that these results ai'e additive to reperfusion therapy
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(Pfeffer MA et al. 1992; AIRE study investigators, 1993; Gruppo Italiono per lo 
Studio délia Sopravvivenza nell'Infarcto Miocardio (GISSI) -3, 1994; ISIS-4 
Collaborative Group, 1995). CONSENSUS II studied acute administration of 
intravenous ACE inhibition in ST elevation MI and gave a neutral result, primarily 
due to the increased incidence of hypotension in the ACE inhibitor group 
(Swedberg et al. 1992). However, some high risk subgroups showed a trend 
towards improved survival and it may be that this strategy would be of benefit in a 
more selected high risk population. Indeed, the HEART trial demonstrated the 
safety and efficacy of early administration of ramipril following AMI, although 
this was by the oral rather than the intravenous route (Pfeffer MA et al. 1997). 
Further studies would be required to investigate this in more detail.
There are numerous interventions at our disposal for the treatment o f ST elevation 
MI, all with proven benefits, albeit at the expense of potential side effects. It is 
clear from most studies that high-risk groups have the most potential benefit from 
each of the strategies outlined. The future may lie in the selection of patients 
suitable for each intervention, based on the risk;benefit ratio of the individual 
rather than the population risk;benefit apparent from the mega-trials. This would 
allow better targeting of therapy, reducing the risk of potentially life threatening 
side effects in those at low risk of an adverse outcome and better use of limited 
resources. For example, prediction of those likely to have an adverse outcome, 
may influence the choice between thrombolytic or mechanical based reperfusion 
strategies and perhaps determine the timing of ACE inhibition or the use of beta- 
bloekers and statins. Perhaps we should attempt to risk stratify all patients at
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presentation and choose our management strategy based on available clinical, 
electrocardiographic and biochemical data.
1.3 Post-infarction Ventricular Remodelling
1.3.1 Historical Review
One of the most powerful predictors of adverse outcome following myocardial 
infarction is post-infarction ventricular remodelling which is associated with 
increased early and late mortality and late morbidity (White HD et al. 1987; 
Pfeffer MA and Braunwald E, 1990; Mahon et al. 1999). Alterations to 
ventricular size, shape and function are the hallmarks of remodelling, caused by 
complex changes within the ventricular architecture. These changes were first 
described by the German pathologist Wiegert in the late 19^ '^  century (Weigert, 
1880), followed by the classic description of regional wall motion changes and 
systolic expansion following acute coronary artery ligation by Temiant in 1935 
(Tennant R and Wiggers CJ, 1935). In 1965, Hort demonstrated that the duration 
of survival was related to left ventricular (LV) volume in the coronary ligation 
model of myocardial infarction in rats, and that infarct size was dependent on the 
duration of ligation. He also noted a relationship between infarct size, wall motion 
abnormalities and LV volume (Hort, 1965).
Since that time, there has been an enormous body of evidence, both in the 
experimental and clinical settings, that changes in LV function, structure and 
volume are important prognostic variables. Jan and Marc Pfeffer’s group elegantly
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demonstrated progressive LV dilatation in the days and weeks following 
experimental infarction in rats in 1979 and that this was related to infarct size 
(Pfeffer MA et al. 1979). A few years later, Hocliman and Bulkley coined the 
“remodelling” as a description of the early thinning of the infarct site with 
subsequent LV dilatation seen in the rat model of coronary arteiy ligation 
(Hochman and Bulkley, 1982). Subsequent work recognised that the remodelling 
process is not confined to the infarct site, but occurs at sites remote from the 
ischaemic area (Weisman et al. 1985; McKay RG et al. 1986), and that survival 
was inversely proportional to the degree of remodelling (Pfeffer MA and 
Braunwald E, 1990).
At this point, it is important to remember that changes within the infarct site and 
alterations to LV structure are necessary for healing of the infarcted region, 
thereby producing a scar. Although these changes could be referred to as 
remodelling, the term really refers to a lack of control of these “healing” 
processes, causing inappropriate alterations to LV structure and function with the 
development of wall motion abnormalities and LV dilatation, through excessive 
changes within the myocyte and collagenous components of the heart, and would 
probably more appropriately be termed “adverse remodelling”. However, in 
keeping with convention, the term “remodelling” will be used in the rest of this 
thesis and should be regarded as being synonymous with “adverse remodelling”.
In man, progressive dilatation following AMI has been studied with serial chest X- 
rays, contrast ventriculography and echocardiography and all have confirmed the 
adverse prognostic importance of the remodelling process (Shanoff HM et al.
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1969; Kostuk WJ et al. 1973; McKay RG et al. 1986; White HD et al. 1987). 
Dilatation is detectable within three hours of the onset of symptoms, and 
progresses over time (Korup et al. 1997). Early echocardiographic parameters 
such as end-systolic volume index, ejection fraction and extent of wall motion 
abnormalities all predict subsequent mortality (Migrino et al. 1997; Sutton et al. 
1997; Galasko et al. 2001).
1.3.2 Pathophvsiologv
The last 2 or 3 decades has brought increased understanding of the pathological 
mechanisms responsible for the phenomenon of ventricular remodelling. 
Myocardial cell necrosis occurs within minutes following acute coronary artery 
occlusion, causing cessation of contractility in that area. This triggers an 
inflammatory cascade with an influx of macrophages, neutrophils and monocytes 
into the infarct zone followed by interstitial oedema and cell death (Fishbein MC 
et al. 1978; Schoen, 1999). Much of the cell death in AMI is due to apoptosis 
(Kajstura et al. 1996), which can also be found in the non-infarcted regions of the 
heart, as well as in the infarct zone (Olivetti G et al. 1996). Additionally, severe 
ischaemia can cause cellular changes without overt infarction, producing 
myocardial vacuolisation and oedema, which can progress to programmed or 
necrotic cell death (Zhao M et al. 1987; Charney et al. 1992; Schoen, 1999). 
Important changes also occur in the extracellular matrix and collagen scaffolding 
of the heart, and this is discussed in detail in Section 1.4.
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Cell death and changes to the extracellular matrix make the infarct zone 
distensible by mechanical forces and abnormal loading conditions, allowing 
myocyte slippage, with thimiing of the infarct site and distension and dilatation of 
the LV cavity (Olivetti G et al. 1990). This serves to increase the area occupied by 
the infarct zone and is termed infarct expansion and is independent of any further 
ischaemic stimuli (Hutchins and Bulkley, 1978; Weisman et al. 1988). Extreme 
expansion can lead to aneurysm formation or even cardiac rupture (Jugdutt and 
Michorowski, 1987; Schuster and Bulkley, 1979), and is more common in anterior 
infarction (Pirolo et al. 1986). Following this initial period of expansion, healing 
is characterised by fibroblast proliferation and collagen deposition resulting in scar 
formation (Fishbein MC et al. 1978). In addition to myocyte hypertrophy and 
interstitial fibrosis, flirther changes to LV geometry occur with progressive 
dilatation (Anversa P et al. 1985; Pfeffer MA and Braunwald E, 1990). These 
changes are known as ventricular remodelling.
1.3.3 Early vs. Late Ventricular Remodelling
Previously, there was a clear distinction made between these early and late 
changes in ventricular architecture and function following ischaemia and 
infarction - early infarct expansion, and the later, adaptive, or probably more 
accurately, maladaptive, process of remodelling, occurring weeks to months to 
years following the acute event. However, it is increasingly recognised that 
remodelling is a continuum, starting during the acute event and progressing 
thereafter, and they are part of the same process, albeit with some key differences 
(Figure 1.4). This has prompted the use of the terms early and late ventricular
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remodelling (Sutton and Sharpe, 2000). Early ventricular remodelling, arbitrarily 
defined as occurring within 72 hours (Sutton and Sharpe, 2000), should be 
regarded as synonymous with infarct expansion and is characterised by expansion 
and thinning of the infarct zone, development of wall motion abnormalities, LV 
dilatation and reduced ejection fraction. This occurs within hours of myocyte 
injury, causing changes both in the infarct zone and in the non-infarcted portion of 
the heart. This process is related to the degree of ischaemic insult and is dependent 
on the marked changes within the collagen framework and extracellular matrix, 
predominantly in the infarct border zone, manifested principally as collagen 
degradation (Section 1.4) (Cleutjens JPM et al. 1995).
Late remodelling follows with further changes to ventricular architecture, volume 
and function. Scar formation and fibrosis of the border zone and areas of the 
ventricle distal to the infarct are also dependent on the dynamics of collagen 
metabolism, this time with synthesis predominating. Infarct scars are healed at 4-6 
weeks, but the process of late remodelling can continue for many months and 
years, often leading to progressive LV dilatation and failure.
Figure 1.4
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1.3.4 Therapeutic Intervention
(a) Patency of the Infarct Related Artery
The open artery hypothesis states that LV remodelling may be prevented, or at 
least attenuated, by achieving or maintaining patency of the infarct related artery. 
Early evidence comes from a study in the pre-thrombolytic era, which showed that 
patency of the infarct related artery is a more important predictor of subsequent 
LV dilatation than infarct size (Jeremy et al. 1987). Further evidence is provided 
by the well established survival benefits of thr ombolytic therapy, where survival is 
directly related to the extent of restoration of antegrade blood flow (Fibrinolytic 
Therapy Trialists, 1994; The GUSTO Angiographic Investigators, 1993; 
Lenderlink et al. 1995). Mechanical catheter based reperfusion strategies achieve 
higher patency rates and may account for the associated reduced mortality and 
event rate compared to thrombolysis (Grines et al. 1999b). There is also direct 
evidence of attenuation of the remodelling process with reperfusion therapy, 
limiting infarct size and LV dilatation, reducing wall motion abnormalities and 
improving left ventricular function and ejection fraction (Touchstone et al. 1989; 
Marino et al. 1989). However, the beneficial effects of an open infarct related 
artery is not solely due to prevention of damage, it seems that patency per se is 
associated with reduced remodelling and improved LV function (Jeremy et al. 
1987), and that this benefit persists even when the infarct related artery is opened 
late and therefore, little or no myocardium subtended by that artery would be 
viable (Horie et al. 1998).
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(b) Inhibition of the Renin-Angiotensin-Aldosterone System
There is clear evidence of systemic activation of the Renin-Angiotensin- 
Aldosterone System (RAAS) following AMI (Rouleau et al, 1993). In patients 
who develop LV failure following AMI, plasma renin activity and angiotensin II 
levels are elevated on admission, peaking a few days later, and remaining high for 
more than one week (MeAlpine HM et al. 1988). In addition to this systemic 
activation, there is some evidence of de novo generation of the RAAS effectors at 
a tissue level (Dzau, 1987) and that tissue levels of cardiac ACE are increased in 
myocytes immediately following myocardial infarction, especially in the infarct 
zone (Sakharov et al. 1987). There is also upregulation of angiotensinogen gene 
expression in the infarcted heart (Lindpaintner et al. 1993). Both systemic and 
local RAAS activation are likely to have intense influence on remodelling and 
healing in AMI, However, given the delay in mounting a systemic RAAS response 
following infarction, coupled with the rapidity of increased activity of ACE at a 
tissue level and increased gene expression at a cellular level, it would be 
reasonable to hypothesise that paracrine regulation of local tissue levels of RAAS 
effectors, independent of the systemic renin-angiotensin axis, plays an important 
role in the remodelling process, especially in the early stages. The effectors of the 
RAAS, angiotensin II and aldosterone, influence remodelling thi'ough their 
profound effects on myocyte growth (Yamazaki et al. 1995), fibroblast function 
and the extracellular matrix (Brilla CG et al. 1995). This is discussed in more 
detail in the next section.
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Animal studies have clearly demonstrated that ACE inliibitors limit LV dilatation 
following infarction and that this attenuation of the remodelling process confers a 
survival benefit (Pfeffer JM et a l 1985; Pfeffer MA et al. 1985). Early 
administration, within 2 days, of captopril to rats is associated with greater 
attenuation of LV dilatation compared to late administration at 21 days, even at 1 
year (Pfeffer JM et al. 1985). Most of the large scale clinical trials of ACE 
inhibitors in humans have administered the drug within 48 hours and all have 
shown clear survival benefits (Pfeffer MA et al. 1992; AIRE study investigators, 
1993; Gruppo Italiono per lo Studio della Sopravvivenza nell'Infarcto Miocardio 
(GISSI) -3, 1994; ISIS-4 Collaborative Group, 1995).
More specific antagonism of the All receptor following myocardial infarction was 
studied in OPTIMAAL, which compared losartan vs. captopril (Dickstein et al. 
2002). This showed no benefit of specific All antagonism over ACE inhibition in 
this setting. Whether more extensive antagonism of the RAAS may have a more 
profound effect on mortality is being tested in the ongoing VALIANT trial, which 
compares combination ACE inhibition and All receptor antagonism with ACEI or 
All receptor blocker alone (Pfeffer MA and et al, 2000).
The results of a large study utilising the aldosterone inhibitor, eplerenone, in the 
context of heart failure complicating a recent myocardial infarction, have recently 
been presented showing an overall survival benefit with the addition of the 
aldosterone antagonist (Pitt B et al. 2003). A recent paper by Hayashi et al 
provides a possible mechanistic explanation (Hayashi M et al. 2003). They found 
that spironolactone administration following MI was associated with an improved
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ejection ôaction and reduced LV end-diastolic index at one month when compared 
to a control group. They also demonstrated suppression of cardiac extraction of 
aldosterone and evidence o f reduced collagen synthesis in the spironolactone 
group, suggesting that inhibition of aldosterone at a local level and changes to 
collagen homeostasis are key in attenuatmg the remodelling process.
(c) Inhibition of the Sympathetic Nervous System
Plasma levels o f the catecholamines, adrenaline and noradrenaline, rise quickly 
following myocardial infarction, peaking at 3 days following the event (McAlpine 
HM et al. 1988; Rouleau et al. 1993). Elevated levels promote arrhythmogenesis 
and increase myocardial oxygen demand. Absolute levels correlate with mortality 
(Sutton and Sharpe, 2000), providing sound rationale for the use of 
pharmacological inhibitors of this system. However, although there have been 
numerous studies demonstrating survival benefit in their acute use (Yusuf et al. 
1985), only one study supports their use in the post-thrombolytic era (The 
CAPRICORN Investigators, 2001).
Nevertheless, super-activation o f the sympathetic nervous system has deleterious 
effects on myocardial structure and function, causing myocyte hypertrophy and 
alterations in the extracellular matrix (Ju et al. 1998; Brilla CG et al. 1995). 
Additionally, acute administration of intravenous beta-blockade reduces the 
incidence of ventricular rupture (ISIS-1 (First International Study of Infarct 
Smvival), 1988) and the recent beta-blocker in heart failure trials have
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demonstrated the efficacy in reducing, and even reversing, remodelling and 
improving survival (Tendera and Ochala, 2001).
1.3.5 Identifieation of earlv remodelling
There are several interventions available to limit the remodelling process in AMI. 
Large-scale clinical trials have convincingly demonstrated the efficacy of 
reperfusion therapy and ACE inhibition in limiting remodelling and improving 
survival. However, most of these studies have been unselected, and although there 
is an overall benefit in the populations studied, it is clear that the greatest benefits 
are seen in those at highest risk. For example, reperfusion of anterior MI has a 
higher absolute benefit than reperfusion of inferior infarcts and ACE inhibitor 
therapy confers the greatest benefit on those with the poorest ejection fraction and 
greatest abnormality of wall motion. As discussed previously, it is therefore 
important to risk stratify patients using the available historical, clinical, 
biochemical and echocardiographical information available.
Older age and diabetes confer a higher risk of remodelling as does anterior 
infarction, failed reperffision, peak enzyme rise, hypotension and presence of heart 
failure (Hammermeister KE et al. 1979; Mahon et al. 1999). However, 
echocardiography within a few days of infarction can also provide important 
predictive information. In addition to information regarding the presence of infarct 
expansion and wall motion abnormalities, the cornerstone of early remodelling, 
end systolic LV volume assessed within a few days of infarction is one of the most 
important predictors of subsequent remodelling and mortality (White HD et al.
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1987). Echo also allows estimation of the extent of myocardial damage by
measurement of wall motion abnormalities, the extent of which are directly related
to subsequent dilatation and mortality (Kitamura et al. 1973; Kan et al. 1986;
Sutton et al. 1994). Indeed, echocardiographic sub-studies of both SAVE and
GUSTO-1 clearly showed that the degree of wall motion abnormality is the most
powerful echocardiographic predictor of both short and long-term mortality
(Sutton et al. 1997; Migrino et al. 1997). This was also true in the TRACE echo
sub-study, where one year mortality was inversely related to degree of wall motion 
abnormality (Kober L et al. 1994).
More recently, Doppler indices of LV filling have been shown to be a powerful
prognostic determinant. In the days following AMI, the heart becomes “stiffer”,
displaying a restrictive filling pattern, representing an impairment of diastolic
function (Williamson et al. 1990; Chenzbraun et al. 1992), the degree of which
can be assessed by measurement of the mitral deceleration time by pulsed wave
Doppler through the mitral valve (Little et al. 1995). Decreased deceleration time,
or restrictive filling, has been documented in patients with larger infarcts (Popovic
et al. 1996), and recently, has been shown to correlate with subsequent
remodelling (Cerisano G et al. 1999). Echocardiography is therefore a powerful
tool 111 the assessment of early remodelling and the prediction of late remodelling 
and associated mortality.
Other non-invasive imaging techniques include radionuclide ventriculography and 
cine-magnetic resonance imaging, both of which can be used to detect serial 
changes of remodelling with a high degree of reproducibility (Cohn PF et al.
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1974; Marshall RC et al. 1978; Longmore DB et al. 1985; Van Rossum AC et al. 
1988; Krainer CM et al. 1993). However, their use is limited by their lack of 
portability and echocardiography is the modality most extensively studied and 
remains the mainstay of non-invasive assessment of LV size and function.
As discussed in sections 1.3.4 (b) and (c), there is neurohormonal activation 
following AMI and that increased levels of the effectors of the RAAS and 
sympathetic nervous systems may be a reflection of early remodelling in addition 
to abnormal haemodynamic loading conditions (McAlpine HM et al. 1988; 
Rouleau et al. 1993; Sutton and Sharpe, 2000; White M et al. 2001). Similarly, it 
is well documented that atrial and hrain natriuretic peptides are elevated 
immediately following acute myocardial infarction (Morita A et al. 1993; White 
M et al. 2001), and correlate with increased LV dimensions at 1 and three months 
(Yoshitomi Y et al. 1998), which may suggest that they have some use in 
identifying those at risk of subsequent remodelling. Furthermore, infusion of atrial 
natriui'etic peptide reduces remodelling, probably through a reduction in 
circulating plasma aldosterone levels(Hayashi M et al. 2001a).
1.4 Myocardial Collagen and the Extra-cellular Matrix
Historically, remodelling was thought to be due primarily to phenotypic changes 
in myocytes. However, it is increasingly recognised that changes in the connective 
tissue compartment (extracellular matrix and non-myocyte cells) account for a 
large degree of the remodelling process. It is therefore important to understand the
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normal structure and function of collagen and the extracellular matrix in health 
and disease.
1.4.1 Myocardial Collagen Structure and Function
The earliest description of collagen was in skeletal muscle in 1907 (Holmgren, 
1907), with the first three sub-types identified in 1971 (Miller et al. 1971), with 
new additions to the class being described each year. There are now 19 identified 
collagen subtypes and they are the most abundant protein form in man, comprising 
nearly one third of total body protein and, to date, more than 30 genes have been 
identified in their production (Brown and Timpl, 1995). Collagen is comprised of 
varying sizes of polypepetide chains. Its final configuration, and subsequent 
strength, is due to repeated folding. RecuiTing triplets of glycine, prolyl and 
hydroxyprolyl facilitate cross-linking within the chain, allowing formation of a 
triple helical configuration of alpha-chains, which weave around each other 
forming a rope-like structure (Nimni ME, 1993).
Although all types share this commonality with regard to structure, changes in 
extracellular aggregates provide a great diversity in properties of subtypes, ranging 
from the high tensile strength of Type I collagen tlu'ough to the more distensible 
and elastic type III collagen. Type I collagen predominates within the heart, 
constituting 75% of the total, with the rest comprising mainly o f type III, with 
lesser amounts of types IV, V and VI also being present (Medugorac and Jacob, 
1983; Weber KT et al. 1988a).
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Collagen provides several fundamental functions in the healthy heart: the 
épimysium surrounds myocytes, forming a three dimensional scaffold, preventing 
distending forces and maintaining myocardial shape and function in both systole 
and diastole; the perimysium weaves between myocytes, maintaining myocyte 
alignment and forming struts facilitating contraction of the heart as a syncitium; 
and the endomysimn providing a vehicle for capillaiy networks and maintaining 
their patency (Robinson TF et al. 1983; Robinson TF et al. 1988; Rossi MA et al. 
1998).
1.4.2 Changes to Mvocardial Collagen in Disease States
Given the ubiquitous nature of collagen within the tissues of the body, changes to 
content and type have been extensively studied, especially in the field of wound 
healing, tissue repair and metabolic and inflammatory bone disease (Mutsaers SE 
et al. 1997). In the sphere of cardiology, most work has focussed on hypertensive 
heart disease, heart failure and myocardial infarction. Many cardiac disease 
processes are ultimately fihrogenic, with replacement fibrosis compensating for 
myocyte loss in end-stage heart disease of whatever aetiology. However, fibrosis 
can also be a response to an acute or chronic stimulus, such as tissue injury, 
haemodynamic changes and neurohormonal activation. All these factors play a 
role in the development of hypertensive heart disease and clinical and laboratory 
studies in this condition have provided insights into the pathophysiology and 
sequelae of fibrotic heart disease.
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(a) Hypertensive Heart Disease
Although collagen constitutes almost 30% of the body’s total protein, it’s light 
weight means it only accounts for 2-4% of wet LV mass in health (Weber KT, 
1989; Nimni ME, 1993). Myocardial fibrosis has been defined as an increase in 
collagen content (collagen concentration X ventricular weight) above normal 
levels (Weber KT, 1989). This simple definition of fibrosis as an absolute 
increase in fibrillar collagen content has allowed investigation o f the myocardial 
response to disease in both human and animal studies in hypertension. Tissue 
obtained by endomyocardial biopsy or at autopsy of hypertensive hearts show 
increased collagen accumulation, predominantly of type I collagen (Weber KT et 
al. 1988a; Bishop JE et al. 1990; Weber KT et al. 1990). Indeed, studies in the 
hypertensive rat heart have shown that collagen can occupy as much as 18% of the 
LV mass (Weber KT et al. 1990).
The absolute collagen content and ratio of collagen sub-types determine the 
viscoelasticity of the extracellular matrix and the overall distensibility or 
compliance of the heart (Mutsaers SE et al. 1997; Pauschinger et al. 1999). 
Therefore, in the hypertrophied heart, fibrosis causes impainnent of ventricular 
relaxation, increasing preload and myocardial oxygen demand. This is seen when 
collagen content is increased by a factor of two (Thiedemann et al. 1983). The 
functional significance of this has been termed diastolic dysfunction and can 
produce heart failui'e even when LV systolic function is preserved (Vasan and 
Benjamin, 2001). Progressive fibrosis disrupts myocyte alignment, reducing
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contractility and ultimately causing LV systolic failure and dilatation (Vasan et al.
1995).
At this point, it is important to emphasise that although left ventricular 
hypertrophy (predominantly due to myocyte hypertrophy) and myocardial fibrosis 
often co-exist, they are not inter-dependent on one another. It is clear that there are 
marked alterations in the distensibility and relaxation properties of the 
hypertrophied, fibrotic heart. This is due to fibrosis rather than as a consequence 
of LVH. This is supported hy studies where LVH is present in the absence of 
significant increases in collagen content, such as anaemia, AV fistulae and 
hyperthyroidism. In these volume overloaded conditions, there is myocyte 
hypertrophy without fibrosis and relaxation properties are normal (Holubarsch et 
al. 1983).
In addition to the adverse haemodynamic effects of fibrosis, it can worsen 
myocardial ischaemia by causing sub-endocardial micro-perfusion abnormalities 
and contributing to a reduction in coronary flow reserve. Fibrosis also results in 
the formation of barriers to the ventricular excitation wave front, causing changes 
to the elctrophysiological milieu, facilitating the creation of re-entrant arrhythmias 
(Cameron et al. 1983; Strain et al. 1983). Indeed, the incidence of ventricular 
arrhytlimias is proportional to the degree of fibrosis (McLenechan JM et al. 
1987). This may partly explain the increased risk of sudden death in hypertensive 
heart disease (Levy et al. 1990).
■ I
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(b) Dilated Cardiomyopathy
Changes to the collagen matrix can be quantitative or qualitative and often both 
will co-exist. Qualitative changes have heen studied most extensively in heart 
failure due to dilated cardiomyopathy. Dilated cardiomyopathy can be associated 
with an overall increase or decrease in collagen content. However, in both 
situations, there are alterations in collagen type which effect the tensile properties 
of the extracellular matrix. This serves to reduce structural integrity, as does 
changes to cross-linking (Weber KT et al. 1988b; Gunja-Smith Z et al. 1996). In 
addition, there is also a phenotypic shift to increased collagen type I/III ratio, 
further altering structural dynamics (Marijianowski et al. 1995). These features 
cause distortion of ventricular architecture, or adverse ventricular remodelling, and 
subsequent LV dilatation and failure.
(c) Myocardial Infarction
As discussed in section 1.3, remodelling occurs following acute myocardial 
infarction and the rapidity of onset serves as a reminder of the dynamic nature of 
collagen metabolism. Early remodelling, within 72 hours, is characterised by 
infarct expansion and the development of wall motion abnormalities (Sutton and 
Sharpe, 2000). This is principally due to changes to collagen content and function 
rather than myocyte loss (Whittaker P et al. 1991). Early remodelling is 
dependent on both quantitative and qualitative changes to the collagen scaffolding. 
Influx of inflammatory cells and bio-active chemokines into the infarct zone alter 
the interstitial milieu, promoting net collagen loss due to immediate breakdown by
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matrix metalloproteinases (section 1.4.4) (Cleutjens JPM et al. 1995). In the rat 
model, there is a 25% loss of collagen within the infarct zone within 24 hours 
(Camion et al. 1983). Loss of supportive viscoelastic collagen and disruption of 
the intermyocyte struts means the ventricle is less able to cope with the abnormal 
haemodynamic loading conditions found following myocardial infarction. 
Myocyte slippage and infarct expansion occurs, adversely altering LV geometry 
and function (Whittaker P et al. 1991; Olivetti G et al. 1990; Kim et ai. 2000). 
Similar changes can occur in ischaemic myocardium, when the ischaemic burden 
has been sufficient to disrupt systolic and diastolic function, but not to cause overt 
myocyte necrosis. Ultrastructural studies have clearly demonstrated changes 
within the extracellular matrix with loss of collagen and disruption to cross-linking 
in the ischaemic, yet viable, stunned myocardium (Zhao M et al. 1987; Charney et 
al. 1992).
In the days following infarction, phenotypically transformed fibroblasts, 
myofibroblasts, invade the infarct zone and collagen production is upregulated. 
Collagen deposition starts within the infarcted area by day 3 and further 
accumulation allows formation of a scar which is normally complete hy 4-6 weeks 
following infarction (Cleutjens JPM et al. 1995). There is a phenotypic shift to 
increased type I collagen compared with type III, further altering structural 
dynamics (Wei et al. 1999). However, it is not just the infarct site which 
undergoes remodelling. Excessive accumulation of collagen in the non-infarcted 
regions increases myocardial stiffness, thereby reducing compliance and function. 
This late remodelling causes further collagen deposition and fibrosis, which can
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continue for many months and years, often leading to progressive LV dilatation 
and failure (Fishbein MC et al. 1978; Pfeffer MA and Braunwald E, 1990),
A tissues response to injury is a time dependent phenomenon and this is elegantly 
demonstrated following myocardial infarction. Collagen metabolism is a dynamic 
process with ongoing synthesis and degradation. It is the balance of these two 
processes which determines the overall collagen content. The immediate response 
following myocardial infarction is one of net degradation of collagen, the balance 
of which changes in favour of net collagen accumulation over a period of a few 
days which often continues for many months. To assess the net collagen balance, 
one must therefore consider both synthesis and degradation, processes that are 
controlled by fibroblasts and the biologically active macromolecules of the 
extracellular matrix.
1.4.3 The Extracellular Matrix and Collagen Metabolism
Although cardio-myocytes constitute 80% of LV volume, they comprise less than 
one third of total cell numher. All other cell types reside within the interstitial 
space and include fibroblasts, endothelial cells, vascular smooth muscle cells and 
macrophages. The non-cellular component o f the interstitial space is called the 
extracellular matrix (ECM) and contains large quantities of collagen, 
predominantly type I, with smaller amounts of type III, elastin, non-collagenous 
glycoproteins and glycosaminoglycans (Frank and Langer, 1974; Weber KT, 
1989). Previously, it was thought that the ECM was an inert substance, merely 
providing a passive framework for myocytes. However, it is increasingly
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recognised that the ECM is a self regulating, extremely biologically active entity, 
containing metabolically active cells such as fibroblasts and activated leucocytes, 
and macro-molecules including matrix metalloproteinases and their tissue 
inhibitors, transforming growth factor-beta, and cytokines. Tight homeostasis of 
matrix components is therefore essential.
Fibrillar collagens are the main component of the ECM and they are produced by 
fibroblasts, which are the principal cell type in the heart, outnumbering myocytes 
by nearly thi*ee to one (Weber KT, 1989). They are pluripotent cells, present in 
vast numbers and are free to move through the interstitial space. They contain 
messenger RNA for the fibrillar collagens and are responsible for collagen 
transcription and production. They secrete procollagen for types I and III into the 
extracellular space. Aminoterminal and carboxyterminal propeptide moieties are 
cleaved, allowing integration of the collagen helix into the growing fibril (Nimni 
ME, 1993). In health, fibroblasts tightly regulate total collagen content, as they not 
only control collagen production, but also are responsible for the production of the 
degradative matrix metalloproteinases (section 1.4.4).
However, tissue injuiy, either acute or chronic, causes recruitment of 
inflammatory mediators from the blood and interstitial space, including 
interleukins. Tumour Necrosis Factors, adhesion molecules and Transforming 
Growth Factor-B. These chemokines cause phenotypic change to the fibroblast, 
producing myo-fibrohlasts, and stimulate collagen mRNA transcription, resulting 
in increased collagen production, and ultimately altering the balance towards a 
fibrogenic state in the longer term (Brilla CG et al. 1995; Nicoletti A and Michel
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JB, 1999). The effectors of the Renin-Angiotensin-Aldosterone System (RAAS) 
also have a marked role in control of collagen metabolism and this is discussed in 
section 1.4.6. Another peptidergic system exhibiting pro-fibrotic attributes is the 
endothelin system. Overexpression of the endothelin I gene in the transgenic 
murine model produces marked interstitial fibrosis in many tissues including the 
kidney, independent of blood pressure changes (Hocher et al. 1997). Additionally, 
in the rat model, antagonism of the endothelin system reduces myocardial fibrosis 
due to hypertension (Karam et al. 1996). It is perhaps not unsurprising that these 
peptidergic systems play an important role in regulating myo-fibroblast activity, as 
myo-fibroblasts express receptors for angiotensin II and endothelin, in addition to 
TGF-B and other cytokines (Weber KT et al. 1997; Sun Y et al. 1998). 
Osteopontin, an adhesive glycophosphoprotein also produced by fibroblasts, also 
plays a key role in matrix organisation tlirough its effects on fibronectin and 
collagen and with its interaction with angiotensin-II, the integrins and other 
cytokines (Denhardt DT and Guo X, 1993; Mukherjee et al. 1995; AshizawaN et 
al. 1996). In the murine knockout model, lack of osteopontin was associated with 
exaggerated LV dilatation and reduced collagen deposition following experimental 
MI (Trueblood NA et al. 2001), confirming its importance in matrix and collagen 
homeostasis.
Collagen production by fibroblasts is therefore tightly regulated. Inhibition of 
fibroblast production of collagen following AMI attenuates the remodelling 
process (Nwogo JI et al. 2001). However, it is important to remember that net 
myocardial collagen content is a product of a dynamic equilibrium between 
collagen synthesis and degradation. One must therefore also consider the
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regulation of collagen breakdown when discussing collagen turnover and 
remodelling. Matrix metalloproteinases are produced hy myo-fibroblasts and 
reside in the interstitial space. They are capable of degrading all components of the 
extracellular matrix, including collagen (Matrisian LM, 1990).
1.4.4 Matrix Metalloproteinases
(a) Structure and Function
Matrix Metalloproteinases (MMPs) are a family of zinc containing, calcium 
dependent endopeptidases with molecular masses ranging from 28-92 kDa. More 
than twenty have heen identified, and all share three fundamental domains -  pre, 
pro and catalytic domains. The functional significance has not been elucidated for 
all identified MMPs, but they can he classified by substrate specificity into the 
collagenases, gelatinises, stromelysins and membrane-type MMPs (MT-MMPs) 
(Dollery CM et al. 1995; McDonnell et al. 1999). MMP-1, or interstitial 
collagenase, is probably the best characterised. It is a 45kDA polypeptide with a 
haemopexin-binding domain linked to the catalytic domain allowing cleavage of 
fibrillar collagens. MMP-1 is the most abundant MMP within the heart, first 
described in 1975, and plays a key role in myocardial matrix remodelling 
(Montfort and Perez-Tamayo, 1975).
Given their powerful degradative ability, MMPs are produced as inactive zymogen 
precursors. Fibroblasts, and activated myo-fibroblasts, secrete MMPs as a 
proenzyme (pro-MMPs) which lie dormant in the interstitial space until activated.
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Activated MMPs can be neutralised by naturally occurring inhibitors -  the Tissue 
Inhibitors of MMPs (TIMPs). In addition to their proteolytic role, MMPs display a 
diversity of biological actions. They are involved in the regulation of Tumour 
Necrosis Factor alpha (TNF-alpha), interleukin 1 (IL-1) and Transforming Growth 
Factor-beta (TGF-beta) (Gearing et al. 1994; Schonbeck et al. 1998), and are also 
capable of increasing their own production by their ability to convert fibroblasts 
into the more active myo-fibroblasts. Clearly it is essential that MMP activity is 
tightly regulated, and this operates at both transcriptional and post-transcriptional 
levels, in addition to regulation through inhibition by TIMPs (figure 1.5) 
(Birkedal-Hansen H et al. 1993).
(b) Regulation of MMP Activity
(i) Transcriptional Regulation
There is low-level background gene expression of MMPs in all tissues. However, 
this expression can be modified at the transcriptional level by a large number of 
modulatory cytokines, hormones and growth factors (figure 1.5). Many of these 
serve to increase MMP gene expression and transcription, including IL-1 and -6, 
platelet-derived growth factor (PDGF) and TNF-alpha (Birkedal-Hansen H et al. 
1993; Schonbeck et al. 1997). It is important to remember that MMPs are also 
involved in the regulation of IL-1, TNF and TGF-beta so the control mechanisms 
of levels o f genetic expression are interlinked (Gearing et al. 1994; Schonbeck et 
al. 1998). More recently, a cell surface glycoprotein has been identified which 
serves to upregulate MMP-1 mRNA expression in a dose dependent manner (Guo
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et al. 1997). This glycoprotein is called extracellular matrix metalloproteinase 
inducer, or EMMPRIN, and its own expression seems to be upregulated in disease 
states (Spinale FG et al. 2000).
Suppression of MMP gene expression also occurs. Transforming growth factor- 
beta (TGF-beta) suppresses MMP-1 transcription (and increases TIMP 
expression). Corticosteroids, heparin, Ang-II and IL-4 also Inhibit MMP 
transcription (Birkedal-Hansen H et al. 1993; Mauviel, 1993; Brilla CG et al. 
1994).
(ii) Pro-enzyme Activation
Pro-MMPs are zymogen precursors and are secreted and stored in the extracellular 
matrix. The active enzyme is liberated following cleavage of latent propetides 
attached to it, usually a 20 amino-acid sequence. This occurs in the ECM 
predominantly through plasmin-dependent stepwise activation, but activation by 
plasmin-independent stepwise activation and by cell surface bound MT-MMP 
occurs, as does intracellular activation, although at much smaller magnitude 
(figure 1.5) (Nagase H, 1997).
The stepwise sequence is so-called due to the stepped nature of activation (Nagase 
H et al. 1990). The first step is usually plasmin mediated, attacking the propeptide 
domain of pro-MMP leaving it susceptible to further proteolysis, usually by an 
active MMP. Plasmin levels and, consequently, the extent of the plasmin-mediated 
response, are regulated by urokinase plasminogen activator (uPA) and
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plasminogen activator inhibitor (PAI), and these systems therefore influence MMP 
activation. Plasmin-independent pathways are also present, the first step being 
performed by other proteinases such as chymase and trypsin (Murphy et al. 1994; 
Nagase H, 1997).
The second step of this stepwise activation is dependent on a second proteinase, 
usually another MMP. This demonstrates the ability of active MMPs to auto- 
induce further activation of latent precursors. Obviously, the extent of this auto­
induction must be tightly regulated. The rate limiting stage has yet to be 
established, but is probably the availability of plasmin which is controlled by the 
plasminogen activator-plasminogen system. MMP activation also occurs as a 
single stage via the cell surface bound, membrane type MMP (MT-MMP) 
(Knauper and Murphy, 1998). Finally, intracellular formation of active MMPs has 
heen described, although the functional significance of this is unclear at present 
(Nguyen et al. 1998).
(Hi) Tissue Inhibitors o f Matrix Metalloproteinases
MMPs are specifically inhibited by a family of naturally occurring glycoproteins -  
the tissue inhibitors of metalloproteinases (TIMPs) (figure 1.5). At present four 
mammalian TIMPs have been identified with up to 40% sequence homology 
between them and all have six disulphide bridges. They are low molecular weight 
proteins (20-30 kDa) and exert their effects by the formation o f irreversible non- 
covalent high affinity bonds in the catalytic domain, in a 1:1 stoichiometric form, 
effectively inhibiting MMP proteolytic activity (Matrisian LM, 1990; Woessner
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JF, 1999), Macrophages, as well as most connective tissue cells including 
fibroblasts, produce TIMPs. TIMP gene expression is upregulated by IL-1 and -6, 
Ang-II, TGF-beta, PDGF and TNF-alpha, in addition to the previously discussed 
effects on MMP gene transcription by these substances (Mauviel, 1993; Chua et 
al. 1996).
The primaiy role for TIMPs would appear to be regulation of activated MMP 
activity by inhibition of their proteolytic properties. However, there are increasing 
data to suggest that TIMP-MMP interaction may be a little more complex and that 
TIMPs have other biologically active roles. For example, membrane type MMP 
can bind TIMP allowing activation of MMP precursors, TIMPs can inhibit pro- 
MMP activation, and TIMP-1 and -2  exhibit growth factor like activity and can 
inhibit angiogenesis (Kikuchi K et al. 1997; Nagase H, 1997; Hayakawa et al. 
1994).
There are other inhibitors of MMPs, the principal one in-vivo being alpha2- 
macroglobulin, but the TIMP system is the key inhibitor of MMP activity, the 
regulation of which is crucial to maintain the ECM homeostasis in healthy tissues. 
Given the importance of MMP activity in remodelling, synthetic MMP inhibitors 
have been developed and studied in a variety of conditions including heart failure, 
myoeardial infarction, coated stents to reduce in-stent restenosis and adjunctive 
treatment of cancers. The earliest compounds were modified tetracycline 
derivatives and most are still related, hased on a hydroxamate structure (Skotnicki 
et al. 1999). This is discussed in more detail in the next section.
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1.4.5 The Role of MMPs and TIMPs in Disease
Tight regulation of MMP and TIMP gene expression and activities are paramount 
for the maintenance of the dynamic turnover of collagen and other components of 
the extra-cellular matrix in healthy tissues. This maintains extracellular turnover to 
sustain the necessary milieu for normal tissue function, growth and remodelling. 
Although there are many physiological examples of supra-expression of one or 
more of the MMP-TIMP components, such as during trophoblast invasion and 
development, endometrial remodelling, ovulation and angiogenesis, disruption of 
the MMP-TIMP balance plays a pivotal role in many disease processes, including 
tumour growth and metastasis, arteriosclerosis, arthritis and heai't disease 
(McDonnell et al. 1999). Of these, tumour growth and metastasis is probably the 
most studied. Indeed some of the MMPs were first localised in tumour tissue and 
many oncogenes express genes for them (Basset et al. 1990).
(a) Genetic Models and Cardiovascular Disease
With regard to MMPs and TIMPs within the cardiovascular arena, their roles are 
probably best illustrated thi'ough genetic studies. Gene-knockout models provide 
invaluable information regarding MMP and TIMP function. MMP-9 deficient 
mice display have attenuated left ventricular enlargement and collagen 
accumulation following experimental myocardial infarction and reduced cardiac 
rupture (Heymans et al. 1999; Ducharme et al. 2000). However, this beneficial 
effect was seen at the expense of impaired angiogenesis and in one study, the 
MMP-9 deficient mice had an increase incidence of subsequent heart failure
54
(Heymans et al. 1999). This illustrates the biological diversity o f MMP function 
and they cannot just be thought of as proteolytic enzymes. Similarly, collagen 
turnover is a finely balanced dynamic equilibrium, and such dramatic changes to 
the equilibrium apparent in genetic knockout models can have untold effects on 
the extracellular matrix and subsequent phenotype.
However, similar protection with regard to cardiac aneurysm and rupture 
following experimental MI is seen in mice deficient in the gene for uPA. 
Diminished uPA activity reduces plasmin-mediated stepwise activation of pro- 
MMP and tlrerefore levels of active MMP, and these animals display reduced LV 
dilatation (Heymans et al. 1999). Conversely, transgenic overexpression of MMP- 
1 in the mouse ventricle leads to LV dysfunction and dilatation (Kim et al. 1999). 
These studies illustrate the importance o f active MMPs in collagen degradation 
duimg early ventricular remodelling (Matrisian LM, 1990). The significance of 
plasmin-mediated activation of MMP is also illustrated in plamsinogen deficient 
mice, where post transplant arteriosclerosis is ameliorated, again illustrating the 
role of active MMPs in the development of arterial remodelling and subsequent 
arteriosclerosis (Moons et al. 1998).
With regai-d to genetic models of TIMP expression, TIMP-1 gene knockout mice 
show increase arteriosclerosis, LV mass and volume and decreased collagen 
content (Roten et al. 1990). Transgenic over-expression o f TIMP-1 inhibits 
vascular smooth muscle cell migration and neointimal proliferation during 
experimental vascular balloon injuty (Dollery CM et al. 1999), leading to the 
assessment in the clinical setting of synthetic MMP inhibitors post angioplasty.
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either systemically or by local delivery via drug eluting stents (Li et al. 2002; 
Cherr et al. 2002).
(b) Heai't Failure
Although genetic studies illustrate the consequences of under and over expression 
of MMP and TIMPs, observational studies of natural expression of MMP and 
TIMP in disease states provide further evidence of the importance of MMP-TIMP 
balance in cardiovascular disease. There is a wealth of experimental evidence that 
dilated cardiomyopathy is associated with increased expression of MMPs, 
especially MMP-1. Studies utilising zymography demonstrate that this increased 
gene expression equates to increased MMP activity (Tyagi et al. 1996; Spinale FG 
et al. 1998; Coker et al. 1998; Spinale FG et al. 2000). Additionally, gene 
expression and production of TIMP-1 and -3 are reduced in both dilated and 
ischaemic cardiomyopathy (Li et al. 1998). There is therefore good evidence in a 
shift in the balance of MMP-TIMP genetic expression and activity in the failing 
heart, which correlates well with the documented reduction in collagen content 
and altered function seen in this condition (Weber KT et al. 1988b; Gunja-Smith 
Z et al. 1996). Furthermore, administration of a synthetic MMP inhibitor reduced 
LV dilatation and wall stress and improves ejection fraction in the experimental 
pacing induced model of heart failure in the pig. It also attenuates collagen loss 
(Spinale FG et al. 1999).
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(c) Myocardial Infarction
Synthetic MMP inhibitors have also been used with some success in experimental
models of myocardial infarction. This is perhaps unsuiprising given the body of
evidence surrounding MMP activity following MI. MMP expression, especially
MMP-1, IS upregulated following MI and again, zymography demonstrates that
this is associated with increased gene product (Carlyle et al. 1997; Herzog et al.
1998; Damelsen et al. 1998). The time-scale for increased MMP production is
diverse among the studies, and may be influenced by reperfiision and other factors.
However, the eailiest evidence of up-regulation of MMP expression appears to be
within a few hours o f infarction (Herzog et al. 1998). Similarly, there appears to
be varying data on TIMP expression following MI. One study demonstrates
suppression o f TIMP-1 expression following myocardial ischaemia (Baghelai et
al. 1998), but another showed increased TIMP-1 mRNA transcription 2 days
following MI (Cleutjens JPM et al. 1995). Even accepting these apparent
discrepancies, it is clear that the TIMP-MMP balance shifts towards increased
MMP activity. Again this is in keeping with the pathological studies of early
remodelling following acute myocardial infarction, the hallmarks of which are
collagen loss, infarct expansion and myocyte slippage (Pfeffer MA and Braunwald 
E, 1990).
Only two studies have examined the use of syntlietic MMP inhibitors in potential 
attenuation of post-infarction remodelling. The drugs were given 4 to 14 days 
following infarction. Both studies demonstrated decreased LV dilatation with 
improved fractional shortening (Rohde et al. 1999; Creemers et al. 1999), This
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was most apparent when MMP inhibitor was given early (Creemers et al, 1999). 
Although these results are encouraging, animals given the broad spectrum MMP 
inhibitor ilomastat, in the study by Creemers et al, also demonstrated delayed 
infarct healing and loss of collagen (Creemers et al. 1999). This apparently 
paradoxical finding is probably explained by the fact that MMPs have diverse 
biological actions, and are not limited to their proteolytic effects on myocardial 
collagen. As previously discussed, MMPs, especially MMP-9, are involved in the 
regulation of biologically active growth factors such as TNF-alpha, TGF-beta and 
IL-1 (Gearing et al. 1994; Schonbeck et al. 1998). A broad spectrum MMP 
inhibitor may interfere with these pathways and have marked effects on the 
regulation and growth of other cellular and matrix components. Similarly, MMP 
inhibition may retard the activation of fibroblasts, thereby paradoxically reducing 
collagen synthesis, and therefore selective inhibition of MMP sub-types may be of 
theoretical benefit. This hypothesis was tested recently in a study in the pig model 
of pacing-induced heart failure(King MK et al. 2003). This group examined 
selective MMP inhibition, given before the development of heart failure, and 
demonstrated reduced wall stress, improved haemodynamics and LV function in 
the group given selective MMP inhibitor, adding support to the hypothesis.
However, all these studies illustrate the time-dependency of MMP-TIMP 
interaction following infarction, underpinning the relative importance of the 
processes of collagen synthesis and breakdown at any given time point in the 
continuum of remodelling. Therefore, the timing of initiation and duration of 
therapy is likely to be of critical importance if therapeutic intervention of the
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MMP-TIMP system is to be considered. It is also important to remember that the 
time dependency may vary between species and even between individuals.
Even accepting these issues, manipulation of the MMP-TIMP system is an 
attractive concept. Phase III clinical trials in Hodgkin’s and non-Hodgkin’s 
lymphoma are ongoing. However, in the field of cardiovascular medicine, 
especially post infarct, there are many questions still to be addressed. These 
include selective vs. broad spectrum inhibition, timing of initiation and the safety 
parameters of these drugs. Like all therapeutic interventions, the risk:benefit ratio 
must be established, and it is likely that the key in potential utilisation of MMP 
inhibition following infarction will be the identification of those high-risk 
individuals who are most likely to benefit.
1.4.6 Evidence of Involvement of the Renin-Angiotensin-Aldosterone Svstem
As previously discussed, there is good evidence of super-activation of the RAAS 
following myocardial infarction, both systemically and at a tissue level (Dzau, 
1987; McAlpine HM et al. 1988; Lindpaintner et al. 1993; Rouleau et al. 1993). 
Furthermore, large-scale clinical trials have demonstrated the ability of ACE 
inhibitors to attenuate the remodelling process and reduce mortality (Pfeffer MA 
et al. 1992; AIRE study investigators, 1993; Gruppo Italiono per lo Studio della 
Sopravvivenza nell'Infarcto Miocardio (GISSI) -3, 1994; ISIS-4 Collaborative 
Group, 1995). Although the effectors of the RAAS, angiotensin II (Ang-II) and 
aldosterone, have modulatory effects on myocyte growth (Yamazaki et al. 1995),
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they also have profound effects on the cells of the extracellular matrix and 
collagen metabolism.
There are many strands of evidence to support this. Firstly, at a genetic level, over­
expression of the ACE gene has been demonstrated in hypertension and this high 
level expression induces the transformation of quiescent fibroblasts to active myo­
fibroblasts (Challah et al. 1995). Furthermore, increased expression has also been 
demonstrated following myocardial infarction (Sun Y et al. 1994). This increase 
in genetic expression is associated with increased tissue levels of ACE and Ang-II, 
and this, coupled with the high AT-1 receptor density displayed by activated 
fibroblasts, means the effect of this system is enhanced following MI. The human 
heart also expresses mineralocorticoid receptors suggesting that the heart is a 
target organ of aldosterone (Lombes M et al. 1995; Kathleen M et al. 2000), and 
suppression by atrial natriuretic peptide reduces plasma aldosterone levels with 
subsequent reduction in LV remodelling (Hayashi M et al. 2001a). Furthermore, 
administration of the mineralocorticoid receptor antagonist spironolactone 
immediately following AMI reduces LV dilatation and improves ejection fraction 
(Hayashi M et al. 2003).
Evidence supports Ang II induction of fibroblast proliferation and up-regulation of 
collagen synthesis (Kato H et al. 1991; Schorb and et al, 1993). Indeed, in-vitro 
studies have shown Ang-II and aldosterone stimulate collagen synthesis in a dose 
dependent manner. The effects of Ang-II are not limited to collagen synthesis. In- 
vitro studies have shown Ang-II to have an inhibitory effect on MMP-1, a feature 
not seen with aldosterone (Brilla CG et al. 1994). It also has a stimulatory effect
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on production of TIMP-1, further altering MMP-TIMP balance (Chua et al.
1996). Antagonism of the RAAS with ACE inliibitors or AT-1 receptor blockers is 
associated with reverse remodelling of myocyte hypertrophy (Tamura et al. 
2000). It is also associated with increased collagen degradation and regression of 
fibrosis in the hypertensive model (Brilla CG et al. 1996; Varo et al. 2000). It is 
therefore clear that the RAAS has an important role in collagen metabolism and 
ECM turnover, partly mediated by its effects on fibroblast activation and MMP 
activity.
1.5 Biochemical Assessment of Collagen Turnover
The gold standard for assessing fibrosis is direct histological examination. 
However, in the field of cardiology, this involves invasive endomyocardial biopsy 
with all its attendant risks. Furthermore, changes to myocardial collagen content 
can be patchy and the biopsied sample may not be representative of the overall 
picture of collagen balance. This has prompted the search for a reliable non- 
invasive method for assessing the degree of fibrosis and overall collagen turnover. 
This may aid in the diagnosis of diseases involving collagen and perhaps allow 
monitoring of therapy.
Historically, determination of urinary hydroxyproline was used as a non-invasive 
indicator of total body collagen content and turnover. Proline residues in collagen 
undergo hydroxylation and it was thought that measurement o f its urinary 
excretion would allow monitoring of collagen flux. However, proline residues on 
other non-collagenous proteins, such as elastin, also undergo hydroxylation. There
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is also a large degree of variation in the extent of hydroxylation between different 
collagen types. These factors make the use of urinary hydroxyproline as a 
measurement of collagen turnover misleading at best, and cannot be recommended 
in clinical practice or in the research setting (Miller and Gay, 1992). In the last 
decade or so, interest has moved to serological markers of collagen turnover and 
the available data supports their superior accuracy (Risteli L and Risteli J, 1990).
1.5.1 Available Serological Assavs
Fibroblasts synthesise procollagen and two terminal propeptide moieties must be 
removed before the collagen molecule can be integrated into the growing fibril 
(Prockop et al. 1979; Nimni ME, 1993). These moieties are one small amino- 
terminal and a larger carboxy-terminal propeptide, both of which may be 
measured in serum or plasma by immunoserologic techniques when they are 
liberated from procollagen. There are two commercially available radio­
immunoassays which are of use in monitoring collagen synthesis. Procollagen 
type I carboxy-terminal propeptide (PICP), also known as C-propeptide for type I 
collagen, is the larger carboxy-terminal propeptide cleaved during synthesis of 
type I collagen fibrils and reflects the degree of synthesis of this collagen type 
(Melkko JT et al. 1990). Similarly, procollagen type III amino-terminal 
propeptide (PIIINP) is the smaller amino-terminal propeptide and is cleaved 
during conversion of procollagen type III and is a marker of synthesis of type III 
collagen (Horslev-Petersen K et al. 1988). However, unlike PICP, PIIINP is 
incompletely cleaved during the production of type III collagen and is also 
released when type III collagen is degraded and, therefore, increased serum levels
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may reflect synthesis or breakdown (Nimni ME, 1993; Risteli J et al. 1995a; 
Risteli J and Risteli L, 1995b).
When assessing collagen content and turnover, it is important to remember that net 
collagen content is a product of a dynamic equilibrium between synthesis and 
breakdown. It is therefore imperative that collagen degradation is also considered. 
Fortunately, there is a radio-immunoassay available for a telopeptide liberated 
during degradation of type I collagen, and serum or plasma levels reflect collagen 
breakdown. It is called C-telopeptide for type I collagen (CITP) and is released by 
endopeptidase cleavage during collagen degradation in a 1:1 fashion (Risteli J and 
Risteli L, 1995b). These propeptides are eliminated by hepatic and renal routes 
and therefore, significant hepatic or renal dysfunction also increase levels (Risteli 
L and Risteli J, 1990).
There are therefore serological tools available to assess both synthesis and 
breakdown of collagen. However, it is unclear as to the contribution of the normal 
heart to the plasma pool of these propeptides.
There are also serological assays (ELISA) to measure the levels of both MMPs 
and TIMPs in the blood, and as previously discussed, collagen breakdown is 
dependent on the balance of MMP and TIMP activity. It is important to note that 
serum levels are not elevated as part of an acute phase response and, therefore, 
these assays probably reflect levels at a tissue level and be useful in the assessment 
of collagen turnover (Timms et al. 1999). However, it is also important to 
remember that there is some cross reactivity between MMPs and the measurement
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does not reflect active MMP but also includes inactive pro-MMP and MMP bound 
with TIMP. Similarly, assay for TIMP does not distinguish between bound and 
unbound TIMP. These features make interpretation of blood levels more difficult. 
Finally, it is well documented that analysis of serum samples is less reliable than 
measurement of these compounds in plasma, and assays of plasma levels is more 
accurate and is therefore to be recommended (Lein et al. 1997; Jung, 1997).
1.5.2 Changes in Heart Disease
The use of immunoserological testing of collagen markers has been extensively 
studied in a variety of clinical conditions. The most widely used marker is PIIINP 
and serum levels of PIIINP are elevated in many conditions involving fibrosis, 
such as rheumatoid artliritis, pulmonary fibrosis, hepatitis and wound healing. 
Indeed, the absolute level appears to correlate with the degree of fibrosis (Low RB 
et al. 1983; Horslev-Petersen K et al. 1986; Haukiporo et al. 1987; Trinchet JC et 
al. 1991). However, as mentioned previously, there are sound theoretical reasons 
for the superiority of PICP as a mai'ker of collagen synthesis, and increased levels 
of PICP have also been demonstrated in liver fibrosis, wound healing and bone 
disease (Savolainen et al. 1984; Parfitt et al. 1987; Schuppan, 1991).
These two markers of collagen biosynthesis are also the most extensively studied 
in the field of cardiology, mainly in arterial hypertension. Serum concentrations of 
both PICP and PIIINP are elevated in patients with untreated hypertension 
(Laviades C et al. 1994; Diez J et al. 1995; Lindsay et al. 2002). There is also 
evidence that elevated levels are associated with increased fibrosis, LV mass and
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incidence of arrhythmias (Diez J et ai. 1995; Diez J et al. 1996). It is also well 
documented that the renin-angiotensin-aldosterone system is powerfully 
fibrogenic and antagonism of it with ACE inhibitors reduces LVH and reverses 
fibrous tissue accumulation in the spontaneously hypertensive murine model 
(Brilla CG et al. 1991; Brilla CG et al. 1995). The raised PIIINP levels found in 
hypertension normalise with treatment with lisinopril, providing further evidence 
that these elevated levels reflect collagen biosynthesis and tissue fibrosis 
(Laviades C et al. 1994). Similarly, antagonism of the RAAS by aldosterone in 
patients with heart failure also reduces serum levels of PIIINP and this is 
associated with improved heart rate variability (MacFadyen et al. 1997). Raised 
serum PIIINP is associated with increased fibrosis in heart failure patients and is 
an independent predictor of mortality (Klappacher et al. 1995). The RALES 
collagen marker substudy in congestive heart failure showed that high baseline 
levels of PIIINP were associated with increased risk of sudden death and that the 
benefit seen with spironolactone treatment was associated with a reduction in the 
serum levels of this marker of collagen turnover (Zannad et a l  2000). Indeed, the 
effect of spironolactone was only significant in patients with elevated baseline 
levels of PIIINP, suggesting that alterations to collagen turnover may be a possible 
mechanism of benefit of spironolactone in the treatment of heart failure.
Serum levels of CITP display a similar picture, with levels also correlating with 
fibrosis and predicting mortality in heart failure (Klappacher et al. 1995). The fact 
that markers of both synthesis and degradation are elevated reflects the complexity 
of collagen flux and matrix turnover. For true assessment of collagen flux, it is 
imperative that both processes are considered. As outlined above, CITP is a
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marker of collagen breakdown and most work has been its use in bone disease 
(Hakala et al. 1993; Charles et al. 1994; Hosoya et al. 1997), with really very 
little being performed in the field of cardiovascular medicine. Indeed, the only 
published cardiovascular studies utilising serum CITP was in a cohort with heart 
failure, mentioned above, a small study in myocardial infarction (Klappacher et al. 
1995; Murakami T et al. 1998), and a recent study in essential hypertension 
(Lindsay et al. 2002). Researchers have focused more on MMP activity as an 
indicator of collagen degradation. Most of these have looked at MMP expression 
in atheromatous plaques. Many in-vitro studies have demonstrated increased 
expression of MMP-1 (interstitial collagenase) and MMP-13 (a variant of 
interstitial collagenase) in atheromatous plaques, with resultant increased 
enzymatic activity (Henney AM et al. 1991; Galis et al. 1995; Sukhova et al. 
1999). It is thought that increased MMP activity may play a role in the transition 
from stable to unstable plaque.
There are only two serological studies in cardiology examining levels of MMPs in 
the blood. One was by Kai and colleagues who looked at plasma levels of MMP-2 
and -9  in a cohort of patients presenting with MI, unstable angina or stable angina 
pectoris (Kai H et al. 1998). They showed that plasma MMP-2 and -9  are 
elevated in patients presenting with an acute coronary syndrome (UAP or MI) 
compared with those with stable symptoms, and remained elevated for several 
days. They postulated that this represented increased MMP activity in 
atheromatous plaque and the increased levels came from plaque and not the 
myocardial ECM.
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The other serological study looking at MMP levels in peripheral blood was 
performed in a small cohort (13 patients) presenting with acute ST elevation 
myocardial infarction (Hirohata S et al. 1997). They performed serial samples for 
MMP-1 and TIMP-1 and demonstrated initial MMP levels below the normal range 
for the first few days which then increased at day 4, peaking 2 weeks later. TIMP- 
1 levels also showed time dependent changes with a very similar picture. Day 5 
levels of both MMP-1 and TIMP-1 positively correlated with LV ejection fraction 
and negatively correlated with LV end systolic volume index. There is no obvious 
mechanistic reason to explain theses findings and they would seem to be 
contradictory to the fact that early remodelling is probably more dependent on 
collagen degradation, and that MMP inhibition improves outcome in experimental 
MI (Creemers et al. 1999). One would therefore expect increased early MMP 
activity and reversal of the correlations seen in Hirohata’s study. However, as 
previously discussed, assays for MMP-1 detects pro-MMP and MMP complexed 
with TIMP in addition to active MMP, and therefore blood levels may not reflect 
actual activity. The same is true of TIMP-1 assay.
Given that there are only limited data with respect to direct markers of collagen 
degradation following MI, it is difficult to know how to interpret this study. There 
is only one published study examining serum levels of CITP as a marker of 
collagen breakdown following MI (Murakami T et al. 1998). Murakami and 
colleagues examined a small cohort of 13 patients with myocardial infarction and 
foimd that serum PICP was reduced immediately following AMI and CITP was 
more than two standard deviations below a normal population mean on admission. 
Both serum PICP and CITP subsequently exhibited a time dependent rise, with
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CITP rising beyond the normal range. PICP had a very weak correlation with 
indices of LV volume but no such conelation was found with CITP. Again it is 
difficult to know how to interpret the results. The numbers involved in this study 
were small and with large standard deviations, making statistical and functional 
inteipretation difficult. In addition, the authors do not offer a hypothesis to explain 
the initial fall then rise of PICP or why the initial CITP was more than 2 standard 
deviations below the mean of their normal population. Furthermore, the use of 
serum for analysis of markers of collagen flux may be less reliable than plasma 
assays (Lein et al. 1997). However, even accepting these limitations it is the only 
study to date which has utilised markers of both processes of synthesis and 
degradation.
The other serological work in MI has mainly focused on PIIINP. A Danish group 
demonstrated elevated PIIINP from the third post-infarction day, peaking around 
day 7 and remained elevated for several months performed three studies, in a small 
cohort of patients presenting with ST elevation MI. There also found a weak 
correlation between peak levels and infarct size as assessed by cardiac enzyme 
release (Jensen LT et al. 1990). This was confirmed in a subsequent studies 
performed by the same group, where they also demonstrated that higher levels 
were associated with a restrictive filling pattern and were predictive of a poor 
outcome including death (Host NB et al. 1995; Poulsen SH et al. 2000). A 
similar pictm'e was demonstrated by an Italian group and, more recently, the same 
group demonstrated reduced ventricular dilatation and serum PIIINP levels 
following AMI with treatment with an aldosterone antagonist started on discharge 
(Modena et al. 2001).
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It is therefore clear that changes to PIIINP, a marker of mainly collagen synthesis, 
provide information on remodelling. However, as previously discussed, PIIINP 
can be also be increased during degradation as it is incompletely cleaved from pro­
collagen during synthesis of collagen type III and some will therefore be liberated 
during breakdown (Risteli L and Risteli J, 1990). This makes it difficult to 
postulate a mechanistic hypothesis, and one must really consider both synthesis 
and degradation when attempting to assess collagen turnover by biochemical 
means.
1.6 Hypotheses
It is clear from the literature that coronary disease is common and that acute 
coronary events are associated with significant morbidity and mortality. 
Ventricular remodelling following myocardial infarction is a powerful adverse 
prognostic indicator, and there are strategies available to reduce the remodelling 
process. Risk stratification is the key and early intervention in patients at high-risk 
of remodelling may have an impact on morbidity and mortality. Echocardiography 
has a role to play in risk stratification, but will only identify early remodelling 
when it has already begun. Early post-infarction remodelling is characterised by 
marked changes to myocardial collagen content and the extracellular matrix, 
causing infarct expansion, myocyte slippage and LV dilatation. Biochemical 
markers of collagen turnover may be a useful tool in identifying those at risk of 
remodelling and allow us to monitor the process. They may also have some use in
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the risk stratification of non ST elevation acute coronary syndromes, as ischaemia
can cause alterations to the ECM in the absence of overt myocyte necrosis.
My hypotheses are:
1) There will be time dependent alterations in plasma levels of markers of 
collagen synthesis and degradation (PICP, CITP and TIMP-1) following acute 
myocardial infarction, reflecting alterations to myocardial collagen content and 
structure.
2) Plasma CITP will be elevated early following AMI with a later rise in PICP 
reflecting collagen degradation as the principal finding during early 
remodelling and collagen synthesis as the principal finding in late remodelling.
3) Increased plasma CITP will reflect early ventricular remodelling as assessed 
by echocardiographic parameters.
4) The changes in plasma levels are not under systemic RAAS control.
5) In CK negative, non-ST elevation acute coronary syndromes, there will be 
time dependent changes in these markers in “high risk” patients as manifested 
by positive troponin I or dynamic ECG changes, and this may reflect a degree 
of remodelling.
6) The changes in plasma levels will be rapid in onset, reflecting rapidity of onset 
of remodelling, and will be further investigated using a human model of acute 
coronary occlusion.
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CHAPTER TWO -  MATERIALS & METHODS
2.1 Summary of Studies Performed
The time-line of studies is illustrated in figure 2,1,
Figure 2.1
Jan 1999 Jan 2000 Jan 2001 Jan 2002
Validation 
of assays
Acute MI Study
Acute MI
Neurohormonal substudy
■ Non-ST elevation ACS
PTCA study
Legend Time-scale for studies
Following intra and inter-assay variability studies, alterations in plasma levels of 
markers of collagen turnover were examined in four distinct populations: healthy 
volunteers, ST elevation MI, non-ST elevation ACS and patients undergoing 
coronary angiography and angioplasty. A total of 30 healthy volunteers were 
studied for estimation of normal ranges and studies of variablitiy within 
individuals. In addition, 64 patients with ST elevation MI, 52 with non-ST
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elevation ACS and 22 undergoing coronary angiography or angioplasty were also 
studied. I undertook study design and obtained ethical approval. I personally 
screened and recruited all participants, performed venesection, analysed ECGs and 
performed and analysed echocardiograms. I also collected and analysed all data.
2.2 Validation of Biochemical Assavs of Collagen Turnover (Chapter 3)
2.2.1 Study Population
The study population for the assessment of assay variability was drawn from a mix 
of patients who agreed to participate in the ST elevation MI and non-ST elevation 
acute coronary syndrome studies, in addition to healthy volunteers and patients 
participating in other studies at Stobhill Hospital. These included patients with 
hypertension and liver disease. These studies were performed from January 1999 
till September of the same year (figure 2.1).
To allow characterisation of normal ranges and intra-individual variability, healthy 
volunteers were recruited from the departments of Biochemistry and Cardiology 
and following advertisement in the local press. Exclusion criteria applicable to 
normal volunteers and patients em'olled in the subsequent studies of acute 
coronaiy syndromes (ST elevation and non ST elevation) and percutaneous 
transluminal coronary angioplasty are listed in table 2.1. They include factors 
influencing collagen metabolism and elimination of plasma propeptides (Risteli L 
and Risteli J, 1990).
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Table 2.1
Patient Characteristics
• Unable to give informed consent
• Psychiatric illness
• Alcohol intake >50 U/week
Conditions Know To Alter Collagen Flux
Surgery within last 6 months
Admission for an acute coronary syndrome within last 6 months 
Percutaneous coronary intervention in last 6 months 
Active tumour 
Pulmonary fibrosis
Rheumatoid disease / Connective Tissue Disease 
Treated hypertension 
Previous MI or heart failure
Conditions Know To Influence Metabolism Of Pro-peptides
• Concurrent steroid or NSAID use
• Concurrent ACE inhibitor, Angiotensin II Receptor Blocker or
spironolactone use
• Liver dysfunction - ALT > 2x ULN
• Renal dysfunction -  Creatinine > 130micromol/l
Legend - Exclusion criteria for all studies
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2.2.2 Study Design
(a) Assay Variability
lOmls of whole blood was venesected with the patient in the recumbent position 
and collected in Lithium Heparin tubes. It is well documented that analysis of 
plasma samples is more accurate and reliable than analysis of serum samples and 
therefore all samples were collected in Lithium Heparin tubes (Lein et al. 1997; 
Jung, 1997). Samples were then centrifuged at 3000rpm for 7 minutes and plasma 
decanted into crystal tubes and frozen at -70°C until use. Intra-assay variability 
was performed by assaying the same investigational sample twice using the same 
assay kit. Inter-assay variability was determined by assaying the same 
investigational sample twice using different kits.
(b) Normal Ranges
Following verbal consent, lOmls of whole blood was venesected from healthy
volunteers in the recumbent position during the morning. Samples were collected
in Lithium Heparin tubes and processed as above.
(c) Intra-individual Variability
Blood was collected from volunteers on two occasions - one in the morning, 
another in the afternoon. Again, samples were collected in Lithium Heparin tubes 
and spun and frozen till use. Verbal consent was obtained prior to venesection.
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2.2.3 Biochemical Method for Assay of Markers of Collagen Turnover
(a) Tissue Inhibitor of Matrix Metalloproteinase-1 (TIMP-1)
Plasma TIMP-1 was measured using a modification of the method developed by 
Plumpton (Plumpton TA et al. 1995). This is a two-step sandwich enzyme linked 
immunosorbent assay (ELISA) assay using a commercially available kit -  
RPN2611 (Amersham Pharmaceuticals, Little Chalfont, UK). 100 microlitres of 
the investigational plasma sample is incubated in a microtitre well coated with 
anti-TIMP antibody following equilibration at room temperature. After incubation 
and washing with buffer solution, the bound TIMP-1 is measured by reaction with 
a second antibody labelled with horseradish peroxidase. The oxidised substrate is 
read in a photospectrometer at 450nm. A value for the amount of TIMP-1 in the 
investigational sample is read directly from a standard curve constructed by 
calculating percentage binding of five standard concentrations prepared in the 
same way.
(b) C-propeptide for Type I Collagen (PICP)
A radio-immunoassay (RIA) was used for the assessment o f plasma PICP (Orion 
Diagnostica, Espoo, Finland). This assay utilises the standard principles of RIA 
with 100 microlitres of the investigational sample containing an unknown amount 
of PICP being mixed with 200 microlitres of radio-active PICP (labelled with 
^^^lodine) (Melkko JT et al. 1990). 200 microlitres of PICP anti-serum (rabbit) is 
added to this mix resulting in competition for the limited number of high affinity
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sites of the antibody (PICP anti-sera) between the labelled and unlabelled PICP. 
After 2 hours of incubation at 37°C, the proportion of radioactive PICP in the 
antigen-antibody complex in the reaction mixture is inversely proportional to the 
amount of unlabelled PICP in the investigational sample. Adding a separation 
agent and centrifuging removes free PICP. The supernatant is decanted and the 
sediment containing the precipitated antigen-antibody complex is counted in a 
gamma camera.
A standard curve is produced after calculation of the binding of five standards 
prepared in the same way. These values are expressed as a percentage of 
maximum possible binding. Bound radio-activity from investigational samples are 
plotted along this curve and PICP values read directly.
(c) C-telopeptide for Type I Collagen (CITP)
A radio-immuno assay (RIA) for CITP was used (Orion Diagnostica, Espoo, 
Finland). Method is identical to that for PICP with ‘^ ^lodine labelled CITP and 
rabbit CITP antiserum replacing labelled PICP and anti-PICP (Risteli J et al. 
1993). Standard curve for bound radioactivity is constructed after assaying five 
standard concentrations of CITP and results of investigational samples read 
directly.
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2.2.4 Analysis of Results
(a) Variability Studies
Two values for each sample were obtained in the intra and inter-assay variability 
studies and in the study of intra-individual variability. A mean o f the two values 
was calculated for each sample and differences expressed as absolute and 
percentage differences of the mean. Correlation between the values was calculated 
and expressed as a co-efficient. The distribution of the collagen markers was 
tested for normality using the Anderson Darling method. Results from the group 
were not normally distributed for PICP and TIMP-1, so log transformation was 
performed prior to testing of statistical significance. Statistical comparison was 
performed using Student’s t test. All statistical analyses were performed using 
Minitab statistical software (Minitab Inc, Pemisylvania, USA). A p value of <0.05 
was considered significant.
(b) Normal Ranges
Values for the group were analysed and expressed as a mean +/- standard 
deviation, including 95% confidence intervals.
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2.3 Acute Myocardial Infarction -  Biochemical. Neurohormonal and 
Functional Studies (Chapters 4 & 5)
2.3.1 Study Population
(a) Recruitment
Patients were recruited from the Coronaiy Care Unit (CCU) at Stobhill Hospital in 
the North of Glasgow over a two and a half year period, from February 1999 till 
August 2001 (figure 2.1). Those presenting with a history suggestive of an acute 
coronary syndrome with ST elevation on a 12 lead ECG were eligible for entry 
into the study. Entry criteria consisted of chest pain for more than 20 minutes and 
presentation within 6 hours from the onset of pain. The CCU at Stobhill hospital 
operates a “back-door” policy, allowing General Practitioners and ambulance 
persomiel to refer directly to CCU, bypassing the busy Accident & Emergency 
department. Patients are brought directly to Coronary cai*e by ambulance and are 
immediately assessed by senior nursing and medical staff following a 12 lead 
electrocardiogram. The efficacy of such a system in reducing time to thrombolysis 
has been demonstrated previously (Burns et al. 1989; Prasad N et al. 1997) and 
the unit currently has a median time to thrombolysis of 28 mins from admission 
and 22 mins from diagnostic ECG. 64% of patients receive thrombolysis within 
the audit standard of 30 minutes. This CCU therefore provided the ideal setting for 
the early identification of patients suitable for inclusion in this study.
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Twenty healthy volunteers were recruited following advertisements in the local 
press. These individuals were on no cardiac medication. This group had a similar 
age and sex distribution to the investigational group.
(b) Inclusion and Exclusion Criteria
All patients presenting within 6 hours of chest pain with an ECG fitting the criteria 
for thrombolysis were considered for inclusion into the study. Standard 
electrocardiographic criteria were adopted regarding eligibility for thrombolysis - 
ST elevation in 2 or more contiguous leads of > 1mm in the limb leads or >2mm in 
the chest leads or new left bundle branch block (LBBB) (Fibrinolytic Therapy 
Trialists, 1994). Exclusion criteria are listed in Table 2.1.
2.3.2 Study Design
All studies were performed in accordance with the Declaration of Helsinki. The 
Local Research & Ethics Committee at Stobhill Hospital agreed study design and 
protocol in December 1998. Written, informed consent was obtained from all 
patients after the study had been explained verbally and by a study information 
sheet. A protocol of investigation is outlined in table 2.2.
Table 2.2
79
Blood for 
markers of 
collagen 
turnover
Blood for
RAAS
effectors
Trans-thoracic
echocardiogram
12 lead ECG
On admission Yes Yes Yes
1 hour post 
thrombolysis
Yes
12 hours Yes
24 hours Yes Yes
Day 2 Yes
Day 3 Yes Yes
Day 4 Yes Yes
Day 30 Yes Yes
Legend Summary of protocol of investigation for Acute Myocardial 
Infarction Study
A cannula was inserted and sequential blood samples drawn at serial time points -  
on admission, at 12 hours, 24 horns, days 2, 3, 4 and 30. Venesection was 
performed with the patient in the recumbent position. lOmls o f blood for plasma 
markers of collagen turnover was collected in Lithium Heparin bottles and 
centrifuged at 3000rpm for 7 minutes. Plasma was distilled and decanted into
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ci-ystal tubes as three equal aliquots. Samples were labelled and frozen at -70  °C 
until use. Samples were not thawed and reffozen. A subgroup of patients had 
further samples collected in Lithium Heparin and EDTA tubes on admission and at 
day 3 for assessment of the effectors of the RAAS (additional lOmls of whole 
blood). These samples were prepared and stored as outlined above.
A 2 dimensional trans-thoracic echocardiogram with detailed Doppler studies was 
performed on day 4 or 5 following admission. Initially, the study design included 
an echo performed at day 30 to assess change in LV dimensions and function over 
this time period. However, this was abandoned for several reasons. Firstly, after 
seeking statistical advice, it was felt that in order to achieve adequate statistical 
power to detect change in measured parameters, the numbers of patients required 
would be so large as to make recruitment impractical. Secondly, many patients 
were reluctant to have a second echocardiogram performed at day 30, but were 
happy to have venesection at that time. Finally, although remodelling is defined as 
a change in LV shape, structure and function, the process can be detected early. It 
is well documented that a single echocardiographic study performed within a few 
days of infarction examining wall motion, LV volume and ejection fraction and 
Doppler interrogation of the mitral inflow identifies those in whom remodelling is 
already evident and therefore having the worst prognosis (Kitamura et al. 1973; 
Kan et al. 1986; White HD et al. 1987; Sutton et al. 1994; Kober L et al. 1994; 
Popovic et al. 1996; Migrino et al. 1997; Sutton et al. 1997; Cerisano G et al. 
1999).
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Patients were invited back 30 days following the index event for repeat blood 
sampling. 12 lead ECGs were performed on admission, 90 minutes following 
initiation of thrombolytic therapy, at 24 hours and on day 30.
2.3.3 Biochemical Method for Assav of Markers of Collagen Turnover
Methods for the assay of plasma TIMP-1, PICP and CITP are identical to those 
outlined in sections 2.2.3 a, b and c.
2.3.4 Assessment of Neurohormones
Patients recruited into the study from March 2000 till September 2001 were 
eligible for the neurohormonal sub-study. In addition to blood taken for assay of 
the above biochemical markers, a further lOmls of blood was venesected in these 
patients on admission and 72 hours post admission. Blood was collected in EDTA 
and Lithium heparin tubes, spun immediately at 3000rpm for 7 minutes and frozen 
at -70 °C until use. Assays for plasma renin and aldosterone estimation were 
performed by Dr Ian Morton at the Blood Pressure Unit, Western Infirmary, 
Glasgow, by standard ELISA technique.
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2.3.5 Echocardio graphv
(a) Data Acquisition and Storage
Detailed transtlioracic echocardiographic studies were performed with the patient 
in the left lateral position in a darkened room using a Vingmed System V 
Ultrasound Machine (General Electronics, Milwaukee, USA) connected to a 
PowerMacintosh G3 computer with digital archiving facilities. Patient archive 
information was stored on both the hard drive of the PowerMacintosh computer 
and optical disks. Unlike previous generations of ultrasound machines, which use 
a fixed output and receiving frequency in the mid-range, the System V 
incorporates secondary harmonic imaging technology using an output frequency 
of l.TmHz, receiving at 2 octaves higher via a phased array probe. As lower 
ultrasonic frequencies give better tissue penetration and higher frequencies 
provide improved image resolution, secondary harmonics allow superior imaging 
with enlianced resolution of the endocardial and epicardial borders, increasing the 
accuracy of wall motion scoring, volume assessment and calculation of ejection 
fraction.
Each examination was recorded onto Super VHS tape and images stored on digital 
optical disks. Acquisition of images was gated to EGG telemetry allowing storage 
of whole cardiac cycles and accurate correlation of single frames to phases of the 
cardiac cycle such as end-systole and end-diastole. Off-line analysis was 
performed using system specific software (EchoPAC) incorporating software for 
wall motion scoring and the assessment of left ventricular volumes and ejection
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fraction. Date of birth was used to code all echo examinations to enable blinding 
to patient history and biochemical results (which were coded by patient name)
(b) Wall Motion Scoring
(i) Method
Images were acquired in four standard views with the patient in the left lateral 
position at end-expiration - parasternal long axis, parasternal short axis at the level 
of the papillaiy muscles, apical 4 chamber and apical 2 chamber. Analysis was 
performed offline by a single observer (AMcG) blinded to the results of 
biochemical analyses. A sixteen segmental scoring system was employed in 
accordance with the American Society of Echocardiography guidelines (figure 
2.2) (Schiller et al. 1989). Each segment was visualised and given a score from 1 
-  5 depending on its movement (table 2.3). Eight segments are visualised in more 
than one view and the overall score for these segments is the mean of both scores. 
The sum of the scores from all segments were totalled and divided by sixteen 
giving a wall motion index. A score of 1 indicates normal movement of all 
segments, i.e. normal wall motion with no regional wall motion abnormality. A 
score of greater than one represents the presence of abnormal wall motion of one 
or more segments. The higher the score above one, the greater the degree of 
regional wall motion abnormality.
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Figure 2.2
Legend Graphical representation of 16 segmental scoring system 
for calculation of wall motion index
Table 2.3
Score Wall Motion
1 Normal wall motion
2 Hypokinesia
3 Akinesia
4 Dyskinesia
5 Aneurysmal
Legend Scoring system for wall motion
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(ii) Intra-operator Variability
Wall motion scoring was performed offline on twenty randomly selected studies 
on two separate occasion with the observer blinded to the previous score. 
Reproducibility was good with all segments in 17 studies being given the same 
wall motion score and a difference in scoring of one segment was seen in three 
studies, altering wall motion index by <10%. However, with regard to overall wall 
motion index, no patient with a normal index on one score was scored as 
abnormal, nor were any patients with abnormal index scored as normal.
(c) Left Ventricular Volume and Ejection Fraction
(i) Method
Standard apical two-dimensional 2 and 4 chamber images were obtained in the 
usual manner. A single operator blinded to biochemical results performed offline 
analysis. End diastole was identified from EGG gating, being defined as the onset 
of the R wave. End systole was identified from visual inspection, being defined as 
the smallest ventricular dimension in that cardiac cycle. Tracing of the endocardial 
contours in both diastole and systole was performed and LV volumes calculated 
from the disc summation method or Simpson’s rule (Schiller et al. 1979; Erbel et 
al. 1982). The mean of three cycles were calculated (avoiding extrasystolic or 
immediate post-extrasystolic beats) and normalised for body surface area, giving 
values for left ventricular end diastolic volume index (LVEDVI) and left 
ventricular end systolic volume index (LVESVI).
8 6
Ejection fraction was calculated as follows;
tLV end diastolic volume -  LV end systolic voluinel X 100 
LV end diastolic volume
This is a well validated method of calculating LV ejection fraction, giving similar 
results to radionuclide ventriculography and cineventriculography at cardiac 
catheterisation (Folland et al. 1979; Starling et al. 1981; Erbel et al. 1983).
(ii) Intra-operator Variability
Analysis of fifteen studies was repeated with no knowledge of previous results. 
Percentage differences in repeated measurement of EVDI and ESVI were <5%, 
corresponding to absolute differences of 2.1 and 1.5 ml/m^ respectively 
(correlation co-efficient 0.99 and 0.99). This is shown graphically in figures 2.3 
and 2.4. Correlation of repeated measurement of LV ejection fraction was 
excellent, with a correlation coefficient of 0.98 (figure 2.5 (a) and (b)).
Figure 2.3
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(d) Mitral Deceleration Time
Method
Pulsed wave Doppler signals were obtained through the tips of the mitral valve 
inflow in the apical four chamber view with the patient in the left lateral position 
at end-expiration. Three cai'diac cycles per study were acquired from patients in 
sinus rhythm. Those with atrial fibrillation were excluded. Offline analysis was 
performed by a single observer blinded to biochemical results, with measurement 
of mitral deceleration time (Dt) being performed on each cycle. Dt was measured 
as the time from the peak of the early mitral inflow (E-wave) to baseline (figure 
2.6). The mean of the three cycles was used for the purposes of analysis.
Figure 2.6
Ac
DT
Legend Diagrammatical representation of a Pulse Wave Doppler 
signal through the tips of the mitral valve leaflet.
91
(H) Intra-operator Variability
Analysis of fifteen studies was repeated with no knowledge of previous results. 
Differences in repeated measurement of Dt was <4% with excellent 
correspondence between measurements (correlation co-efficient 0.98) (figure 2.7
(a) and (b)).
2.3.6 Electrocardiographv
Standard 12 lead electrocardiograms were performed on admission on a 
Pagewriter XL A (Hewlett Packard, USA) to identify patients eligible for 
tlii’ombolysis using the standard criteria (Fibrinolytic Therapy Trialists, 1994). A 
further 12 lead ECG was obtained at 90 minutes post thrombolytic therapy for 
non-invasive assessment of reperfusion, using the criteria developed by Hogg et al 
- >50% reduction in ST segment elevation in one lead (Hogg KJ et al. 1988).
2.3.7 Mortalitv Data
Mortality data at six months was obtained from The Common Services Agency, 
Edinburgh. Although the study was not formally powered to assess relationship of 
the investigational variables to mortality, these data allow us to better assess the 
risk of the overall study group and to examine trends in mortality. Cause of death 
was not ascertained.
Figure 2.7
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2.3,8 Statistical Analysis
(a) Power Calculation
Dr David Young, Lecturer at the Robertson Centre for Biostatistics, University of 
Glasgow, provided a power calculation for this study. It was based on a pilot study 
of 18 patients with ST elevation MI and was calculated from the mean and 
standard deviation of plasma values of TIMP-1, PICP and CITP in this group 
compared to the mean and standard deviation in a normal population (table 2.4). 
The larger of the standard deviations was used as the common one for both 
groups, giving a more conservative sample size. Given the large differences 
between group means in the pilot study, recruitment of only 8 patients would give 
a 95% power to detect a difference in TIMP-1 of 974ng/ml using a two group t- 
test with a 0.05 two sided significance test. With regard to CITP, 24 patients 
would be required to have a similar power to detect a 2.09ng/ml difference. Given 
the marked heterogeneity in the levels of plasma PICP in the pilot group, the 
standard deviation for this group was high. As we had elected to use the higher of 
the standard deviations as the common one, 93 patients would be required to 
detect a difference of 44ng/ml with 95% power. It was therefore elected to reduce 
power to 90%, requiring 64 patients to be recruited.
No published data aie available for correlation of these markers with 
echocardiographic parameters of remodelling. We wished to dichotomise patients 
into two groups -  those with evidence of remodelling and those with no evidence
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of remodelling. The power calculation was based on a pilot study of patients with 
echocardiographic evidence of remodelling and it was decided that recruitment 
should continue until at least this number had adequate echo studies indicative of 
remodelling, allowing adequate comparisons between the groups. However, it was 
felt that recruitment of this number of patients for this study was unrealistic, so 
recruitment continued until at least 24 patients (sufficient for comparison of 
TIMP-1 and CITP) had adequate echo studies demonstrating evidence of early 
remodelling.
(b) Analysis of Results
As previously stated, statistical analyses were performed using Minitab statistical 
software (Minitab Inc, Pennsylvania, USA). Methods of analysis were discussed 
with Dr Young. All continuous variables are expressed as mean +/- one standard 
error of the mean. Two of the three biochemical variables were not normally 
distributed so log transformation was performed to allow parametric statistical 
testing methods. Repeated measurements were tested by repeated measurement of 
analysis of variance. Student’s t test was used for comparison of means. Multiple 
regression models were constructed using Minitab. A p value of <0.05 was 
considered significant.
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Table 2.4
TIMP-1
Test significance level 0.050 0.050 0.050 0.050
1 or 2 sided test? 2 2 2 2
Group 1 mean 2150 2150 2150 2150
Group 2 mean 202 202 202 202
Difference in means 1948 1948 1948 1948
Common standard deviation 974 974 974 974
Effect size 2 2 2 2
Power (%) 80 90 95 99
Number required 6 7 8 11
CITP
Test significance level 0.050 0.050 0.050 0.0501 or 2 sided test? 2 2 2 2
Group 1 mean 4.69 4.69 4.69 4.69
Group 2 mean 2.6 2.6 2.6 2.6
Difference in means 2.09 2.09 2.09 2.09
Common standard deviation 1.36 1.36 1.36 1.36Effect size 1.54 1.54 1.54 1.54Power (%) 80 90 95 99
Number required 14 19 24 34
PICP
Test significance level 0.050 0.050 0.050 0.050
1 or 2 sided test? 2 2 2 2
Group 1 mean 173 173 173 173Group 2 mean 129 129 129 129Difference in means 44 44 44 44
Common standard deviation 59.8 59.8 59.8 59.8Effect size 0.736 0.736 0.736 0.736Power (%) 80 90 95 99Number required 54 64 93 133
Legend Power calculation for TIMP-1, CITP and PICP for Acute 
MI study.
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2.4 Non ST Elevation Acute Coronary Syndrome Study (Chapter 6)
2.4.1 Study Population
Once again, the Coronary Care Unit at Stobhill Hospital was used to identify 
patients appropriate for the study. Recruitment took place from August 1999 till 
December 2000 (figure 2.1). Those presenting with a history suggestive of an 
acute coronary syndrome without ST elevation on a 12 lead ECG were considered 
for the study. For inclusion, pain had to be typical of myocardial ischaemia and 
occur at rest or on minimal exercise and be present for at least 20 minutes. 
Furthermore, presentation had to be within 6 hours of the onset of pain. Patients 
with ECG fitting the criteria for reperfusion therapy were excluded. Exclusion 
criteria are listed in table 2.1 and include factors influencing collagen metabolism 
and elimination o f plasma propeptides. In addition, patients with bundle branch 
block on ECG, concurrent digoxin therapy or permanent pacemaker in situ were 
excluded due to difficulty in interpreting the ST/T segments of a 12 lead 
electrocardiogram.
2.4.2 Study Design
The Local Research & Ethics Committee at Stobhill Hospital agreed study design 
and protocol in December 1998. Written, informed consent was obtained from all 
patients after the study had been explained verbally and by a study information 
sheet. A protocol of investigation is outlined in table 2.5.
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A cannula was inserted and sequential blood samples drawn at serial time points 
with the patient in the recumbent position -  on admission, at 12 hours, 24 hours, 
and 48 hours. lOmls of blood for plasma markers of collagen turnover was 
collected in Lithium Heparin bottles and centrifuged at 3000rpm for 7 minutes. A 
further 7mls of blood for assessment of troponin 1 was venesected at 12 hours 
following admission and collected in SST tubes. Plasma was distilled and 
decanted into crystal tubes and frozen at -70 °C until use.
12 lead electrocardiograms were performed on admission and at 24 hours. Further 
ECGs were performed if the patient developed further pain.
Table 2.5
Blood for 
markers of 
collagen 
turnover
Blood for 
troponin I
12 lead ECG
On admission Yes Yes
12 hours Yes Yes
24 hours Yes Yes
48 hours Yes
During pain Yes
Legend Summary of protocol of investigation for non ST elevation 
ACS study
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2-4.3 Biochemical Analyses of Markers of Collagen Turnover
Plasma PICP, CITP and TlMP-1 were measured according to the methods outlined 
in sections 2.2.3a, 2.2.3b and 2.2.3c.
2.4.4 Risk Stratification
(a) Definition
Patients were dichotomised into high and low-risk groups based on ECG criteria 
and measurement of plasma Troponin 1. High-risk was defined as the presence of 
dynamic ST depression/sequential T wave changes and/or Troponin I >0.4ng/ml at 
12 hours post admission. Low-risk was defined as the absence of ECG changes 
and a negative Troponin.
(b) Electrocardiography
Standard 12 lead electrocardiograms performed on a Pagewriter XLA (Hewlett 
Packard, USA) were used to aid risk stratification in this group of patients with 
unstable coronary syndromes. ECGs were performed on admission, at 24 hours 
and during pain to assess ST segment deviation and T wave morphology. ST 
depression was defined as planar or down-sloping ST depression of 0.5mV, 80ms
after the J point in two or more contiguous leads which was not there on prior
ECGs (if available). Up-sloping ST depression was discounted. Sequential ECG
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changes were defined as new biphasic T waves or T wave inversion in two or 
more contiguous leads on ECGs performed subsequent to admission.
(c) Troponin I
A Microparticle Enzyme Immunoassay technique (MEIA) was used for the 
quantitative determination of cardiac troponin I in the plasma using a 
commercially available reagent pack (troponin I No 3C29-66, Abbott 
Laboratories, Illinois, USA) and an automated assay system subject to external 
quality control (AxSYM System, Abbott Laboratories, Illinois, USA).
Standards and diluted plasma (100 microlitres) were combined with microparticles 
coated with murine monoclonal antibody to troponin I (anti-troponin I) at room 
temperature. The troponin I in the sample binds to the microparticles forming an 
antigen-antibody complex. An aliquot of the sample/microparticle mixture is 
transferred to a glass fibre matrix cell where the microparticles bind irreversibly. 
Conjugated goat anti-troponin antibody is then added, binding the troponin I of the 
antigen-antibody complex, forming an antibody-antigen-antibody complex. After 
incubation and washing with buffer solution, 4-Methylumbelliferyl phosphate is 
added and the fluorescent product formed measured by the optical assembly. The 
rate of the fluorescent product is directly proportional to the amount of troponin I 
in the investigational sample and is read from a standard calibration curve 
generated by analysis of six known troponin I concentrations.
1 0 0
Based on data from Abbott Laboratories and the 95 '^' percentile values from
population studies, the expected values for normal healthy individuals is
<0.4ng/ml. In the study, values ahove 0.4ng/ml were considered to represent 
myocardial muscle damage.
2.4.5 Mortalitv Data
As with the ST elevation MI study, this study was not formally powered to assess 
relationship of the investigational variables to mortality, but the mortality data at 
SIX months obtained from The Common Services Agency, allows examination of 
trends. Cause of death was not ascertained.
2.4.6 Statistical Analvsis
(a) Power Calculation
Di Young assisted with a power calculation based on a pilot study of 15 patients 
with unstable angina -  eight high risk, seven low risk (table 2.6). Recruitment of 
52 patients would give a 90% power to detect a difference in plasma CITP 
between the groups of 0.95ng/ml assuming a common standard deviation of 1.5, 
using a two group t-test with a two sided significance test. With regard to PICP, 
136 patients would be required to have a similar power to detect a 23.2ng/ml 
difference in means using the same analysis. Given the difficulty in recruiting such 
numbers, it was decided to recruit 52 patients for this study. Only 33 patients had
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samples taken for TIMP-1 analysis, giving a 90% power to detect a difference 
between the groups of 91.4 ng/ml.
(b) Analysis of Results
Due to the lack of normality of distribution of the biochemical variables, log 
transformation was performed prior to parametric statistical analysis. All 
continuous variables are expressed as mean +/- one standard error of the mean. 
Repeated measurement of analysis of variance was employed for changes over 
time. Student’s t test was used for comparison of means. A p value of <0.05 was 
considered significant.
1 0 2
Table 2.6
TIMP-1
Test significance level 0.050 0.050 0.050 0.050
1 or 2 sided test? 2 2 2 2
Group 1 mean 362 362 362 362
Group 2 mean 270.6 270.6 270.6 270.6
Difference in means 91.4 91.4 91.4 91.4
Common standard deviation 110 110 110 110
Effect size 0.831 0.831 0.831 0.831
Power (%) 80 90 95 99
Number required 24 32 39 55
CITP
Test significance level 0.050 0.050 0.050 0.050
1 or 2 sided test? 2 2 2 2
Group 1 mean 4.5 4.5 4.5 4.5
Group 2 mean 3.55 3.55 3.55 3.55
Difference in means 0.95 0.95 0.95 0.95
Common standard deviation 1.5 1.5 1.5 1.5
Effect size 0.633 0.633 0.633 0.633
Power (%) 80 90 95 99
Number required 41 52 66 93
PICP
Test significance level 0.050 0.050 0.050 0.050
1 or 2 sided test? 2 2 2 2
Group 1 mean 146.7 146.7 146.7 146.7
Group 2 mean 169.9 169.9 169.9 169.9
Difference in means -23.2 -23,2 -23.2 -23.2
Common standard deviation 58.8 58.8 58.8 58.8
Effect size 0.395 0.395 0.395 0.395
Power (%) 80 90 95 99
Number required 102 136 168 238
Legend - Power calculation for CITP, PICP and TIMP-1 for 
non-ST elevation ACS study.
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2.5 Percutaneous Transluminal Coronary Angioplasty Study (Chapter 7)
2.5.1 Study Population
Patients undergoing elective percutaneous transluminal coronary angioplasty 
(PTCA) at Glasgow Royal Infirmary were eligible for inclusion into this study 
which was performed from May 2000 till December 2001 (figure 2.1). Only those 
patients undergoing percutaneous coronary intervention to a single coronary artery 
were recruited to the study. Exclusion criteria included those listed in table 2.1 and 
patients in whom interpretation of ST/T segments of the 12 lead electrocardiogram 
would be difficult -  those with permanent pacemaker systems, LBBB or 
concurrent digoxin therapy. All patients were ACE inhibitor naive. All studies 
were performed on a Phillips Integris H3000 system (Phillips, Rotterdam, 
Holland).
To correct for possible changes in biochemical markers seen due to either catheter 
manipulation within the vasculature and coronary ostia or to the effects of intra­
coronary contrast injection, a cohort of patients undergoing elective diagnostic 
coronary angiography was recruited during the same time period as a control 
group.
2.5.2 Study Design
Study design and protocol was passed by The Local Research & Ethics Committee 
at Stobhill Hospital in September 1999. Written, informed consent was obtained
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from all patients after the study had been explained verbally and by a study 
information sheet. A protocol of investigation is outlined in table 2.7.
Sequential blood samples were obtained at serial time points with the patient in the 
recumbent position. Patients undergoing PTCA had blood drawn at eight time 
points - prior to the procedure, 1 minute following first balloon inflation, at the 
end of the procedure, then 4, 8 and 16 hours post procedure. Due to the fact 
diagnostic coronary angiography is performed as a day case, the control group had 
samples taken on only three occasions -  prior to angiogram, immediately at the 
end of the test and at 4 hours post procedure. A further 7mls of blood for 
assessment of troponin I was venesected at 16 hours following admission. All 
samples were collected in Lithium Heparin tubes and centrifuged at SOOOrpm for 7 
minutes. Plasma was distilled and decanted into crystal tubes and frozen at -70 °C 
until use.
Table 2.7
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PTCA Angiography
Bloods for plasma 
markers of collagen 
turnover
Blood for
troponin
I
ECG Bloods for plasma 
markers of collagen 
turnover
Pre­
procedure Yes Yes Yes
During
pain/ECG
changes
Yes
Post balloon 
inflation Yes
End of 
procedure Yes Yes
4hrs Yes Yes
8hrs Yes
16hrs Yes Yes
Legend Protocol of investigation for PTCA study.
2.5.3 Biochemical Analyses of Markers of Collagen Turnover
Plasma PICP and CITP were measured according to the methods outlined in 
sections 2.2.3b and 2.2.3c. TIMP-1 could not be measured due to problems with 
the TIMP assay as discussed in Chapter 3.
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^'5-4 Assessment of Periprocedural Ischaemia
(a) Electrocardiography
All patients undergoing PTCA had 12 lead electrocardiograms performed prior to 
the procedui'e using a Pagewriter XLA (Hewlett Packard, USA). Continuous EGG 
monitoring was performed in the cardiac catheterisation laboratory and was 
analysed for ST segment fluctuation using a Siemens EGG monitoring system 
(Siemens, Stockholm, Sweden). Correlation with symptoms of chest pain was 
documented. Transient ST segment elevation or depression during balloon 
inflation was taken as electrocardiographic evidence of induced ischaemia.
(b) Troponin I
In 2001, a standardised assay for troponin I was introduced across all sites in 
North Glasgow University NHS Trust. Quantification of plasma troponin I in the 
PTCA study was performed using this new assay and the method is therefore 
different from that outlined in section 2.3.4(b). This assay, AD VIA Centaur cTnl 
(Bayer Corporation, New York, USA), is automated and used in routine clinical 
practice. It is subject to external quality control. It is a two-site sandwich 
immunoassay using direct chemiluminometric technology.
An aliquot o f 100 microlitres o f investigational agent is mixed with 100 
microlitres of reagent containing polyclonal goat antibody to troponin I, labelled 
with acridinium ester. Following incubation at 37°C for 2.5minutes, the second
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antibody is added (monoclonal murine anti-troponin I). Acid and base reagents are 
added initiating chemiluminescent reaction. A photometric system is employed to 
assess the amount of relative light units (RLUs), the amount of which is directly 
proportional to the amount of troponin I in the investigational sample. Calibration 
is carried out on a regular basis using known controlled concentrations of troponin 
I.
Based on data supplied the company, the minimum detectable concentration is 
O.Olng/ml. The between run standard deviation was 0.02ng/ml on average with a 
95% confidence interval of 0.07ng/ml. The 99*’’ percentile for normal volunteers is 
0.07ng/ml and levels above this in the study were considered positive for 
myocardial damage.
2.5.5 Statistical Analvsis
(a) Power calculation
The main outcome for this study was change in plasma markers of collagen 
turnover following controlled occlusion of a coronary artery during balloon 
inflation. Therefore, power calculation was performed using the mean values in a 
normal population as a baseline, but using standard deviations observed in the 
pilot study from the non ST elevation acute coronary syndrome population. We 
felt it more appropriate to use the standard deviation from this group rather than 
that of a normal population as we hypothesised that these patients would behave 
more like the acute coronary syndrome group due to the ischaemic stimulus of
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balloon inflation. Recruitment of 14 patients undergoing elective PTCA would
give a 90% power to detect a rise in CITP from baseline of 25% and a 90% power
to detect a 50% rise in PICP, assuming a standard deviation of 1.5 and 58.8
respectively, using a two group t-test with a 0.05 two sided significance test (table 
2.8).
Table 2.8
CITP
Test significance level 
1 or 2 sided test?
First condition mean 
Second condition mean 
Mean difference
Standard deviation of differences 
Effect size 
Power (%)
N
10% 25% 50% 75%
0.050 0.050 0.050 0.0502 2 2 2
3.2 3.2 3.2 3.2
3.52 4.0 4.8 5.6
-0.32 -1.2 -1.6 -2.41.5 1.5 1.5 1.50.21 0.8 1.1 1.6
90 90 90 9088 14 6 4
PICP
Test significance level 
1 or 2 sided test?
First condition mean 
Second condition mean 
Mean difference
Standard deviation of differences 
Effect size 
Power (%)
N
10% 25% 50% 75%
0.050 0.050 0.050 0.0502 2 2 2
193 193 193 193
212.3 241.2 289.5 337.8
-19.3 -48.2 -96.5 -142.858.8 58.8 58.8 58.8
0.33 0.82 1.64 2.43
90 90 90 90
165 69 13 3
Legend Power calculation for CITP and PICP for PTCA study.
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(b) Analysis of Results
All continuous variables are expressed as mean +/- one standard error of the mean. 
Log transformation allowed parametric testing. Results are expressed as absolute 
values and percentage change from baseline. Repeated measurement of analysis of 
variance was performed to detect a change of variables over time and, if 
significant, Student’s t test was used for direct comparison of means between the 
two groups. A p value of <0.05 was considered significant.
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CHAPTER THREE -  VALIDATION OF BIOCHEMICAL ASSAYS 
OF COLLAGEN TURNOVER
3.1 Introduction
As discussed in chapter one, plasma markers of collagen turnover may be useful in 
the monitoring of the remodelling process following ischaemic events. Type I 
fibrillar collagen is the predominant collagen type within the heart and therefore, 
markers of synthesis and degradation of this collagen type were used in all of my 
studies (Frank and Langer, 1974; Weber KT, 1989). C-propeptide for type I 
collagen (PICP) is cleaved from pro-collagen allowing integration of the collagen 
helix into the growing fibril and is therefore a marker of synthesis (Melkko JT et 
al. 1990; Nimni ME, 1993). Similarly, C-telopeptide for type I collagen (CITP) is 
cleaved during collagen breakdown and is an indicator of degradation (Risteli J et 
al. 1993; Risteli J and Risteli L, 1995b). Tissue Inhibitor of Matrix 
Metalloproteinase-I (TIMP-I) is a marker of inhibition of collagen degradation due 
to its inhibitoi-y action on the powerful family of proteolytic enzymes, the matrix 
metalloproteinases (Matrisian LM, 1990).
The radioimmunoassays for PICP and CITP have been used in the setting of 
metabolic and metastatic bone disease for more than 10 years, mainly at an 
experimental level (Azria, 1989; Charles et al. 1994; Hosoya et al. 1997). 
However, only limited data are available in other populations. In addition, given 
the longitudinal nature of my studies, repeated measurements of plasma PICP and 
CITP are required. It is therefore essential that the assay methods are reliable and
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robust with accurate reproducibility and good quality control. Similar 
characteristics are necessary for the ELISA assay for plasma TIMP-1. Indeed, few 
studies using plasma TIMP-1 in any population exist and subsequently, less 
information on quality control and reproducibility is known regarding this assay.
We sought to determine the intra and inter assay variablities of the three assays to 
assess whether the quality control would be adequate for repeated measurement 
for each test in a longitudinal study. Additionally, we aimed to characterise plasma 
levels of TIMP-1, PICP and CITP in a normal population drawn from the 
surroimding district of a similar age and sex distribution to the study populations. 
From this, a normal range and mean can be calculated for a local normal 
population. Finally, we wished to examine the within individual variability of 
plasma level of all three markers, to exclude variation of a diurnal nature. All 
analyses were performed on plasma samples rather than on serum due to the 
increased accuracy and reliability of measurement in plasma (Lein et al. 1997; 
Jung, 1997).
However following the replacement of the antibody to TIMP-1 in assay RPN2611 
by Amersham in December 1999, further studies were required for validation of 
the new Amersham TIMP-1 assay. Although the company provided data showing 
apparent similar curve shape and sensitivity and no change to assay recovery or 
linearity, absolute values for TIMP-1 were several times higher with the new 
assay. Amersham stated a correlation between the assays of 0.88 on 16 samples, of 
which only four were from samples collected in Lithium Heparin tubes. The 
company provided a correction factor from a regression equation to allow
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comparison between the assays. We therefore felt that additional experiments for 
quality control purposes were necessary. To this end, we wished to examine 
variability between the two assays for plasma TIMP-1. However, given the 
concerns regarding the apparent discrepancies between the two kits, alternative 
assays for TIMP-1 were considered. The original kit from Amersham was based 
on an assay developed by Professor Tim Cawston’s group in Newcastle. He had 
the original cell line and supplied us with the same monoclonal antibody to TIMP- 
1 used in the kit from Amersham. We therefore decided to compare the new assay 
from Newcastle with the original Amersham kit.
3.2 Methods
3.2.1 Assav Variability
Samples were randomly selected from a mixed patient population for the 
assessment of intra-assay and inter-assay variability. This included samples drawn 
from patients with hypertension, post myocardial infarction and liver disease in 
addition to samples from a normal population to allow assessment of variability 
across a wide range of absolute values for each of plasma TIMP-1, PICP and 
CITP. Assay methods for the three substances are outlined in Chapter 2, section
2.2.3 (a), (b) and (c).
Intra-assay variability was performed by repeated measurement of samples using 
the same assay kit. 30 samples were used for plasma TIMP-1, 20 each for PICP 
and CITP. Inter-assay vai'iability was performed by measurement of samples on
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two separate occasions using different assay kits. 15 samples were used for TIMP- 
1, 20 for PICP and CITP. A mean of the two values was calculated for each 
sample and differences expressed as absolute and percentage differences of the 
mean. Results for PICP and TIMP-1 were not normally distributed, so were log 
transformed prior to statistical comparison between groups using Student’s t test. 
Correlation co-efficient was also calculated, A p value of <0.05 was considered 
significant. Data are presented in the non-logarithmic format.
The two kits from Amersham were compared by measuring plasma TIMP-1 on 20 
randomly selected plasma samples from a mixed population. The Newcastle assay 
for TIMP-1 was compared with the old Amersham kit on 40 samples across a 
range of patient groups and a range of levels. The methodology for the Newcastle 
assay for TIMP-1 is identical to that outlined in Chapter 2, section 2.1.3(a) with 
one exception. In the Amersham assay, horseradish peroxidase is directly bound 
to the second antibody, but in the Newcastle assay, the peroxidase is bound to 
streptavadin and is added to biotin bound second antibody. There is therefore one 
additional step in this method.
3.2.2 Normal Ranges
A local newspaper, the Kirkintilloch Herald, ran an article on cardiac research at 
Stobhill Hospital in early 1999 and repeated in early 2001 calling for help with 
ongoing studies from healthy volunteers in the surrounding area. The response 
from the public was excellent and 20 volunteers agreed to have blood venesected 
for assay o f TIMP-1, PICP and CITP. These volunteers had no past medical
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history of note and were not on any cardiac medication. They were of a similar age 
and sex distribution to the ST elevation MI study to reduce the influence of age 
and sex when comparing results.
3.2.3 Intra-individual Variability
The variability of plasma level of PICP and CITP within healthy individuals was 
examined by performing assays on blood drawn on two separate occasions. Ten 
people volunteered for this study from a mixture of staff from the Biochemistry 
and Cai'diology Departments and members of the public. A mean of the two values 
was calculated for each sample and differences expressed as absolute and 
percentage differences of this mean. Statistical comparison was performed using 
Student’s t-test following log transformation, and correlation co-efficient 
calculated.
3.3 Results
3.3.1 Assav Variabilitv
Absolute and percentage differences between results were calculated for both the 
within and between assay studies and results expressed as percentage difference 
from mean with 95% confidence intervals. Each result is also shovm in graphical 
form in a scatter plot for correlation and in the form of a Bland-Altman graph.
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Intra-assay variability for plasma TIMP-1 was 4% (95% Cl 3.23 -  4.87) with a 
correlation co-efficient of 0.99. Raw data are shown in table 3.1 and correlation 
demonstrated in figure 3.1 (a & b). Inter-assay variability was 4.4% (95% Cl 3.36 
-  5.46) with a correlation co-efficient of 0.99 and is demonstrated in figure 3.2 (a 
& b). Absolute values shown in table 3.2. Linearity was demonstrated to 900 
ng/ml. No statistically significant differences in means were noted using Student’s 
t-test.
Table 3.1
TIMP-I sam plel TIMP-1 sa m p le l Average
absolute
difference % difference
213 205 209 8 3.8
118 125 121 7 5.8
146 152 149 6 4.0
108 115 111.5 7 6.3
241 256 248 15 6.0
121 126 123.5 5 4.0
182 183 182.5 1 0.5
162 168 165 6 3.6
129 117 123 12 9.8
110 118 114 8 7.0
152 158 155 6 3.9
102 103 102.5 1 1.0
286 296 291 10 3.4
126 121 123.5 5 4.0
364 356 360 8 2.2
764 774 769 10 1.3
243 250 246.5 7 2.8
114 122 118 8 6.8
186 194 190 8 4.2
110 110 110 0 0.0
165 170 167.5 5 3.0
250 263 256.5 13 5.1
158 147 152.5 11 7.2
133 139 136 6 4.4
107 111 109 4 3.7
111 117 114 6 5.3
135 146 140.5 11 7.8
102 104 103 2 1.9
248 257 252.5 9 3.6
146 153 149.5 7 4.7
Mean 7.3ng/ml 4%
Legend - Intra-assay variability for plasma TIMP-1. Absolute and 
percentage differences between values are also shown.
Figure 3.1
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Table 3.2
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TIMP-1
Assavl TIMP-1
A ssay2 A verage A bsolute
difference
% difference
731 714 722.5 17 2.4
623 629 626 6 1.0
572 547 559.5 25 4.5
826 783 804.5 43 5.3
153 165 159 12 7.5
191 203 197 12 6.1
128 136 132 8 6.1
107 109 108 2 1.9
194 202 198 8 4.0
136 145 140.5 9 6.4123 131 127 8 6.3
146 141 143.5 5 3.5
367 356 361.5 11 3.0
308 323 315.5 15 4.8
Mean
12.7ng/ml 4.4%
Legend Inter-assay variability for plasma TIMP-1. Absolute and
percentage differences between values are also shown.
Figure 3.2
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With regard to PICP, we demonstrated linearity to 300 nanogrammes/ml with intra 
and inter assay variabilities of 3.1% (95% Cl 1.9 -  4.38) and 6.9% (95% Cl 4.82 
-9 .1 4 ) respectively. The lower limit of detection was 12ng/ml. The correlation co­
efficient was 0.99 for intra-assay variability (table 3.3 & figure 3.3 (a & b)). 
Correlation co-efficient was 0.94 for inter-assay variability and is demonstrated in 
figure 3.4 (a & b) with absolute values shown in table 3.4. There were no 
statistically significant differences noted using students t-test analysis of the 
means.
T able 3.3
sam ple 1 sam ple 2 Average
absolute
difference % difference
124 127 125.5 3.0 2.4
104 104 104.0 0.0 0.0
112 116 114.0 4.0 3.5
157 159 158.0 2.0 1.3
113 118 115.5 5.0 4.3
112 103 107.5 9.0 8.4
200 191 195.5 9.0 4.6
143 148 145.5 5.0 3.4
217 206 211.5 11.0 5.2
145 144 144.5 1.0 0.7
101 99 100.0 2.0 2.0
288 291 299.0 3.0 0.7
108 110 109.0 2.0 1.8
118 119 118.5 1.0 0.8
130 144 137.0 14.0 10.2
106 105 105.7 1 0.9
161 155 158.0 6.0 3.8
159 162 160.5 3.0 1.9
232 240 236.0 8.0 3.4
133 127 130.0 6.0 4.6
M ean 4.6ng/ml 3.1%
Legend - Intra-assay variability for plasm a PICP com paring sam ple  
one and two. A bsolute and percentage differences between values are also shown.
Figure 3.3
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Table 3.4
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PICP A ssay 1 PICP A ssay 2 Average
Absolute
difference
%
difference160 138 149 22 14.8242 222 232 20 8.6163 183 173 20 11.6165 178 171.5 13 7.6205 192 198.5 13 6.564 59 61.5 5 8.1156 154 155 2 1.3235 237 236 1 0.5125 128 126.5 3 2.4137 128 132.5 9 6.895 88 91.5 7 7.7106 122 114 16 14140 135 137.5 5 3.8200 240 220 40 18150 157 153.5 7 4.6302 312 307 10 3.3114 120 117 6 5.1154 149 151.5 5 3.3125 118 121.5 7 5.8126 119 122.5 7 5.7Mean 10.9ng/ml 6.9%
Legend - Inter-assay variability for plasma PICP comparing assay 
one and two. Absolute and percentage differences between values are also shown.
Figure 3.4
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Intra and inter assay variabilities for plasma CITP were 3.7% (95% Cl 2 -  5.4) and 
6.4% (95% Cl 4.5 -  8.3) respectively. Correlation co-efficients were 0.98 and 
0.99, Intra-assay variability is demonstrated in figure 3.5 (a & b) with raw data in 
table 3.5. Figui*e 3.6 and table 3.6 show data for inter-assay variability. Again, no 
statistically significant differences were demonstrated using students t-test analysis 
of the means.
Table 3.5
CITP 
sam ple 1
CITP
sam ple2 Average
absolute
difference % difference
5.7 5.8 5.75 0.1 1.7
5.6 5.8 5.70 0.1 1.8
3.4 3.4 3.40 0.0 0.0
6.1 5.6 5.85 0.5 8.5
8.9 8.9 8.90 0.0 0.0
3.9 3.8 3.85 0.1 2.6
4.7 4.9 4.80 0.2 4.2
3.6 3.7 3.65 0.1 3.5
4.2 4.8 4.50 0.6 13.2
4.2 4.0 4.10 0.2 4.2
2.4 2.4 2.40 0.0 0.0
4.9 5.0 4.95 0.1 2.0
3.5 3.2 3.35 0.3 9.5
7.6 7.3 6.45 0.3 4.3
3.1 3.0 3.05 0.1 3.2
4.6 4.6 4.60 0.0 0.0
4.4 4.4 4.40 0.0 0.0
5.3 5.0 5.15 0.3 5.2
5.9 5.8 5.85 0.1 1.4
Mean 0.17ng/ml 3.7%
Legend - Intra-assay variability for plasma CITP comparing sample 
one and two. Absolute and percentage differences between values are also shown.
Figure 3.5
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CITP
A ssayl
CITP
A ssay2 Average
Absolute
difference % difference
2.8 2.9 2.85 0.1 3.5
3.4 3.7 3.55 0.3 8.5
3.5 3 3.25 0.5 15.4
3.7 3.4 3.55 0.3 8.5
2.7 2.7 2.7 0 0
5.1 5.6 5.35 0.5 9
4.8 4.9 4.85 0.1 2.1
6.5 7.4 6.95 0.9 12.9
2.9 3.2 3.05 0.3 9.8
3.2 3.5 3.35 0.3 9
9.3 10 9.65 0.7 7.25
10.7 11.5 11.1 0.8 7.2
4.2 4.5 4.35 0.3 6.9
6.6 7 6.8 0.4 5.9
5.4 5.5 5.45 0.1 1.8
2.4 2.5 2.45 0.1 4.1
3.2 3.1 3.15 0.1 3.2
4.7 5.1 4.9 0.4 8.2
4.6 4.8 4.7 0.2 4.3
M ean 0.32 ng/ml 6.4%
Legend - Inter-assay variability for plasma CITP comparing assay 
one and two. Absolute and percentage differences between values are also shown.
Figure 3.6
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There was no significant correlation between the two Amersham assays for TIMP- 
1 (original and revised). We confirmed that absolute values were much higher 
with the revised assay with a large within assay variability. With regard to the 
Newcastle assay, there was a correlation between it and the original Amersham 
assay with a correlation coefficient of 0.77. Although some values were very 
similar using the two kits, the two assays varied by as much as 125% in some 
patients. Correlation and variability are demonstrated in figure 3.7 a & b 
respectively with raw data in table 3.7. The differences were significant using 
students t-test analysis, p<0.0001. Therefore, only the Amersham assay was used 
in any of the studies.
Table 3.7
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Diagnostic group Amersham Newcastle Absolute difference % difference
Hypertension 266 410 144 42.6
Hypertension 160 410 250 87.7
Hypertension 176 310 134 55.1
Hypertension 165 580 415 111.4
Hypertension 265 1150 885 125.1
MI 2160 2100 -60 -2.8
MI 1894 1840 -54 -2.9
MI 475 460 -15 -3.2
MI 688 800 112 15.1
MI 714 860 146 18.5
MI 549 550 1 0.2
MI 787 780 -7 -0.9
MI 924 760 -164 -19.5
MI 1092 790 -302 -32.1
MI 1841 4548 2707 120.3
MI 522 740 218 34.5
MI 2841 3260 419 13.7
MI 1117 1980 863 55.7
MI 517 650 133 22.8
MI 1497 2010 513 29.2
MI 1007 2820 1813 94.7
MI 903 3010 2107 107.7
MI 564 500 -64 -12
MI 1548 1220 -328 -23.7
MI 774 610 -164 -23.7
MI 223 430 207 63.4
NORMAL 300 370 70 20.9
NORMAL 225 260 35 14.4
NORMAL 130 400 270 101.9
NORMAL 603 750 147 21.7
NORMAL 242 470 228 64
NORMAL 334 300 -34 -10.7
NORMAL 210 290 80 32
NORMAL 210 230 20 9.1
NORMAL 180 250 70 32.6
NORMAL 237 300 63 23.5
NORMAL 272 340 68 22.2
NORMAL 268 340 72 23.7
NORMAL 666 2370 1704 95
NORMAL 178 570 392 104.9
Mean 386ng/ml 42.4%
Legend - Comparison of Amersham and Newcastle assays for plasma 
TIMP-1 with absolute and percentage differences illustrated.
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3.3.2 Normal Ranges
20 volunteers donated blood for assay of plasma TIMP-1, PICP and CITP. Results 
are expressed as mean for the group +/- 1 standard deviation with 95% confidence 
intervals. The group consisted of 15 men and 5 women with a mean age of 59 
years (range 36-86). All tliree assay results were normally distributed. Mean 
plasma TIMP-1 in this cohort was 202 ng/ml +/- 22 (95% Cl 1 8 9 -2 1 5 ) with a 
range from 164 to 267ng/ml. Normal range for plasma PICP was 80 to 207 ng/ml 
with a mean of 129 +/- 32 (95% Cl 114 -  143). Mean plasma CITP was 2.6ng/ml 
+/- 0.3 (95% Cl 2.4 -  2.8) with a range from 1.9 -  3.9, These values are expressed 
in tabular form in table 3.8.
Table 3.8
Mean SD 95% Cl Minimum Maximum
TIMP-1 202 22 189-215 164 267
PICP 129 32 114-143 80 207
CITP 2.6 0.3 2 .4 -2 .8 1.9 3.9
Legend - Normal mean with standard deviation and range of plasma 
TIMP-1, PICP and CITP in a group of 20 healthy volunteers.
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3.3.3 Intra-individual Vaiiabilitv
10 people volunteered to have blood sampled on two occasions at different times 
of the day. Again results are expressed as percentage difference from mean with 
95% confidence intervals. The within individual variability for plasma PICP was 
6.1% (95% Cl 3.9 -  8.3) with a correlation coefficient o f 0.95. This is 
demonstrated in table 3.9 and figure 3.8 (a & b). The mean intra-individual 
variability for plasma CITP was 4.8% (95% Cl 2.2 -  7.4) with a correlation 
coefficient of 0.98 (see table 3.10 and figure 3.9 (a & b)). The differences in mean 
values for the two samples were not statistically significant. Intra-individual assay 
was not performed for TIMP-1 as these studies were performed after the 
discontinuation of the Amersham assay.
Table 3.9
Sample 1 Sam ple 2 Mean
Absolute
difference % difference
132 133 132.5 1 0.8
142 132 137 10 7.3
113 106 109.5 7 6.4
123 115 119 8 6.7
154 140 147 14 9.5
120 114 117 6 5.1
104 97 100.5 7 7.0
119 122 120.5 3 2.5
167 149 158 18 11.4
136 130 133 6 4.5
Mean 8ng/m l 6.1%
Legend - Within individual variability of plasma PICP from blood 
drawn on two separate occasions.
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Table 3.10
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Sample 1 Sam ple 2 Mean
Absolute
difference % difference
2.9 2.8 2.85 0.1 3.5
3.1 3 3.05 0.1 3.3
2.2 2.2 2.2 0 0.0
2.1 1.9 2 0.2 10.0
2 1.9 1.95 0.1 5.1
3.4 3.1 3.25 0.3 9.2
2.3 2.1 2.2 0.2 9.1
1.7 1.7 1.7 0 0.0
2.9 2.8 2.85 0.1 3.5
2.4 2.3 2.35 0.1 4.3
Mean 0.12ng/ml 4.8%
Legend - Within individual variability of plasma CITP from blood 
drawn on two separate occasions.
Figure 3.9
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3.4 Discussion
We have demonstrated good quality control for assays of plasma PICP, CITP and 
TIMP-1 (Amersham assay) with intra-assay variabilities of less than 4% and inter­
assay variabilities of <7%. Linearity across a large range of absolute values has 
also been demonstrated. The tight within assay variability allows comparison of 
absolute values and the good between assay variability allows accurate 
measurement of repeated values necessary for a longitudinal study.
However, regarding the assay for TIMP-1, there was great disparity between the 
original Amersham kit and the revised kit from Amersham. The differences noted 
may be due to different binding properties of the antibodies involved and their 
differing affinity for unbound or bound TIMP-1. Indeed the company provided 
data showing that the revised kit recognised TIMP-1 complexed with MMP-1, a 
feature not present in the original assay. In addition, the assays may have different 
cross reactivity with other TIMPs or TIMP-MMP complexes. The variation seen 
between the two assays was not limited to any one patient group and no reason for 
this became apparent. The differing results between the original Amersham kit and 
the assay based on the antibody from Newcastle are a little more difficult to 
explain. The antibodies were from the same cell line and the assay methodology 
the same except for the additional step of streptavadin bound peroxidase and biotin 
bound second antibody. The disparity between measured plasma TIMP-1 between 
the two assays may be due to alterations in binding to the second antibody due to 
the additional steps in the Newcastle based assay due to the interference of 
streptavadin or biotin. However, one would expect this result to be consistent and
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predictable, yet there were wide variations absolute and percentage differences 
between the assays. This was not limited to one patient group and was 
demonstrated across a wide range of absolute values. Alternatively, it may have 
been due to an, as yet unknown, matrix effect. Whatever the explanation, only 
good quality control and reproducibility was demonstrated with the original 
Amersham kit and it was therefore decided that only those samples measured with 
this assay would be used in subsequent studies.
We have also established normal ranges for plasma levels of TIMP-1, PICP and 
CITP in a normal population to allow comparisons with experimental populations. 
These ranges are small with a small standard error of the mean, allowing use of the 
mean for the purposes of comparison to the mean of other populations.
Finally, we have shown no significant inter-individual variability for plasma levels 
of TIMP-1, PICP and CITP, excluding an effect of diurnal variation. This is 
important given the longitudinal nature of subsequent studies where samples are 
taken at different times.
3.5 Conclusions
I have demonstrated good quality control for the above three assays with tight 
intra and inter assay variabilities. I have also established normal ranges and 
excluded diurnal variation.
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CHAPTER FOUR -  TIME COURSE OF PLASMA MARKERS OF 
COLLAGEN TURNOVER FOLLOWING ACUTE MYOCARDIAL 
INFARCTION
4.1 Introduction
Ventricular remodelling following myocardial infarction is a powerful adverse 
prognostic indicator (White HD et al. 1987; Pfeffer MA and Braunwald E, 1990; 
Mahon et al. 1999), and changes to collagen content and structure within the 
extracellular matrix are important in its development (Whittaker P et al. 1991). 
Biochemical assessment of myocyte necrosis, by the measurement of serum 
Troponin or standard cardiac enzymes, is routinely performed following 
myocardial infarction, but to date there has heen no similar focus on biochemical 
assessment of collagen turnover.
Type I collagen is the principal collagen type within the heart, with lesser amounts 
of types III and IV (Frank and Langer, 1974; Weber KT, 1989), and its 
metabolism can be assessed biochemically (Risteli L and Risteli J, 1990; Risteli J 
and Risteli L, 1995b). Procollagen type I carboxy-terminal propeptide (PICP) is 
cleaved in a 1:1 stoichiometric fashion from procollagen during the formation of 
Type I collagen and is therefore a marker of collagen synthesis (Melkko JT et al. 
1990). Similarly, C-telopeptide for type I collagen (CITP) is released by 
endopeptidase cleavage by matrix metalloproteinases during collagen degradation 
and is a marker of breakdown (Risteli J et al. 1995a). Clearly, MMP activity must 
be tightly regulated and they are specifically inhibited by a family of naturally
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occurring glycoproteins -  the tissue inhibitors of metalloproteinases (TIMPs), 
which act by binding irreversibly to active MMPs, effectively halting proteolytic 
activity (Matrisian LM, 1990; Woessner JF, 1999; Woessner JF, 1999).
Previous studies have demonstrated increased levels of serum procollagen type III 
amino-terminal propeptide (PIIINP), a marker of collagen type III synthesis, 
following myocardial infarction peaking at day 7 and remaining elevated for many 
months, and that peak levels correlate positively with infarct size and inversely 
with survival (Jensen LT et al. 1990; Host NB et al. 1995). The prognostic 
significance of raised PIIINP following AMI has been confirmed in several 
studies, where both early and late elevation has been shown to correlate with 
indices of cardiac dysfunction, the development of heart failure and reduced 
survival (Uusimaa P et al. 1997; Modena et al. 1998; Poulsen SH et al. 2000). 
However, it is important to remember that net collagen content is a product of a 
dynamic equilibrium between collagen synthesis and degradation and that 
alterations to both processes may be important in the remodelling process.
It is also important to remember that it is type I collagen, rather than type III, 
which represents the most abundant collagen type within the heart (Medugorac 
and Jacob, 1983; Wei et al. 1999), and there are only limited data available on the 
time course of alterations in serum levels of markers of synthesis of type I 
collagen following myocardial infarction (Uusimaa P et al. 1997; Poulsen SH et 
al. 2001). Similarly, information regarding serological testing of collagen 
degradation is limited to one small study in 13 patients (Murakami T et al. 1998). 
We therefore sought to characterise the time course of changes in plasma markers
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of turnover of type I collagen following myocardial infarction in a larger cohort of 
patients presenting with their first acute myocardial infarction. To facilitate full 
assessment of collagen flux, we measured sequential changes in plasma PICP as a 
marker of collagen synthesis, CITP as a marker of collagen degradation, and 
Tissue Inhibitor of Matrix Metalloproteinase-1 (TIMP-1) as a marker of inhibition 
of degradation. We also sought to determine whether plasma levels of these 
markers correlated with peak serum creatine kinase (CKmax) and whether they 
predicted adverse clinical outcomes of heart failure or death. Finally, we aimed to 
determine whether there was a relationship between plasma levels of these 
markers and plasma levels of renin and aldosterone given the importance of the 
renin-angiotensin-aldosterone system (RAAS) in ventricular remodelling 
(McAlpine HM et al. 1988; Lindpaintner et al. 1993), and the consequences of its 
effectors on fibroblast function and collagen metabolism (Kato H et al. 1991; 
Brilla CG et al. 1994; Brilla CG et al. 1995; Chua et al. 1996).
4,2 Methods
Detailed methodology can be found in Chapter 2, section 2.3.
4.2.1 Patient Population
The study population comprised of 71 patients presenting with a history of 
suspected acute myocardial infarction with electrocardiographic criteria for 
thrombolysis on the admission ECG - ST elevation or new left bundle branch 
hlock (Fibrinolytic Therapy Trialists, 1994). Patients with previous myocardial
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infarction were not included in the study. Entry criteria consisted of chest pain for 
more than 20 minutes and presentation within 6 hours from the onset of pain. 
Seven patients were later excluded from the study when subsequent cardiac 
enzymes failed to confirm infarction, giving a study population of 64. Heart failure 
was defined as the development of crepitations in at least 1/3 of both lung fields or 
signs of pulmonary oedema on chest radiography during hospital admission. 
Exclusion criteria were eoncurrent fibrotic disease (pulmonary fibrosis, 
rheumatoid arthritis, treated hypertension, etc), conditions affecting metabolism of 
propeptides (renal disease defined as serum creatinine >130micromol/l, liver 
disease defines as ALT > 2x ULN, ACE inhibitor use, etc), active tumour, and the 
inability to provide informed consent. A full list of exclusion criteria can be found 
in Chapter 2 (table 2.1).
4.2.2 Blood Sampling and Biochemical Analyses
A cannula was inserted and sequential blood samples drawn at serial time points -  
on admission, at 12 hours, 24 hours, days 2, 3, 4 and 30. Venesection was 
performed with the patient in the recumbent position. lOmls of blood was 
collected in Lithium Heparin bottles and centrifuged at 3000rpm for 7 minutes. 
The separated plasma was divided and frozen at -70°C until use. A subgroup of 20 
patients had additional samples taken on admission and day 3 for measurement of 
plasma renin and aldosterone.
Plasma PICP was measured by a radioimmunoassay technique utilising a 
polyclonal antibody directed against PICP (Orion Diagnostica, Finland) (Melkko
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JT et al. 1990). In our laboratory, intra and inter assay variabilities are 3.1 and 
6.9% respectively and the mean plasma level (+/- ISD) in our local population is 
129 +/- 32 ng/ml. Plasma CITP was measured using a similar radio-immunoassay 
technique (Orion Diagnostica, Finland) (Risteli J et al. 1993). Intra and inter assay 
variabilities are 3.7 and 6.4% respectively with a local population mean of 2.6 +/-
0.3 ng/ml. Plasma TIMP-1 was measured using a two-step sandwich ELISA 
technique (Amersham Pharmaceuticals, UK) (Plumpton TA et al. 1995). Due to 
the unexpected discontinuation of the original TIMP-1 ELISA kit by Amersham 
Pharmaceuticals (Chapter 3), only 30 patients had serial assessment of plasma 
TIMP-1. Intra and inter assay variabilities for plasma TIMP-1 are 4.0 and 4.4% 
respectively (Amersham assay) and the normal mean in the local population is 202 
+/- 22 ng/ml. Plasma renin and aldosterone were measured by standard ELISA 
techniques. Measurements of creatine kinase were performed daily from 
admission and peak CK (CKmax) was determined for each patient. Mortality data 
was provided by the Common Services Agency, Edinburgh.
4.2.3 Statistical Analysis
All biochemical variables were tested for normality and log-transformed where 
necessary to allow parametric testing. All data are presented in the non- 
logaritlunic format. Continuous variables are expressed as mean (SEM) and 
changes over time were tested for significance by repeated measurement of 
analysis of variance. Student’s t test was employed for comparison of means and 
Pearson’s correlation co-efficient tested correlation between variables. Statistical
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analyses were performed using Minitab statistical software (Minitab Inc, 
Pennsylvania, USA) and a p value <0.05 was considered statistically significant.
4.3 Results
4.3.1 Baseline Characteristics
Forty-six patients (72%) were male. Mean age was 62 years, range 31 -  85. All 
presented within 6 hours of onset of pain, with a median time to presentation of
4.2 hours. The majority presented with inferior ST elevation -  40/64 (62%). 
Nineteen patients (30%) presented with anterior ST elevation, the remaining 5 
(8%) having LBBB. Most patients (58/64) received intravenous thrombolytic 
therapy - 39 streptokinase, 19 tissue plasminogen activator. 71% of those 
thrombolysed had successful reperfusion based on ECG criteria (Hogg KJ et al. 
1988). No patient had a second dose of thrombolytic therapy or underwent rescue 
angioplasty. Seventeen (27%) had clinical or radiographic evidence of congestive 
heart failure (CHF). Four patients (6%) died during the 30 day follow up period 
with a further five failing to survive to 6 months.
4.3.2 PICP
There was a sequential increase in plasma PICP over the study time period 
(p<0.001, figure 4.1). Mean admission level was within the normal range at 124 
(4.4) ng/ml and increased slightly over the first few days, peaking on day 30 at 
194 (9) ng/ml (O/A vs. D30 - p<0.001), more than two standard deviations above
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the mean for a normal population. There was no correlation between admission or 
peak PICP and CKmax. PICP levels on admission were similar in those with CHF 
and those with no evidence of heart failure (121 vs. 126 ng/ml, p=0.67), as were 
peak levels at 30 days. Similarly, there was no significant difference in admission 
levels between non-survivors and survivors (127 vs. 124 ng/ml, p=0.83), nor 
between inferior, anterior LBBB infarcts (115 vs. 125 vs. 129 ng/ml, p=0.13). 
However, the pattern of change was different between infarct sites, with a mean 
increase in plasma PICP of 52 ng/ml for inferior infarcts vs. 82 ng/ml and 72 
ng/ml for anterior and LBBB infarcts respectively (p=0.03, inferior vs. non­
inferior). There was no difference in admission PICP levels or in pattern of change 
between those who reperfused and those who did not, nor between tlirombolysis 
and no thrombolysis or between different thrombolytic agents.
Figure 4.1
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4.3.3 CITP
The group mean admission plasma CITP was elevated at 3.8 (0.25) ng/ml, more 
than two standard deviations higher than the normal population mean. There was a 
significant change over time (p=0.001, figure 4.2) with mean plasma CITP levels 
rising further from admission values within the first few days peaking at 5.2 (0.27) 
ng/ml on Day 2 (0/A  vs. D2 - p<0.001). Plasma CITP returned towards admission 
levels by day 30, but remained elevated above the normal population mean. There 
was no correlation between plasma CITP at any time point and CKmax. Patients 
who developed CHF had significantly higher plasma levels of CITP on admission 
than those who remained free of heart failure (5.0 vs. 3.3 ng/ml, p=0.04) Non­
surviving patients also had a higher admission CITP than surviving patients (5.7 
vs. 3.4 ng/ml) but this did not reach statistical significance (p=0.06). Although 
there was no significant difference in admission CITP levels for the three infarct 
sites (inferior 3.3 vs. anterior 4.0 vs. LBBB 3.8 ng/ml, p=0.12), anterior and 
LBBB sites were associated with a higher peak level on day 2 (anterior 5.5 and 
LBBB 5.2 vs. 4.4 ng/ml, p=0.03). Again, there was no difference between those 
who reperfused and those who did not, nor between tlirombolysis and no 
thrombolysis or between different thrombolytic agents.
145
Figure 4.2
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4.3.4 TIMP-1
In the 30 patients studied, mean plasma TIMP-1 was markedly elevated on 
admission compared to the mean of a normal population -  775 (101) vs. 202 (22) 
ng/ml. There was a sequential change over time (p<0.001, figure 4.3). Mean level 
increased further within 12 hours, peaking at 24 hours (0/A  vs. 24h -  p<0.001). 
Levels reached a plateau before falling substantially to a mean of 499 (45) ng/ml 
at day 30. However, this is still outwith the normal range and more than two 
standard deviations above normal population mean. Again no correlation with 
CKmax was observed. No significant difference in admission or peak TIMP-1 was 
found between those who developed heart failure and those who did not, survivors
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and non-survivors, administration of thrombolysis or thrombolytic used. There 
was a trend to higher peak levels of TIMP-1 in anterior and LBBB sites compared 
to inferior site, but this did not reach statistical significance.
Figure 4.3
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4.3.5 Renin/Aldosterone
On admission, plasma renin activity was within the normal range in 18/20 patients 
with a mean admission level of 49 (14) microunits/ml (range 3-270). This rose 
beyond the normal range by the third day to a mean of 107 (32) microunits/ml 
(range 4-480) but this rise was not statistically significant (p=0.11). However, of 
the 11 with heart failure, admission level was 92 (26) microunits/ml rising to 207 
(55) on day 3, compared to 14 (3) on admission rising to 24 (4) in the nine patients 
with no clinical or radiographic evidence of failure, p<0.05. There was no
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significant change in aldosterone in either group with admission and day 3 levels 
being within the normal range. There was no correlation between plasma levels of 
renin or aldosterone and plasma CITP, PICP or TIMP-1.
4.4 Discussion
4.4.1 Time Course
This is the largest study to date to utilise markers of both eollagen synthesis and 
degradation in the non-invasive assessment of changes in collagen metabolism 
following myocardial infarction, and has demonstrated time-dependent changes in 
plasma concentrations of PICP, CITP and TIMP-1 following acute MI. Plasma 
levels of PICP display little change over the first few days, remaining within the 
normal range before peaking at day 30, In contrast, changes in plasma levels of 
CITP occur earlier and are more pronounced. Mean plasma CITP was elevated on 
admission, increasing further within the first few days and returning towards the 
normal range by day 30. These patterns of change are consistent with what is 
known regarding the pathophysiology of ventricular remodelling.
Early and late phases of the remodelling process are characterised by different 
changes within the extracellular matrix. Breakdown of collagen by matrix 
metalloproteinases is the key in early remodelling (Camion et al. 1983; Whittaker 
P et al. 1991; Cleutjens JPM et al. 1995), allowing myocyte slippage, infarct 
expansion and LV dilatation (Olivetti G et al. 1990; Whittaker P et al. 1991; Kim 
et al. 2000). Indeed, there is as much as 25% collagen loss within 24 hours
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following MI in the rat model (Cannon et al. 1983). Given that CITP is liberated 
from collagen during breakdown, the early elevation of plasma CITP 
demonstrated in this study is in keeping with these observations.
Conversely, late remodelling is characterised mainly by collagen synthesis and 
interstitial fibrosis, with further changes to LV geometry, structure and function 
(Fishbein MC et al. 1978; Pfeffer MA and Braunwald E, 1990). Again, the pattern 
of change of plasma levels of PICP, a marker of collagen synthesis, is consistent, 
with levels within the normal range in the early phase, peaking at day 30. This 
appears at odds with previous studies showing early elevation of PIIINP, another 
marker of collagen biosynthesis, following AMI (Jensen LT et al. 1990; Host NB 
et al. 1995; Uusimaa P et al. 1997; Poulsen SH et al. 2000). However, one 
should remember that unlike PICP, PIIINP is incompletely cleaved during the 
production of type III collagen and is also released when collagen is degraded. 
Levels are therefore influenced by the degree of collagen breakdown and this may 
explain the increased serum levels observed in these studies (Risteli J and Risteli 
L, 1995b).
Even though PICP is purely a mai'ker of collagen synthesis, and type I collagen, 
not type III, is the principle myocardial collagen type, there are limited data in the 
published literature with regard to changes in serum levels o f PICP in the setting 
of acute MI. Uusimaa et al examined serum levels of PICP and PIIINP following 
MI (Uusimaa P et al. 1997). They found no significant early change in PICP, 
mirroring the findings in our study. However, this is in contrast to their finding of 
early elevation of PIIINP, the levels of which, and area under the curve, correlated
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with indices of cardiac dysfunction. This apparent disparity between these two 
markers of collagen biosynthesis could be explained in one of two ways. One 
mechanism would be that synthesis of type III collagen occurs early following 
AMI, with later synthesis of type I collagen. However, as previously discussed, 
type I collagen predominates in the heart, and indeed, there is a phenotypic shift 
from type III to type I collagen following AMI (Medugorac and Jacob, 1983; Wei 
et al. 1999), making this explanation unlikely. A more plausible mechanism for 
this disparity would be that the early elevation of PIIINP is a reflection of early 
collagen breakdown. This is supported by the finding of early elevation of CITP, 
a specific marker of collagen degradation, in our study. However, regardless o f the 
mechanism, one should not focus on a solely on collagen synthesis. Remodelling 
should be regarded as a continuum and changes to both processes of synthesis and 
degradation will occur throughout the process, albeit with differing emphases at 
different time points.
I have also demonstrated that plasma levels of TIMP-1 display a time-dependent 
change following myocardial infarction. Levels are markedly elevated on 
admission, rising further before falling towards normal range by 30 days. If 
collagen breakdown is the principal finding during the early phase of remodelling, 
one may have expected that levels of TIMP-1 should be reduced, given that TIMP- 
1 is a marker of inhibition of degradation. However, the assay for TIMP-1 does 
not differentiate between free TIMP-1 and TIMP-1 complexed with MMP. MMP 
expression is up-regulated within a few hours of infarction and is associated with 
increased enzymatic activity (Carlyle et al. 1997; Herzog et al. 1998; Danielsen 
et al. 1998) and the importance of active MMPs in the pathophysiology of matrix
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remodelling is well documented (Matrisian LM, 1990). This, coupled with the 
experimental evidence from this study of increased collagen breakdown, as 
manifested by raised CITP, suggests that the TIMP-MMP balance shifts towards 
increased MMP activity following MI. It is therefore likely that the rise in plasma 
levels of TIMP-1 is in response to increased collagen degradation and I 
hypothesise that these increased levels reflect TIMP-1 bound to MMP.
4.4.2 Relationship with Plasma Renin and Aldosterone
No relationship was observed between plasma levels of PICP, CITP or TIMP-1 
and plasma renin or aldosterone on admission or at day 3. Although there is clear 
evidence of systemic activation of the RAAS following myocardial infarction 
(McAlpine HM et al. 1988; Rouleau et al. 1993; Lindpaintner et al. 1993), 
plasma levels do not peak for a few days (McAlpine HM et al. 1988). However, 
there is evidence of early de-novo generation of these effectors at a tissue level 
(Dzau, 1987) with associated increased tissue activity immediately following 
infarction (Sakharov et al. 1987). Given the importance of RAAS effectors on 
collagen metabolism (Brilla CG et al. 1995) (Lindpaintner et al. 1993) it is likely 
that both systemic and local RAAS activation have influence on remodelling 
following myocai'dial infarction. However, given the delay in mounting a systemic 
RAAS response, coupled with the rapidity of increased activity of ACE at a tissue 
level and increased gene expression at a cellular level, it would be reasonable to 
hypothesise that paracrine regulation of local tissue levels of RAAS effectors, 
independent of the systemic renin-angiotensin-aldosterone axis, plays an important 
role in the remodelling process, especially in the early stages. This may, in part,
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explain the lack of relationship between plasma levels of the markers of collagen 
flux and plasma renin and aldosterone levels. It is also documented that increased 
extraction of circulating aldosterone is important in the remodelling process 
(Hayashi M et al. 2001b), and this study did not examine trans-cardiac gradients 
of any effectors of the RAAS, which may have unmasked a relationship with 
plasma levels of PICP, CITP or TIMP-1.
4.4.3 Site of Infarct. Thrombolyis and Renerfusion
In this study, admission levels of all three markers of collagen turnover were non- 
significantly higher in those presenting with anterior ST elevation or LBBB 
infarcts. Although there was a sequential rise in these markers in all three groups, 
the elevation was more marked in anterior and LBBB infarcts (significant for 
PICP and CITP, trend for TIMP-1). This study provides serological evidence of 
increased remodelling of the collagenous component of the heart in infarctions of 
these sites and is entirely in keeping with the fact that anterior ST elevation and 
new LBBB infarcts are associated with a worse prognosis compared to inferior 
infarcts (Hammermeister KE et al. 1979; Mahon et al. 1999).
Interestingly, there was no significant difference in plasma levels of these three 
markers, or in pattern of change, in those who had thrombolytic therapy vs. those 
who did not. It is well recognised that botli streptokinase and tissue plasminogen 
activator have effects on collagen metabolism, probably mediated by plasmin 
(Kosow DP, 1979; Hoylaerts M et al. 1982; Nagase H et al. 1990), the effect of 
which is probably more significant with streptokinase (Rao AK et al. 1988).
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Previous studies have demonstrated immediate elevation in serum levels of PIIINP 
during tlirombolytic infusion, with later elevation in PICP (Peuhkurinen KJ et al. 
1991; Peuhkurinen K et al. 1996), In our study, there was no observed difference 
in levels of any marker of collagen turnover between those who received 
thrombolysis and those who did not. However, only 6 patients did not receive 
thrombolytic therapy, allowing only limited comparison between the groups. 
Similarly, there was also no significant difference between streptokinase and tPA 
on levels of markers of collagen turnover in our study, unlike the study by 
Peuhkurinen et al (Peuhkurinen K et al. 1996). However, the early elevation in 
that study was seen during infusion of the thrombolytic agent and settled to 
baseline levels within hours of discontinuation of the drug, before rising again two 
to three days following infarction, the degree of which was similar between the 
two agents studied. In our study, the timing of blood sampling would have 
“missed” the acute elevation seen with thrombolytic infusion, as assays were 
performed on admission, prior to the onset of thrombolysis, with the second 
sample being taken at 12 hours, at which point, the acute effects of the agent 
would have not been apparent. Therefore, the direct effect of thrombolysis on 
plasma markers of collagen turnover can effectively be discounted in this study.
A somewhat surprising finding in this study was the apparent lack of effect of 
successful reperfusion on serological evidence of altered collagen turnover. 
Successful reperfusion is known to improve survival and limit remodelling 
(Jeremy et al. 1987; Touchstone et al. 1989; Marino et al. 1989; Fibrinolytic 
Therapy Trialists, 1994). However, the majority of patients in this study
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reperfused (>70%), only allowing limited comparison between those who 
reperfused and those who did not.
4.4.4 Plasma Levels vs. Tissue Activity
One of my hypotheses was that plasma levels of PICP and CITP reflect the 
processes of collagen synthesis and degradation within the myocardium. Although 
this is speculative, the fact that the difference in the pattern of change of these 
markers over time following acute myocardial infarction is consistent with the 
pathophysiology of ventricular remodelling provides some indirect evidence to 
support this hypothesis. In addition, this study provides another strand of evidence 
to support plasma levels of these markers as reflections of changes in collagen flux 
at a tissue level. Collagen degradation is the principal process in early remodelling 
(Cleutjens JPM et al. 1995) which is associated with the development of heart 
failure and reduced survival (McKay RG et al. 1986; Pfeffer MA and Braunwald 
E, 1990; Korup et al. 1997). In this study, although admission and peak plasma 
CITP did not correlate with peak creatine kinase release, a surrogate of infarct 
size, levels were significantly higher in those who developed heart failure. There 
was also a trend towards higher levels in non-surviving patients compared to those 
who survived. No such association was observed between plasma PICP or TIMP-
1. However, although these flndings provide some supportive evidence of the use 
of plasma markers of collagen turnover as indicators of the remodelling process 
following myocardial infarction, further studies examining the relationship of 
these markers with functional changes within the heart will provide additional 
information in this regard.
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4.4.5 Study Limitations
Although the assay methodologies are robust with good intra and inter-assay 
vaiiabilities, the assay for TIMP-1 could not distinguish between flee TIMP-1 and 
TIMP-1 bound with MMP, making interpretation of levels more difficult. 
Furthermore, due to the unexpected change in antibody in the ELISA for TIMP-1, 
only 30 patients had full biochemical assessment of collagen turnover, including 
TIMP-1, reducing statistical power to detect relationships between plasma TIMP-1 
and effectors of the RAAS, development of heart failure and prognosis. In 
addition, levels of MMP-1 in plasma are below the reliable detection limit of the 
available assays and therefore could not studied. However, plasma CITP was 
studied as a marker of collagen breakdown and can be considered an indirect 
marker of MMP activity.
This study also employed peak CK as an indicator of degree of myocardial 
necrosis. A more robust method would have been calculation of CK release curves 
and measurement of area under the curve. However, due to logistical reasons, this 
was not performed. This may have influenced the relationship between CK and 
markers of collagen turnover.
4.5 Conclusions
This study demonstrates time-dependent changes in plasma levels of CITP, PICP 
and TIMP-1 following myocardial infarction. Raised CITP, a marker of collagen
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breakdown, is associated with the development of heart failure and a trend towards 
an adverse outcome. Levels may reflect early remodelling and may be useful in 
monitoring the remodelling process.
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CHAPTER FIVE -  INCREASED COLLAGEN DEGRADATION 
PREDICTS EARLY VENTRICULAR REMODELLING 
FOLLOWING ACUTE MYOCARDIAL INFARCTION
5.1 Introduction
One of the most powerful predictors of adverse outcome following myocardial 
infarction is post-infarction ventricular remodelling which is characterised by 
alterations to ventricular size, shape and function (White HD et al. 1987; Pfeffer 
MA and Braunwald E, 1990; Mahon et al. 1999). Since the first description by 
Tennant and Wiggers in 1935 (Tennant R and Wiggers CJ, 1935), there has been 
an enormous body of evidence that alterations to LV function, structure and 
volume are important prognostic variables (Shanoff HM et al. 1969; Kostuk WJ et 
al. 1973; Pfeffer MA et al. 1979; McKay RG et al. 1986). These changes are 
evident within a few hours of the onset of symptoms and progress over time 
(Korupetal. 1997).
Early ventricular remodelling, defined as occurring within 72 hours (Sutton and 
Sharpe, 2000), is characterised by expansion and thinning of the infarct zone, 
development of wall motion abnormalities, LV dilatation and reduced ejection 
fraction (Pfeffer MA and Braunwald E, 1990; Sutton and Sharpe, 2000). 
Echocardiographic parameters such as end-systolic volume index, ejection fraction 
and extent o f wall motion abnormalities all predict subsequent mortality (Kitamura 
et al. 1973; White HD et al. 1987; Kober L et al. 1994; Sutton et al. 1997; 
Migrino et al. 1997; Galasko et al. 2001). More recently, Doppler indices of LV
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filling have been shown to provide additional prognostic information following 
infarction. The development of a restrictive filling pattern, a reflection of impaired 
diastolic function (Williamson et al. 1990; Chenzbraun et al. 1992), can be 
assessed by measurement of the mitral deceleration time (Little et al. 1995). 
Decreased mitral deceleration time is associated with larger infarcts and correlates 
with subsequent remodelling (Cerisano G et a l  1999).
Early identification of remodelling is important, as there are strategies available to 
reduce the remodelling process, such as maintaining the patency of the infarct 
related artery and the use of ACE inhibitors, which confer a survival benefit 
(Jeremy et al. 1987; Touchstone et a l  1989; Pfeffer MA et a l  1992; AIRE study 
investigators, 1993; ISIS-4 Collaborative Group, 1995). The early phase of 
remodelling following infarction is associated with changes to the extracellular 
matrix, both in the infarct zone and in the non-infarcted portion of the heart, 
manifested principally as increased collagen degradation (Cleutjens JPM et al. 
1995). Indeed, there is as much as 25% net collagen loss within the first 24 hours 
following MI (Cannon et al. 1983) which facilitates myocyte slippage, infarct 
expansion and LV dilatation (Whittaker P et al. 1991; Kim et al. 2000).
Type I collagen is the principal collagen type within the heart (Weber KT, 1989), 
and its metabolism can be assessed biochemically (Risteli L and Risteli J, 1990; 
Risteli J and Risteli L, 1995b). During the formation of Type I collagen, the 
propeptide moiety, procollagen type I carboxy-terminal propeptide (PICP), is 
cleaved from procollagen and is therefore a marker of collagen synthesis (Melkko
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JT et al. 1990). Similarly, during collagen degradation, C-telopeptide for type I 
collagen (CITP) is liberated and is a marker of breakdown (Risteli J et al. 1995a).
I have previously demonstrated time-dependent alterations in plasma levels of 
both PÏCP and CITP following acute myocardial infarction with early elevation of 
plasma CITP and late elevation of PICP. Admission and peak CITP were 
significantly higher in those who subsequently developed clinical or radiographic 
evidence of heart failure (Chapter 4). No such association was found with plasma 
levels of PICP. I hypothesise that raised plasma levels of CITP may reflect the 
increased degradation of collagen in the early stages following infarction and 
therefore may be a marker of early remodelling. To investigate this further, a 
cohort of patients presenting with their first acute myocardial infarction from the 
observational study previously described (Chapter 4) were studied in more detail 
with a comprehensive echocardiographic examination on the fourth day following 
infarction. Given the importance of abnormal wall motion index (WMI) on 
echocardiography performed in the sub-acute phase of AMI (Kober L et al. 1994), 
and its correlation with mortality, patients were dichotomised by the presence or 
absence of wall motion abnormality. In addition, I fully assessed collagen flux by 
the sequential measurement of plasma levels of PICP and CITP over time. I aimed 
to determine the relationship of plasma levels of PICP and CITP with 
echocardiographic indices of early remodelling including WMI and whether 
admission levels provide prognostic information with regard to its subsequent 
development.
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5.2 Methods
Detailed methodology can be found in Chapter 2, section 2.3.
5.2.1 Patient Population
The study population comprised 51 patients presenting with their first myocardial 
infarction and eligible for reperfusion therapy based on the admission 12 lead 
electrocardiogram - ST elevation or new left bundle branch block (Fibrinolytic 
Therapy Trialists, 1994). Entry criteria consisted of chest pain for more than 20 
minutes, presentation within 6 hours from the onset of pain. Exclusion criteria 
were concurrent fibrotic disease (pulmonary fibrosis, rheumatoid arthritis, treated 
hypertension, etc), conditions affecting metabolism of propeptides (renal disease 
defined as serum creatinine >130micromol/l, liver disease defines as ALT > 2x 
ULN, ACE inhibitor use, etc), active tumour, and the inability to provide informed 
consent. A full list of exclusion criteria can be found in Chapter 2 (table 2.1).
Patients were categorised on the presence or absence of early signs of remodelling 
on echocardiographic studies performed on the fourth day post event. Given that 
previous studies have demonstrated that the degree o f wall motion abnormality in 
the sub-acute phase following AMI is the most powerful echocardiographic 
predictor of both short and long-term mortality (Kober L et al. 1994; Sutton et al. 
1997; Migrino et al. 1997), this echo parameter was used to dichotomise patients 
into those with echocardiographic evidence of early remodelling and those with no 
such evidence. Biochemical variables were assessed in accordance with this
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grouping, although correlation with other echocardiographic parameters was 
assessed with the group as a whole.
5.2.2 Echocardiographic Assessment of Remodelling
Detailed 2-dimensional and Doppler examinations were performed by a single 
observer (AMcG) on Day 4 following the index event, using a Vingmed System V 
Ultrasound Machine (General Electronics, Milwaukee, USA) connected to a 
PowerMacintosh G3 computer with digital archiving facilities. Images were 
acquired in the four standard views with the patient in the left lateral position at 
end-expiration. Offline analysis was performed by a single observer (AMcG) 
blinded to the results of biochemical analyses.
(a) Wall Motion Index
A  sixteen segmental scoring system was employed in accordance with the 
American Society of Echocardiography guidelines (Schiller et al. 1989). The sum 
of the scores from all segments were totalled and divided by sixteen giving a wall 
motion index (WMI). A score of 1 indicates normal movement of all segments, 
whereas a score of greater than one represents the presence of abnormal wall 
motion of one or more segments. The higher the score above one, the greater the 
degree of regional wall motion abnormalities and percentage of muscle affected. 
As mentioned previously, patients were dichotomised depending on the presence 
or absence of wall motion abnormality -  i.e. WMI >1 or WMI=1.
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(b) Mitral Deceleration Time
Pulsed wave Doppler signals were obtained thi'ough the tips o f the mitral valve 
inflow in the apical four chamber view at end-expiration. Mitral deceleration time 
(Dt), defined as the time from the peak of the early mitral inflow (E-wave) to 
baseline, was measured in three cycles (avoiding extrasystolic or immediate post- 
extrasystolic beats) and a mean calculated for the purposes of analysis.
(c) Left Ventricular Volumes and Ejection Fraction
End diastole was identified from ECG gating, being defined as the onset of the R 
wave. End systole was identified from visual inspection, being defined as the 
smallest ventricular dimension in that cardiac cycle. Tracing of the endocardial 
contours in both diastole and systole was performed from stored 2 dimensional 
images acquired in the apical two and four chamber views and LV volumes 
calculated from the disc summation method or Simpson’s rule (Schiller et al. 
1979; Erbel et al. 1982). The mean of three cycles was calculated (avoiding 
extrasystolic or immediate post-extrasystolic beats) and normalised for body 
surface area, giving values for left ventricular end diastolic volume index 
(LVEDVI) and left ventricular end systolic volume index (LVESVI).
Ejection fraction was calculated by the following equation, which has been 
validated previously (Folland et al. 1979; Starling et al. 1981; Erbel et al. 1983):
(LV end diastolic volume -  LV end svstolic volume! X 100 
LV end diastolic volume
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5.2.3 Blood Sampling and Biochemical Analyses
Blood was drawn from an indwelling cannula with the patient in a recumbent 
position at serial time points -  on admission, at 12 hours, 24 hours, and days 2, 3, 
4 and 30. lOmls of blood was collected in Lithium Heparin bottles, centrifuged at 
3000rpm for 7 minutes and the separated plasma frozen at -70°C until use.
Plasma PICP was measured by standard radioimmunoassay (Orion Diagnostica, 
Finland) (Melkko JT et al. 1990). We have previously demonstrated intra and 
inter assay variabilities of 3.1 and 6.9% respectively with a local population mean 
(+/- ISD) of 129 +/- 32 ng/ml (Chapter 3). Plasma CITP was also measured by 
radio-immunoassay (Orion Diagnostica, Finland) (Risteli J et al. 1993) with intra 
and inter assay variabilities of 3.7 and 6.4% respectively. Mean plasma level in 
our local population is 2.6 +/- 0.3 ng/ml.
5.2.4 Statistical Analysis
Statistical analysis was performed using Minitab statistical software (Minitab Inc, 
Pemisylvania, USA). Non-normally distributed variables were log-transformed to 
allow parametric testing. However, all data are presented in the non-logarithmic 
format. Continuous variables are expressed as mean (SEM) and changes over 
time were tested for significance by repeated measurement o f analysis of variance. 
Student’s t test was employed for comparison of means and Pearson’s correlation 
co-efficient tested correlation between variables. Multiple regression models were
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constructed using Minitab, A p value <0.05 was considered statistically 
significant.
5.3 Results
5.3.1 Baseline Characteristics
The majority of patients (74%) were male with a mean age of 59 years (range 31 -  
85). The median time to presentation was 4.1 hours (range 2.4 - 5.8). Thirty-two 
(63%) presented with inferior ST elevation, 15 (29%) with anterior ST elevation, 
and the remainder (8%) having new LBBB. More than 90% (46/51) received 
intravenous thrombolytic therapy (28 streptokinase and 18 tissue plasminogen 
activator) with 72% having non-invasive evidence of successful reperfusion on 12 
lead ECG performed at 90 minutes post thrombolysis (Hogg KJ et al. 1988). No 
patient had a second dose of thrombolytic or underwent rescue angioplasty.
Patients were dichotomised depending on the presence or absence of wall motion 
abnormalities on echocardiography. Twenty-three patients (45%) had no wall 
motion abnormalities and therefore had a wall motion index (WMI) of 1. The 
remaining 28 patients (55%) had evidence of wall motion abnormality and had a 
WMI greater than one (range 1.06 to 2.36). Baseline characteristics for both 
groups are shown in table 5.1. Mean age was similar in both groups with 
comparable percentage of diabetic patients, overall thrombolytic usage and 
reperfusion rates. However, there were significantly more anterior infarcts in the
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abnormal wall motion group and therefore more received tPA rather than 
streptokinase as thrombolytic therapy in this group.
Table 5.1
Normal WMI 
N(%)
Abnormal WMI 
N(%)
Number 23 28
Mean Age 56 63
Male 16(70) 22 (79)
Diabetes 5(22) 8(29)
Mean admission BP 148/90 146/90
Inferior MI 18(78) 14 (50)
Anterior MI 4(18) 11(39)
LBBB 1(4) 3(11)
Thrombolysis 21 (91) 25 (89)
% tPA 19 50
% reperfused 76 68
% ACEI use 83 89
Legend Baseline characteristics
5.3.2 PICP
Both groups of patients demonstrated a sequential rise in plasma PICP over the 
study time period (p<0.001, figure 5.1). Admission means for both groups were 
within the 95 ’^^ confidence interval for the mean of a normal population (114- 
143ng/ml), although admission PICP was lower in the abnormal wall motion 
group compared to the group with normal WMI (114 vs. 143ng/ml, p<0.05, figure 
5.2). They displayed a similar pattern of change over the study period with a slight 
rise in the first few days, peaking by day 30, again with lower levels in the 
abnormal WMI group (160 vs. 195ng/ml, p<0.05, figure 5.2).
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Figure 5.1
Time course of plasma PICP
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Legend - Time course of plasma PICP following myocardial 
infarction for patients with evidence of wall motion abnormalities (abnormal 
WMI) and with no wall motion abnormalities (normal WMI).
Figure 5.2
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Legend - Comparison of group means (with 2S“* and 75*** centiles and 
+/- ISD shown) for plasma level of PICP on admission (O/A) and peak levels at 
day 30 (peak) for both groups.
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5.3.3 CITP
A time dependent rise in plasma levels of CITP was also seen in both groups with 
levels rising within 12 hours in both groups, reaching a plateau, before falling 
towards admission levels by day 30 (p<0.001, figure 5.3). The changes over time 
are parallel in the two groups with the main difference being plasma CITP on 
admission. The group with abnormal wall motion index had a mean admission 
level of 4.5 (0.6) ng/ml. This is outwith the normal range, being two standard 
deviations above the mean for a normal population (normal population mean 2.6 
(SD 0.3) ng/ml, range 1.9 ~ 3.9). This was significantly higher than the admission 
mean for the group with no evidence of wall motion abnormalities which was 
within the normal range (4.5 vs. 3.1, p<0.05, figure 5.4). Peak levels of CITP were 
also higher in the abnormal WMI group (6.3 vs. 4.8, p<0.05, figure 5.4).
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Figure 5.3
Time course of plasma CITP
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Legend - Time course of plasma CITP following myocardial 
infarction for patients with evidence of wall motion abnormalities (abnormal 
WMI) and with no wall motion abnormalities (normal WMI).
Figure 5.4
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Legend - Comparison of group means (with 25**' and 75*^  centiles and 
+/- ISD shown) for plasma level of CITP on admission (O/A) and peak levels at 
day 30 (peak) for both groups.
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5.3.4 Correlation with Wall Motion Index
In addition to raised plasma levels of CITP and reduced levels of plasma PICP at 
all time points in the group with abnormal wall motion index, the absolute plasma 
level of CITP on admission positively correlated with wall motion index (r = 0.53, 
p<0.01, figure 5.5). Similar findings were found with peak CITP (data not shown). 
As both groups show similar pattern of change of plasma CITP over time, we 
assessed the use of admission CITP as a predictor of subsequent development of 
wall motion abnormalities. Using the mean plasma level of CITP of a normal 
population + 2 standard deviations as a partition value, an admission level of 
greater than 3.2ng/ml gives a positive predictive value of 74% for the development 
of wall motion abnormalities and a negative predictive value of 65%. In a multiple 
regression analysis, anterior infarct and admission CITP were independent 
multivariate predictors of wall motion score. No relationship was demonstrated 
with admission or peak plasma PICP (figure 5.6), peak CK, use of thrombolysis, 
thrombolytic agent or evidence of reperfusion.
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Figure 5.5
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Legend - Scatterplot of admission level of plasma CITP with wall 
motion index on day 4. Correlation coefficient 0.53, p<0.01.
Figure 5.6
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Legend - Scatterplot of admission level of plasma PICP with wall
motion index on day 4. Correlation coefficient 0.07, p=NS.
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5.3.5 Relationship with Mitral Deceleration Time
The group with wall motion abnormalities had a lower mean Dt than the group 
with normal wall motion (187 vs. 217ms, p<D.05). As with wall motion index, 
absolute level of admission plasma CITP correlated with mitral deceleration time 
(Dt), this time negatively (r = -0.38, p<0.01, figure 5.7). Using the same partition 
value as previously, Dt was lower in those with admission CITP >3.2 ng/ml 
compared to those with lower admission levels (183 vs. 221ms, p<0.05, figure 
5.8). Again, no relationship with plasma PICP was demonstrated (figure 5.9). Dt 
was not related to infarct site, peak CK, use of thrombolysis or reperfusion status.
Figure 5.7
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Legend - Scatterplot of admission level of plasma CITP with mitral
deceleration time (Dt) on day 4. Correlation coefficient -0.38, p<0.01.
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Figure 5.8
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Legend - Comparison of Dt (mean +/- ISD with 25^ '‘ and 75*’‘ centiles 
shown) for Dt on day 4 using admission level of plasma CITP of 3.2ng/ml as a 
partition value
Figure 5.9
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Legend - Scatterplot of admission level of plasma PICP with mitral
deceleration time (Dt) on day 4. Correlation coefficient -0.13, p-NS.
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Eg.lationship with LV Volumes and F.jection Fraction
Mean end diastolic volume index was similar in the group with wall motion 
abnormalities compared to the group with normal WMI (69.8 vs. 60.0 mls/m2, 
p=NS). Mean end systolic index was higher in the abnormal WMI group (40.7 vs.
28.6 ml/m2, p<0.05) with a resultant lower ejection fraction (42% vs. 53%, 
p<0.001) (figure 5.10). However, there was no correlation between absolute 
admission levels o f CITP or PICP with LV end diastolic or end systolic volumes 
or ejection fraction (figures 5.11 and 5.12) and no significant difference in these 
variables using 3.2ng/ml as a partition value for admission CITP.
Figure 5.10
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Legend -  Comparison of mean LV end diastolic volume index
(LVEDVI), mean end systolic volume index (LVESVI) and mean LV ejection
fraction (LVEF) between the group with normal wall motion index vs. abnormal 
index.
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Figure 5.11
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Admission CITP and LVEF
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Legend - Scatterplot of admission level of plasma CITP with (a) LV 
end-diastolic volume index (LVEDVI) (Correlation coefficient -0.12, p=NS), (b) 
LV end-systolic volume index (LVESVI) (Correlation coefficient -0.12, p=NS) 
and (c) LV ejection fraction (LVEF) (Correlation coefficient -0.04, p=NS) on day 
4.
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Figure 5.12
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Admission PICP and LVEF
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Legend - Scatterplot of admission level of plasma PÏCP with (a) LV 
end-diastolic volume index (LVEDVI) (Correlation coefficient -0.04, p=NS), (b) 
LV end-systolic volume index (LVESVI) (Correlation coefficient -0.13, p=NS) 
and (c) LV ejection fraction (LVEF) (Correlation coefficient -0.05, p=NS) on day 
4.
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5.4 Discussion
5.4.1 Normal vs. Abnormal Wall Motion Index
This study demonstrates time-dependent alterations in plasma markers of both 
collagen synthesis and degradation in patients presenting with their first acute 
myocardial infarction and delineates the relationship of these markers with 
established echocardiographic parameters of early ventricular remodelling. 
Patients with abnormal wall motion index on echocardiography on day 4 
following infarction, the most powerful echocardiographic predictor of subsequent 
mortality (Kan et al. 1986; Sutton et al. 1994; Korup et al. 1997; Sutton et al. 
1997, Migrino et al. 1997), displayed higher levels of mean plasma CITP on 
admission, and at all other time points, than the group with normal WMI. Higher 
peak level was also demonstrated in this group. With regard to mean plasma PICP, 
this was lower at all time points in the abnormal WMI group, although mean 
admission levels were within the normal range in both groups.
Although patients were categorised depending on the presence or absence of wall 
motion abnormalities, other echocardiographic parameters of remodelling were 
reflected within this dichotomy, supporting the use o f wall motion as a 
dichotomous variable. Patients in the abnormal WMI group also displayed a 
significantly higher end-systolic volume index, lower Dt and lower ejection 
fraction than in those with normal WMI and a trend towards higher end-diastolic 
volume index, all of which is in keeping with changes seen in early remodelling.
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5'4.2 Plasma Levels of CITP and PICP as Reflection of the Remodelling Process
We have previously demonstrated time-dependent alterations in plasma levels of 
PICP and CITP (Chapter 4). This current study provides evidence to support that 
plasma levels of these markers reflect functional changes within the heart. The 
differences found in plasma levels of PICP and CITP between the groups are 
consistent with the pathophysiology of remodelling following infarction. Early 
remodelling is characterised by a net loss of myocardial collagen content due to 
collagen degradation (Cannon et al. 1983; Cleutjens JPM et al. 1995), allowing 
the development of a restrictive ventricular filling pattern, progressive LV 
dilatation and reduced ejection fraction in addition to the development of wall 
motion abnormalities (Olivetti G et al. 1990; Whittaker P et al. 1991; Williamson 
et al. 1990; Kim et al. 1999). The early elevation in plasma levels of CITP, 
produced during collagen breakdown, demonstrated in this study in the group with 
echocardiographic evidence of early remodelling is likely to reflect increased 
collagen degradation. Collagen is primarily degraded by active matrix 
metalloproteinases (MMPs) (Birkedal-Hansen H et al. 1993). Previous studies 
have shown early up-regulation of MMP genetic expression within a few hours of 
infarction (Herzog et al. 1998) which is associated with increased gene product 
(Carlyle et al. 1997; Herzog et al. 1998; Danielsen et al. 1998). The finding in 
our study of raised plasma levels of CITP, a product of collagen breakdown, is in 
keeping with these previous studies.
Conversely, plasma levels of PICP, a marker of collagen synthesis is lower in the 
group with evidence o f remodelling. This may be due to reduced synthesis in this
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group or higher synthesis in the group who did not develop wall motion 
abnormalities. Although this study cannot answer that question directly, one must 
remember that net collagen content is a product o f a dynamic equilibrium between 
synthesis and degradation, It is therefore clear from this study that the group with 
abnormal wall motion display evidence of increased degradation and reduced 
synthesis o f collagen compared to those with normal wall motion, and therefore, 
the balance is shifted m favour of collagen breakdown. It is this shift in balance 
which supports that the observed changes in plasma levels of these propeptides are 
a reflection o f remodelling, rather than a generalised increase in collagen turnover 
ill a non-specific response to simple ischaemic injury.
It is clear from this study that this shift in favour of collagen degradation is 
apparent on admission. MMP expression is upregulated within hours of an 
ischaemic insult, resulting in immediate collagen breakdown(Cleutjens JPM et al. 
1995; Herzog et al. 1998). The flnding of elevated CITP on admission samples is 
entirely in keeping with this timescale. In contrast, although admission plasma 
levels of PICP were lower in the abnormal WMI group, absolute levels were 
within the normal range in both groups. Elevation above the normal range is not
apparent until day 30, a finding consistent with the timescale of scar
formation(Cleutjens JPM et al. 1995).
1 8 0
5.4.3 Relationship of Plasma CITP and PICP to Wall Motion Score and Mitral 
Deceleration Time
111 addition to the differing levels of CITP and PICP between the groups with 
normal and abnormal WMI, absolute plasma levels of CITP on admission, and at 
peak, positively coiTelated with wall motion score and negatively correlated with 
mitral deceleration time (Dt). Indeed, using two standard deviations above a 
normal population mean as a partition value, an admission CITP level of 
>3.2ng/ml provided a 74% positive predictive value for the subsequent 
development of wall motion abnormality. Admission level less than this value 
provided a negative predictive power of 65%. Furthermore, those with admission 
CITP >3.2ng/ml had evidence of lower Dt than those with admission CITP 
<3.2ng/ml, reflecting the restrictive filling pattern seen in patients with 
remodelling (Popovic et al. 1996; Cerisano G et al. 1999). It is therefore clear 
that admission value o f plasma CITP provides important information with respect 
to remodelling and is an independent predictor for the development of 
echocardiographic parameters of early remodelling. No such relationship was 
observed with admission levels of PICP, again reflecting that collagen degradation 
is the principal finding in the early phases following infarction.
Previous work by Poulsen et al has demonstrated early elevation of plasma PIIINP 
following AMI, the degree of which predicted LV remodelling, including the 
development of a restrictive filling pattern on echo (Poulsen SH et al. 2000). They 
concluded that this reflected increased collagen synthesis. However, as previously 
discussed, PIIINP is also liberated during collagen breakdown and levels may
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reflect an increase in this process rather than increased synthesis (Risteli J and 
Risteli L, 1995b). Indeed, studies examining PICP, a pure marker of synthesis, 
show no such early elevation (Uusimaa P et al. 1997). PIIINP was not utilised in 
this study due to its lack of specificity to either process. This study related 
echocardiographic parameters of remodelling to specific markers of collagen 
synthesis or degradation and provides a clearer insight into the dynamics of 
collagen tui'nover following AMI and its relationship with the remodelling 
process,
5.4.4 Relationship of Plasma CITP and PICP to LV Volumes and Ejection Fraction
There was no association between absolute plasma levels of CITP or PICP on 
admission, or at any other time point, with LV end-diastolic or end-systolic 
volumes or ejection fraction. This may appear to be at odds with the finding that 
mean LVEDVI and LVESVI were higher and LVEF lower in the group with 
abnormal wall motion, who had higher mean CITP and lower PICP. It also 
appears to contradict previously published data suggesting that LV end-systolic 
volume and ejection fraction are powerful indicators of remodelling (White HD et 
al. 1987). However the lack of correlation with plasma markers of collagen 
turnover probably reflects the heterogeneity of the remodelling process and should 
not be regarded as an indication of failure of plasma markers to reflect the 
remodelling process. Indeed, recent results from the GISSÏ-3 echo sub-study 
showed that in-hospital dilatation and dysfunction were not associated with 
progressive dilatation and deterioration of function over time (Giamiuzzi et al. 
2001). This was thought to be due to the marked heterogeneity of dilatory and
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compensatoiy haemodynamic responses to infarction, and therefore it is perhaps 
not surprising that absolute plasma levels of CITP or PICP were not associated 
with these parameters. However, elevated plasma CITP on admission is associated 
with the development o f wall motion abnormalities which was found to predict 
outcome in the CIS SI-3 study, including the development of progressive LV 
dilatation and reduction in global LV function. This is in keeping with the echo 
sub-studies of TRACE, SAVE and GUSTO-1 which also found wall motion score 
to be an independent predictor of subsequent mortality (Kober L et al. 1994; 
Sutton et a l 1997; Migrino et al. 1997).
5.4.5 Studv Limitations
Given that the presence of wall motion abnormality was used to dichotomise 
patients, baseline characteristics of the two groups were not the same. Not 
surprisingly, anterior infarction and left bundle branch block were more common 
in the group who developed wall motion abnormalities, comprising half of this 
group compared to less than one quarter in those with normal wall motion. As a 
consequence, the rate of tPA usage as thrombolytic therapy was higher in this 
group. This is consistent with the fact that anterior and LBBB infarctions are 
associated with a poorer prognosis(Hammermeister KE et al. 1979; Mahon et al. 
1999). However, even adjusting for these variables, admission CITP provides 
additional prognostic information, being an independent predictor for the 
development of wall motion abnormalities. No relationship was demonstrated with 
absolute values of PICP and echocardiographic parameters of remodelling. Given
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the heterogeneity of plasma PICP within the patient population, a larger sample
size may have increased power to detect such relationship.
As previously discussed, the differences in mean levels of both CITP and PICP 
between the groups is apparent from admission and changes over time parallel 
each other. It is therefore likely that the divergence of values for plasma CITP and 
PICP started before admission, even thougli all patients in this study presented 
within 6 hours o f the onset of pain. Further studies examining changes in these 
levels in the very early phase following pain or in a model o f acute coronary 
occlusion are required to investigate this further.
Finally, a single echocardiogram, rather than serial studies, was used to 
demonstrate a relationship between plasma markers of collagen turnover and 
remodelling. However, although remodelling is defined as a change in LV shape, 
structure and function, the process can be detected at an early stage and should be 
regarded as a continuum. The early phase is synonymous with infarct expansion 
and is characterised by the development of wall motion abnormalities, early 
dilatation and reduction in ejection fraction (Sutton and Sharpe, 2000). A single 
echocardiographic study performed within a few days o f infarction allows 
identification of the early phase of remodelling and has been shown to correlate 
well with prognosis (Kitamura et al. 1973; Kan et al. 1986; White HD et al. 
1987; Sutton et al. 1994; Kober L et al. 1994; Popovic et al. 1996; Migrino et al. 
1997; Sutton et al. 1997; Cerisano G et al. 1999). This study would have been 
underpowered to detect change in LV dimensions over time.
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5.5 Conclusions
This study demonstrates changes in plasma levels of CITP and PICP over time 
following myocardial infarction with raised levels of CITP and reduced PICP in 
patients with echocardiographic evidence of early remodelling. Admission CITP, a 
marker of collagen breakdown, predicts the development of subsequent wall 
motion abnormalities and is associated with reduced mitral deceleration time. It 
therefore provides early prognostic information following infarction and this study 
supports its use in the identification of patients at high risk of developing 
remodelling and raises the possibility of early initiation of cardioprotective 
strategies such as primary PCI, the early administration o f ACE inhibitors, and 
potentially the use of synthetic MMP inliibitors.
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CHAPTER SIX -  SEROLOGICAL EVIDENCE OF EARLY 
REMODELLING IN ‘‘HIGH RISK” NON ST ELEVATION ACUTE 
CORONARY SYNDROMES
6.1 Introduction
Patients with non ST elevation acute coronary syndromes (ACS) represent a wide 
spectrum of risk of subsequent morbidity and mortality, with a 30 day mortality 
rate of up to 9% in high risk groups (Antman et al. 1996), and combined rate of 
death, MI or urgent revascularisation of more than 40% (Antman et al. 2000). 
Ischaemia sufficient to cause dynamic ST changes or sequential T wave changes 
on the 12 lead ECG is associated with an adverse outcome (Nyman et al. 1993; 
Camion et al. 1997; Kaul et al. 2001), as is elevation of serum troponin (Hamm et 
al. 1992; Antman et al. 1996; Galvani et al. 1997).
In addition to causing these electrocardiographic changes and producing elevation 
in serum troponin, a high ischaemic burden also causes alterations to the 
collagenous component o f the heart within the extra-cellular matrix, even in the 
absence of overt infarction (Zhao M et al. 1987). Collagen turnover can be 
assessed biochemically (Risteli L and Risteli J, 1990; Risteli J and Risteli L, 
1995b), and I have previously shown changes in plasma markers of collagen 
turnover following myocardial infarction and demonstrated their value in the non- 
invasive assessment o f ventricular remodelling (Chapters 4 and 5). I hypothesise 
that a degree of ventricular remodelling occurs in some patients presenting with 
acute coronary syndromes, even in the absence of myocyte necrosis. Due to the
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marked heterogeneity of this patient population, remodelling is likely to occur at 
the more “high-risk” end of the spectrum and I hypothesise that plasma markers of 
collagen turnover may reflect this.
I therefore examined changes in plasma levels of procollagen type I carboxy- 
terminal propeptide (PICP) and C-telopeptide for type I collagen (CITP), markers 
of synthesis and degradation respectively (Risteli J and Risteli L, 1995b), in a 
cohort of patients presenting with non-ST elevation acute coronary syndromes. 
Plasma levels of Tissue Inhibitor of Matrix Metalloproteinase-1 (TIMP-1), as a 
marker of inhibition of degradation, were also measured. Patients were 
dichotomised into high and low-risk groups based on the 12 lead ECG and 
troponin assay. High-risk was defined as the presence of dynamic ST 
depression/sequential T wave changes and/or troponin I >0.4ng/ml at 12 hours 
post admission. Low-risk was defined as the absence of ECG changes and a 
negative troponin.
6.2 Methods
Detailed methodology can be found in Chapter 2, section 2.4.
6.2.1 Patient Population
52 patients presenting to the Coronary Care Unit with a history suggestive of an 
acute coronary syndrome without ST elevation on a 12 lead ECG were considered 
for the study. Inclusion was based on history alone - chest pain typical of
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myocardial ischaemia and occurring at rest starting within six hours of 
presentation and being present for at least 20 minutes. Patients with ECG fitting 
the eriteria for reperfusion therapy or factors affecting assessment of ST/T 
segments, such as bundle branch block, concurrent digoxln therapy or the presence 
of a permanent pacemaker were excluded. Other exclusion criteria are listed in 
Chapter 2 (table 2.1),
6.2.2 Risk Stratification
Patients were dichotomised into high and low-risk groups based on ECG criteria 
and measmement of plasma troponin I as outlined above.
(a) Electrocardiography
12 lead ECGs were performed on admission and at 24 and 48 hours to assess ST 
segment deviation and T wave morphology. Additional ECGs were performed if 
the patient developed further pain. ST depression was defined as planar or down- 
sloping ST depression of 0.5mV, 80ms after the J point in two or more contiguous 
leads that was not there on prior ECGs (if available). Up-sloping ST depression 
was discounted. Sequential ECG changes were defined as new biphasic T waves 
or T inversion in two or more contiguous leads on ECGs performed subsequent to 
admission (Cannon et al. 1997).
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(b) Troponin I
Cardiac troponin I was measured at 12 hours following admission using a 
microparticle enzyme immunoassay technique using a commercially available 
reagent pack (Troponin I No 3C29-66, Abbott Laboratories, Illinois, USA). The 
95*'’ percentile for a normal population in this assay is 0.4ng/ml and values above 
this were considered positive.
6.2.3 Blood Sampling and Biochemical Analyses
Sequential venous blood samples were taken for the measurement of plasma 
TIMP-1, PICP and CITP -  on admission (0/A), at 12 hours, 24 and 48 hours. This 
time period was chosen as we have previously demonstrated that in ST elevation 
MI, changes in these plasma markers occur within the first 24 hours and reach a 
plateau by 48 hours (Chapter 4).
To avoid the discomfort of repeated venepuncture, blood was drawn from an 
indwelling cannula. Samples were spun at 3000rpm and the plasma frozen until 
use. Plasma PICP and CITP were measured by commercially available radio­
immunoassays (Orion Diagnostica, Finland) using previously validated techniques 
(Melkko JT et al. 1990; Risteli J et al. 1993). Within assay variabilities are <4% 
with a <7% between assay variability. Due to the unexpected discontinuation of 
the original TIMP-1 ELISA kit by Amersham Pharmaceuticals (Chapter 3), only 
33 patients had serial assessment of plasma TIMP-I. Intra and inter assay 
variabilities for plasma TIMP-1 are 4.0 and 4.4% respectively.
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6.2.4 Statistical Analv.sis
Statistical analysis was performed using Minitab statistical software (Minitab Inc, 
Pennsylvania). All continuous variables are expressed as mean +/- one standard 
error o f the mean. Changes over time were investigated by repeated measures of 
analysis of variance. Since biochemical variables were not normally distributed, 
log transformation was applied prior to statistical analysis. However, all variables 
are presented in the non-logarithmic format. Two-tailed Student’s t test was used 
for comparison of means and a p value o f <0.05 was considered significant.
6.3 Results
1 Baseline Characteristics and Risk Strafificatmr.
Twenty of the 52 patients had no dynamic or sequential ECG changes and had 
levels o f troponin I <0.4 ng/ml at 12 hours and were categorised as “low-risk”. Of 
the 32 in the “high-risk” category, 13 had both ECG changes and positive 
troponin, 7 had only ECG changes and 12 were positive for troponin but had no 
ECG changes (figure 6.1). No patients had elevation in standard cardiac enzymes 
(defined as more than 2x upper limit o f normal). Baseline demographics of the two 
groups are illustrated in table 6.1. Males comprised nearly two thirds o f the 
patients in both groups. Mean age was similar as was admission blood pressure 
and number of diabetics. Slightly more patients in the high-risk group received 
low molecular weight heparin (94% vs. 85%) and IV GTN (25% vs. 10%), but 
similar rates o f aspirin and beta-blocker usage were seen. This disparity is
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probably due to the presence of dynamic ST/T changes in a cohort of the high-risk 
group.
Figure 6.1
52 Patients
Troponin I >0.4ng/ml
(25 patients)
Troponin I <0.4ng/ml
(27 patients)
ECG Changes No ECG Changes
(13) (12)
ECG Changes No ECG Changes
(7)
T
HIGH-RISK
(20)
LOW-RISK
Legend - Risk stratification based on troponin I and ECG findings.
Table 6.1
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HIGH-RISK
N(%)
LOW-RISK
N(%)
Number 32 20Mean age 63 61Male 21 (66) 13 (65)Diabetes 6(19) 3(15)Mean admission BP 144/88 146/80Aspirin 32 (100) 19(95)LMWH 30 (94) 17(85)Beta-blockers 7(22) 4(16)IV GTN 6(25) 2(10)
Legend Baseline demographics of high and low risk groups.
6.3.2 PICP
Mean admission levels of PICP were within the normal range in both low and 
high-risks groups at 135 (7) ng/ml vs. 131 (1) ng/ml respectively (high vs. low, 
p=ns). There was no significant change in plasma level of PICP from admission to 
48 hours in either group, with the values at each time point in one group being 
superimposed on the other (figure 6.2). Means at all four time points were within 
two standard deviations of the mean for a normal population. There was no 
correlation of plasma PICP with absolute level of plasma troponin.
Figure 6.2
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Legend Changes (mean (SEM)) in plasma PICP over time.
6.3.3 CITP
The low-risk group showed no change over time and values at each time point 
were again within two standard deviations of the mean for a normal population at
2.6 (0.18) ng/ml. However, mean admission levels of CITP were higher in the 
high-risk group, 3.7 (0.16) ng/ml vs. 2.6 (0.18) ng/ml (p<0.001) and rose further in 
this group within 12 hours, reaching a plateau with a mean level of 4.7 (0.19) 
ng/ml at 48 hours (figure 6.3) (ANOVA, p<0.01). There was no significant change 
over time in plasma CITP from baseline in the low-risk group. Similar degrees of 
elevation were seen in those with positive troponin and those with negative 
troponin but with dynamic or sequential ECG changes. Of those with a positive 
troponin I, there was no significant correlation between absolute troponin level 
and admission CITP.
Figure 6.3
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Legend Changes (mean (SEM)) in plasma CITP over time.
6.3.4 TIMP-1
Mean plasma TIMP-1 in the low-risk group was also within two standard 
deviations of a normal population mean at 227 (19) ng/ml and showed no 
significant change over time. Mean TIMP-1 was within the normal range at all 
time points in this group. However, mean admission levels of plasma TIMP-1 
were significantly elevated in the high-risk group at 302 (19) ng/ml (high vs. low, 
p<0.01) and rose further to a mean peak level of 400 (21) ng/ml (figure 6.4) 
(ANOVA, p<0.01).
Figure 6.4
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Legend Changes (mean (SEM)) in plasma TIMP-1 over time.
6.4 Discussion
6.4.1 Time Course
This is the first study to examine the pattern of change in plasma markers of 
collagen turnover in patients presenting with non-ST elevation acute coronary 
syndrome with no elevation in standard cardiac enzymes. We have demonstrated 
that patients with a diagnosis of non-ST elevation ACS based on history alone, in 
the absence of electrocardiographic changes and with a negative cardiac troponin 
I, display no time-dependent changes in any marker of collagen turnover. 
However, in those with high-risk features, there are sequential changes over time 
of plasma levels of both CITP and TIMP-1. No changes were seen in plasma 
levels of PICP. In this group, plasma levels of both CITP and TIMP-1 are
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significantly higher at admission than levels in the low-risk group, being out with 
the normal range, and rise further over the next 48 hours.
6.4.2 Interpretation of Results
To allow interpretation of these findings, one must remember that CITP is 
produced during the degradation of Type I Collagen by endopeptidase cleavage by 
matrix metalloproteinases, and is therefore a marker of collagen breakdown 
(Risteli J et al. 1995a). Similarly, PICP is cleaved from procollagen during the 
production of Type I collagen and is consequently a marker of collagen synthesis 
(Melkko JT et al. 1990). This study therefore demonstrates serological evidence 
of increased collagen breakdown in the high-risk group with no associated 
alteration in synthesis, shifting the balance in favour of net collagen loss in the 
first 48 horns following ischaemia.
With respect to plasma TIMP-1, the elevation in the high-risk group may be 
explained by the fact that the assay does not differentiate between free, active 
TIMP-1 and inactive TIMP-1 bound with MMP. Therefore, the increase in TIMP- 
1 may be in response to increased MMP activity and be a reflection of TIMP 
complexed with MMP rather than increased free TIMP.
6.4.3 Comparison to ST Elevation MI Studies
I have previously demonstrated time dependent changes in plasma levels of PICP, 
CITP and TIMP-1 following ST elevation MI, and that early elevation in plasma
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levels of CITP are associated with an adverse outcome and echocardiographic 
evidence of remodelling (Chapters 4 & 5). In this study of patients presenting with 
non-ST elevation acute coronary syndromes, low risk patients with no ECG 
changes and no evidence of myocardial necrosis had plasma levels of all three 
markers within the reference range. However, high risk ACS was associated with a 
time dependent rise in both CITP and TIMP-1. Admission levels of CITP in this 
group were similar to those with ST elevation MI with a normal wall motion index 
(3.7 vs. 3.1 ng/ml, p=0.3). Peak levels were also similar (4.7 vs. 4.8 ng/ml, p=0.9). 
This is in contrast to those presenting with ST elevation MI and early remodelling 
evident on echocardiography, where admission CITP was 4.5 ng/ml rising to 6.3 
ng/ml at peak.
It is likely that the similar elevation in plasma CITP seen in the “high-risk” ACS 
and ST elevation MI with no echocardiographic evidence of remodelling groups 
are a reflection of changes occurring within the collagenous component of the 
heart. This may represent subtle remodelling of the extracellular framework, not 
sufficient to be evident on echocardiography. The similarity in CITP levels is also 
in keeping with the fact that mortality from high risk ACS approaches that of 
simple ST elevation MI (Antman et al. 1996; Levy, 1998; Antman et al. 2000).
6.4.4 The Role of Collagen Degradation
The pattern of change in the ST elevation MI studies (Chapters 4 & 5) is in 
keeping with the principal pathological finding of increased collagen degradation 
by matrix metalloproteinases within the extracellular matrix in early phase of
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remodelling following infarction (Caimon et al. 1983; Whittaker P et al. 1991; 
Cleutjens JPM et al. 1995). However, even in the absence of myocyte necrosis, 
severe ischaemia causes recruitment of inflammatory mediators from the blood 
and interstitial space, including interleukins, adhesion molecules and Tumour 
Necrosis Factors which upregulate the genetic expression of matrix 
metalloproteinases (Birkedal-Hansen H et al. 1993; Brilla CG et al. 1995; 
Schonbeck et al. 1997; Nicoletti A and Michel JB, 1999), thereby increasing 
proteolytic activity and causing net collagen loss. It is likely that this phenomenon 
is dependent on the degree of ischaemic burden and this is supported by our 
findings in this study of increased plasma levels of CITP, a marker of collagen 
breakdown, in patients at the “high-risk” end of the spectrum of non-ST elevation 
ACS. It is also interesting that we found similar evidence of collagen degradation 
in the group with positive troponin and those with negative troponin but with 
dynamic ECG changes. This suggests it is not cell death that is the stimulus for 
remodelling but may be the ischaemia itself.
6.4.5 Studv Limitations
The ruptured plaque is the keystone of acute coronaiy syndromes (Davies, 2000), 
and increased MMP expression and activity have been implicated in the 
progression from stability to instability (Kaartinen M et al. 1994; Lee RT et al. 
1996). Previous studies have shown increased levels of MMP-2 and TIMP-1 in the 
coronary sinus immediately following PTCA (Hojo et al. 2002), raising the 
possibility that this may be a reflection of plaque rupture and plaque remodelling. 
The degree of elevation in this study was mild (<10% change). In our study, the
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degree of elevation in CITP in the high risk ACS group is much higher and is 
similar to that seen in ST elevation ML It would appear more likely that the 
majority of change in CITP in our study is a reflection of collagenous remodelling 
of the cardiac extracellular matrix rather than of plaque remodelling in the 
coronary artery.
Another potential confounding variable is the use of low molecular weight heparin 
(LMWH). It is well documented that heparin administration is associated with 
suppression of aldosterone synthesis (Conn JW et al. 1966; Levesque H et al. 
1990), and given the importance o f the RAAS effectors on collagen metabolism 
(Brilla CG et al. 1995; Lindpaintner et al. 1993), one cannot discount the 
potential effect of LMWH on collagen homeostasis in this study. However, no 
change in plasma markers of collagen turnover was demonstrated in the low risk 
ACS group, the majority of whom (85%) also received LMWH. I would therefore 
propose that LMWH administration had little effect in this study.
6.5 Conclusions
In patients presenting with non-ST elevation acute coronaiy syndrome, time- 
dependent changes in plasma levels of CITP and TIMP-1 are associated with the 
presence of high-risk features of dynamic changes on the 12 lead 
electrocardiogram or a positive troponin. No changes are seen in patients with 
chest pain in the absence of these high-risk features. This may reflect a degree of 
remodelling in the high-risk group and may aid risk stratification of patients 
presenting non-ST elevation ACS.
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CHAPTER SEVEN -  TIME COURSE OF EARLY CHANGES IN 
PLASMA MARKERS OF COLLAGEN TURNOVER 
FOLLOWING PERCUTANEOUS TRANSLUMINAL CORONARY
ANGIOPLASTY
7.1 Introduction
Changes to the collagen framework of the heart are important in the development 
of ventricular remodelling following myocardial infarction (MI) (Cannon et al. 
1983; Whittaker P et al. 1991; Cleutjens JPM et al. 1995). Plasma markers of 
collagen turnover may be useful in the non-invasive assessment of left ventricular 
remodelling in patients presenting with acute coronary syndromes including MI 
(Chapters 4, 5 & 6), providing additional information with regard to prognosis 
(Chapter 5).
I have previously demonstrated time-dependent changes in plasma levels of 
procollagen type I carboxy-terminal propeptide (PICP) and C-telopeptide for type 
I collagen (CITP), markers of synthesis and degradation respectively (Risteli J and 
Risteli L, 1995b), following infarction (Chapter 4). The changes in plasma levels 
are rapid with CITP being elevated on admission with further change over the first 
few days. Admission values of CITP have a 74% predictive power for the 
subsequent development of wall motion abnormalities and are associated with 
other echo cardiographe parameters of remodelling (Chapter 5). Plasma levels of
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PICP also show time-dependent changes, but do not provide additional prognostic
information.
These changes are in response to ischaemia and infarction due to abrupt coronary 
artery occlusion (Zhao M et al. 1987; Cleutjens JPM et al. 1995) which causes 
production and activation of matrix metalloproteinases (MMPs), the activity of 
which determines the extent of collagen breakdown (Carlyle et al. 1997; Herzog 
et al. 1998; Danielsen et al. 1998). Although previous studies have shown early 
up-regulation of matrix MMP genetic expression within a few hours of infarction 
(Herzog et al. 1998), which is associated with early collagen breakdown at a 
tissue level (Whittaker P et al. 1991; Cleutjens JPM et al. 1995), there are only 
limited data available on whether this is reflected in plasma levels of markers of 
collagen turnover (CITP and PICP). In my previous studies of myocardial 
infarction (Chapters 4 & 5), the differences in plasma levels of CITP and PICP 
between groups displaying evidence of remodelling and those with no such 
evidence were apparent from admission, suggesting the divergence in levels 
between the groups occurs early. Similar patterns of change were also 
demonstrated in high risk vs. low risk patients presenting with non-ST elevation 
acute coronary syndromes (Chapter 6). As all patients in these studies were 
recruited within 6 hours of the onset of symptoms, this divergence must start
within a few hours of the ischaemic stimulus, for the difference in levels to be 
apparent at presentation.
I therefore sought to examine the early time course of plasma levels of CITP and 
PICP in a human model of controlled acute coronary artery occlusion. To this end
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I recruited a cohort of patients undergoing percutaneous coronary intervention and 
performed sequential blood sampling to assess temporal dynamics o f plasma CITP 
and PICP.
7.2 Method
Detailed methodology can be found in Chapter 2, section 2.5.
7.2.1 Patient Population
Fourteen patients undergoing elective percutaneous coronary intervention (PCI) to 
a single lesion in a single coronary artery in our regional cardiac catheterisation 
laboratory were recruited for this study. Exclusion criteria included factors 
influencing collagen metabolism or elimination of propeptides, such as surgery 
within the last six months, hypertension, renal or hepatic dysfunction, in addition 
to factors making interpretation of the electrocardiogram difficult, such as the 
presence of a permanent pacemaker system, LBBB or concurrent digoxin therapy. 
All patients were naïve to ACE inhibitors, angiotensin II receptor blockers and 
spironolactone. To exclude changes in plasma markers of collagen turnover due to 
catheter manipulation in the aorta and coronary ostia or to the effects of intra­
coronary injection of contrast media, a group of eight patients undergoing day- 
case elective coronary angiography were recruited as a control group (Control).
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7.2.2 Blood Sampling and Biochemical Analyses
To avoid the discomfort of repeated venepuncture, blood was drawn ftom an 
indwelling venous cannula. In the angioplasty group, 6 sequential samples were 
taken for the measurement of plasma PICP and CITP at serial time points -  pre­
procedure (Pre), 1 minute following first balloon inflation (1 min), at the end of 
the procedure (End), 4 hours following procedure (4h) then at 8 and 16 hours. 
Given that elective diagnostic coronary angiography is performed as a day case, 
blood was drawn on only three occasions for the measurement of these 
propeptides -  pre-procedure (Pre), at the end of the angiogram (End) and at 4 
hours post procedure (4h). Blood was spun at SOOOrpm and plasma frozen until 
use.
Plasma PICP and CITP were measured by commercially available radio­
immunoassays (Orion Diagnostica, Finland), as described previously (Melkko JT 
et al. 1990; Risteli J et al. 1993). Within assay variability is <4% in our 
laboratory, with a <7% between assay variability. Troponin was measured by 
standard immunoassay (Bayer Corporation, New York, USA).
7.2.3 Assessment of Peri-procedural Ischaemia
The presence of peri-procedural ischaemia was identified in the cohort undergoing 
PCI by continuous electrocardiographic monitoring in the catheterisation 
laboratory and by the measurement of plasma troponin I at 16 hours. A positive 
troponin (>0.07ng/ml) or transient ST segment elevation or depression >lm m  in
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two leads during balloon inflation was taken as evidence of induced ischaemia. 
Cut off values for troponin I are different in this study compared to that used in 
Chapter 6 due to utilisation of different assays in the two studies (Chapter 2, 
section 2.5.4b).
7.2.4 Statistical Analysis
Statistical analysis was performed using Minitab statistical software (Minitab Inc, 
Pennsylvania, USA). All continuous variables are expressed as mean +/- one 
standard error of the mean. Given this study is designed to specifically look at the 
early temporal dynamics of serological markers of collagen turnover, results are 
also expressed as percentage change from baseline. Changes over time were 
investigated by repeated measures of analysis of variance. Biochemical variables 
were not normally distributed so underwent log transformation prior to using a 
two-tailed Student’s t test for comparison of means, although all data are presented 
in the non-logarithmic format. A p value of <0.05 was considered significant. This 
study was designed with 90% power to detect a change in CITP from baseline of 
25% and 90% power to detect a 50% change in PICP in the angioplasty group.
7.3 Results
7.3.1 Baseline Characteristics
Mean age in the PCI group was 60 years vs. 65 in the Control group undergoing 
diagnostic angiography with similar percentage of male patients in both groups
204
(64 vs. 62.5%). In the PCI group, the eulprit artery was the left anterior descending 
in 6 patients, the right coronaiy arteiy in five and the circumflex artery in the 
remaining three. Intra-coronary stents were deployed in the majority of cases 
(12/14). The mean time of balloon inflation was 54 seconds with an average of 1.8 
inflations per procedure. Ten had elevated troponin at 16 hours (mean 1.3, range 
0.7 -  2.9 ng/ml) and nine had ST elevation or depression on the ECG during 
balloon inflation. Only one patient had no evidence of ST segment shift and a 
negative troponin, and was classed as not showing evidence of peri-procedural 
ischaemia.
7.3.2 CITP
Mean CITP pre-procedure in the PCI group was 3.1 ng/ml with a sequential rise in 
group mean CITP over time, peaking above the normal range at 4.7ng/ml by 16 
hours (p<0.05). Mean CITP in the Control group was within the normal range at 
all time points (figure 7.1a). With regard to percentage change from baseline, all 
patients bar one in the PCI cohort demonstrated a sequential rise in plasma CITP, 
starting immediately post balloon inflation and continuing thereafter. The largest 
proportional rise was between 8 and 16 houis with peak CITP at 16 hours being an 
average of 48% higher than pre-procedure values (figure 7.1b). There was no 
significant change over time in the Control group, although sampling was not 
extended beyond 4 hours. There was also no significant change in plasma CITP in 
the patient with negative troponin and no ECG changes.
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7.3.3 PICP
Changes over time of plasma PICP within the PCI group were initially 
heterogeneous with some patients displaying an early rise following angioplasty 
and others showing an early fall in plasma PICP. Group mean initially rose over 
during the procedure, then fell below pre-procedural values by eight hours, with a 
trough at 16 hours (figure 7.2 a & b), although this does not reach statistical 
significance (143 vs. 113ng/ml, p=0.09). There was no significant change over 
time in the Control group, although sampling was not extended to 16 hours.
Figure 7.2
(a)
207
Pre
Plasma PICP over Time
180 n 
160 - 
f  140 - 
1  120  ^
g  100 -
K 80 -
40 - 
20 -
-^ P C I  
-m— Control
1 min End 4h 8h 16h
(b)
Percentage Change in PICP over Time
15 n
10 -
Pre 1 mil End 16h
-10 -
•PCI
Control
Legend - Pattern of change of plasma PICP in PCI and Control 
groups demonstrated as (a) Mean absolute values at each time point and (b) 
Mean percentage change from baseline.
208
7.4 Discussion
I have demonstrated time-dependent changes in plasma levels of CITP following 
myocardial ischaemia caused by transient occlusion of a single epicardial coronary 
artery during percutaneous coronary interventional procedures. No such changes 
were demonstrated in the control group undergoing routine angiography. The 
ischaemic burden of the PCI group was high as manifested by the high proportion 
of dynamic ST segment shift and rate of positivity for troponin.
The changes to plasma levels of PICP were heterogeneous within the group 
undergoing PCI, with no significant change in the group mean within the first few 
hours. Although levels in the group decreased by 8 hours with a trough at 16 
hours, this did not reach significance. The heterogeneity of plasma PICP response 
to ischaemia may be reflected by the wide normal range and standard deviations.
In contrast to PICP, the changes in plasma CITP were consistent within the group 
as a whole. Elevation in plasma CITP was evident as early as 1 minute following 
first balloon inflation, although did not reach statistical significance until 8 hours. 
There was a further increase at each time point, peaking at 16 hours at an average 
o f nearly 50% higher than levels prior to procedure. This is in keeping with the 
studies of MMP activation discussed previously and illustrates the rapidity of 
collagen degradation following ischaemia and infarction (Zhao M et al. 1987; 
Whittaker P et al. 1991; Cleutjens JPM et al. 1995). Indeed, there is up to a 25% 
reduction in myocardial collagen content in the first 24 hours following AMI 
(Cannon et al. 1983). This is in contrast to increased collagen production which
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occurs in the following days and weeks (Fishbein MC et al. 1978; Pfeffer MA and 
BraunwaldE, 1990).
The early phase of histological evolution of myocardial infarction is therefore 
characterised by collagen degradation, and the finding in this study of early 
elevation of plasma levels of CITP is entirely in keeping with this. The rapidity of 
change of this propeptide may explain the divergence of plasma level of CITP at 
admission between patients who develop signs of remodelling and those who do 
not (Chapter 5) in the setting of ST elevation MI and between patients with high 
risk and low risk acute coronary syndromes (Chapter 6).
7.5 Study Limitations
There is some evidence of mild elevation in MMP and TIMP-1 levels following 
percutaneous intervention and the authors felt this was reflective of plaque 
remodelling rather than representing myocardial collagenous remodelling (Hojo et 
al. 2002). However, as discussed in section 6,5, the degree of elevation of plasma 
markers o f collagen turnover seen in high risk ACS patients (Chapter 6) would 
appear to be far greater than one would expect from coronary arterial plaque 
remodelling. In the ACS study, “high risk” was defined as positive troponin or 
dynamic ST segment shift. It is therefore unsurprising that the pattern of elevation 
in plasma CITP at 16 hours in this PTCA study is similar to that seen in patients 
with high risk ACS, given that the majority had elevated Troponin (10/14), and 
only one patient had neither elevated Troponin or dynamic ECG changes. 
Therefore, the ischaemic burden is similar between the groups, and this is reflected
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in a similar degree of collagen breakdown in the immediate post ischaemic period. 
The ischaemic burden of patients in Hojo et aPs study is not clear and may be 
significantly different to that experienced by this study population. Furthermore, 
they demonstrated only mild elevation in plasma levels of MMP and TIMP-1 
(<10%) compared to the 50% increase in CITP seen in my study. I would 
therefore suggest that the majority of change in CITP is a reflection of myocardial 
collagen degradation rather than of plaque remodelling in an epicardial coronary 
artery.
7.6 Conclusions
The early dynamism of plasma levels of markers of collagen turnover further 
support their use in the non-invasive assessment of collagen turnover in 
ventricular remodelling following acute ischaemic events.
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CHAPTER EIGHT -  SUMMARY AND CONCT TINTONS
8.1 Summary of Results
The series of studies contained within this thesis demonstrates time-dependent 
alterations in plasma levels of markers of collagen turnover following a variety of 
ischaemic insults -  ST elevation myocardial infarction, non-ST elevation acute 
coronary syndrome and coronary arterial occlusion during percutaneous coronary 
intervention. Our data supports our original hypotheses that levels of these 
markers would display an early change following ischaemic events and that they 
may be useful in the non-invasive assessment of the remodelling process (Chapter 
1, section 1.6).
Chapter Tliree illustrated that the methodology for the assays is sound with good 
reproducibility, as reflected by the excellent intra- and inter-assay variabilities for 
all three markers (TIMP-, PICP and CITP), ranging from 3.1 -  6.9%. We also 
showed that there was no diurnal variation and defined a mean and range for all 
three markers in a local normal healthy population of a similar age and sex 
distribution to our study groups.
The remaining chapters were concerned with ischaemic coronary syndromes. As 
previously discussed, acute coronary syndrome is an umbrella term for all 
presentations with acute onset ischaemic chest pain, and represents a continuum 
from the traditional diagnostic categories of unstable angina through to acute 
myocardial infarction with a wide range of morbidity and mortality. Chapters Four
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and Five studied those at highest risk, patients presenting with their first ST 
elevation acute myocardial infai'ction (MI). Chapter Four demonstrated time- 
dependent changes in plasma levels of CITP, PICP and TIMP-1 following MI. In 
this study, raised CITP on admission, a marker of collagen breakdown, was 
associated with the development of heart failure and a trend towards an adverse 
outcome. This study also showed that the changes in these markers of collagen 
turnover were not related to systemic activation of the renin-angiotensin- 
aldosterone system, although no examination of cardiac utilisation of RAAS 
effectors was made.
Chapter Five examined the relationship of plasma levels of CITP and PICP with 
the remodelling process following ST elevation MI. Patients were dichotomised 
using established echocardiographic parameters of remodelling. In this study, 
marked differences in plasma levels of both CITP and PICP were seen between 
the group with abnormal wall motion on echo at day 4 and those with no such 
echo evidence of remodelling, with raised levels of CITP and reduced PICP being 
apparent in the remodelling group. Furthermore, absolute levels o f these markers 
provided information regarding the subsequent development of remodelling. 
Admission CITP predicted the development and extent of wall motion 
abnormalities and was associated with reduced mitral deceleration time, another 
echo parameter of remodelling. In summary, this study demonstrated that early 
measurement of a plasma marker of collagen breakdown correlated with, and 
predicted, the development of echocardiographic parameters of remodelling, 
thereby providing early prognostic information following infarction.
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Chapter Six was concerned with patients presenting with non-ST elevation acute 
coronary syndromes (ACS), and demonstrated time-dependent changes in plasma 
levels of CITP and TIMP-1 in patients with high-risk features such as dynamic 
changes on the 12 lead electrocardiogram or a positive troponin. No changes were 
seen in patients with chest pain in the absence of these high-risk features and this 
would support our hypothesis that these markers of collagen turnover reflect a 
degree of remodelling in the “high-risk” end of the wide spectrum of risk 
encompassed by the term non-ST elevation ACS, and that it is likely that 
ischaemia is the stimulus rather than myocardial necrosis per se. Indeed, the 
degree of elevation in high risk ACS mirrors that of ST elevation MI without overt 
echo evidence of remodelling. It is well documented that collagenous remodelling 
within the extracellular matrix can occur without overt myocyte necrosis (Zhao M 
et al. 1987), and interestingly the prognosis in these two groups is similar 
(Antman et al. 1996; Levy, 1998; Antman et al. 2000).
In the non-ST elevation ACS study (Chapter 6), the divergence of plasma CITP 
between the high and low-risk groups was apparent from admission. The same is 
true of plasma levels of both CITP and PICP following ST elevation MI with 
divergence between those with echo evidence of remodelling and those without, 
also being evident at admission (Chapter 5). The immediate temporal dynamics of 
alterations in plasma levels of CITP and PICP following ischaemia were therefore 
examined in Chapter Seven, using percutaneous coronary intervention as a human 
model of aeute coronary artery occlusion. This study demonstrated early elevation 
in plasma CITP following transient coronary occlusion. Although it took up to 8 
hours for this rise to reach statistical significance, CITP rose steadily over time,
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being apparent immediately following balloon inflation and persisting long after 
the cessation of the ischaemic stimulus. Therefore, the rapidity of change of 
plasma levels following ischaemia, coupled with the predictive value of plasma 
levels, make the measurement of this propeptide an attractive option in the early 
non-invasive assessment of the remodelling process.
8.2 Comparison with Previous Studies and the Pathophysiology of 
Remodelling
This is the largest series of studies examining the use of plasma markers of 
collagen turnover in the non-invasive assessment of remodelling following 
myocardial ischaemia. Most previous studies have focused on the markers of 
collagen synthesis, PICP and PIIINP, and have shown that increased plasma levels 
are associated with fibrosis in hypertensive heart disease and heart failure 
(Laviades C et al. 1994; Diez J et al. 1995; Klappacher et al. 1995). However, 
these are chronic conditions, with continual fibrogenic stimuli acting on the 
extracellular matrix (ECM). This is quite different from the acute changes to the 
ECM and myocardial collagen seen during remodelling following ischaemia and 
myocardial infarction.
With respect to plasma maikers and myocardial infarction, PIIINP is the best 
studied and has been shown to be elevated immediately following infarction 
(Jensen LT et al. 1990; Host NB et al. 1995; Uusimaa P et al. 1997; Modena et 
al. 1998; Poulsen SH et al. 2000), and one might assume this to reflect collagen 
synthesis and subsequent fibrosis. However, although fibrosis is a key component
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of the remodelled ventricle, this is a feature of late remodelling, occurring weeks 
to months to years after the initial event, probably reflecting end stage maladaptive 
response to injury (Fishbein MC et al. 1978; Pfeffer MA and Braunwald E, 1990; 
Wei et al. 1999). Therefore, the finding of increased levels of PIIINP early 
following infarction in these studies appears inconsistent with pathological data.
Conversely, our finding of early elevation in plasma levels of CITP is much more 
in keeping with the known pathophysiology of early remodelling following MI, a 
process characterised by net collagen loss (Cannon et al. 1983; Whittaker P et al. 
1991; Cleutjens JPM et al. 1995). We also found late elevation of PICP at 1 
month, again consistent with pathological data of scar formation which is 
complete 4-6 weeks after the event (Fishbein MC et al. 1978). One possible 
explanation for the apparent discrepancy between the results of PICP in our 
studies compared to the previous studies utilising PIIINP may be the fact that 
unlike PICP, PIIINP is incompletely cleaved during collagen production and is 
therefore also released when collagen is degraded (Risteli J and Risteli L, 1995b). 
As a result, levels are influenced by the degree of collagen breakdown, and the 
apparent early rise seen in these studies may be a consequence of increased 
degradation. Indeed, the time course of elevation of PIIINP in previous studies 
mirrors that of CITP in our studies.
One must also remember that net collagen content is the product of a dynamic 
equilibrium between synthesis and degradation, and these previous studies 
examined one marker in isolation. Our series of studies examined both sides of 
collagen balance, providing information with respect to both synthesis and
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breakdown, increasing our understanding of the processes involved and assessing 
their use as indicators of the remodelling process, not only in myocardial 
infarction, but in other ischaemic chest pain syndromes,
8.3 Potential Applications and Areas for Further Study
Acute coronary events are associated with significant morbidity and mortality and 
there are many strategies available to reduce this risk in both the settings of ST 
elevation myocardial infarction and non-ST elevation acute coronary syndromes. 
However, the key lies in identifying those most likely to benefit from these 
interventions, so as to avoid unnecessary risks and best utilise limited resources.
Ventricular remodelling following ST elevation myocardial infarction is a 
powerful adverse prognostic indicator. Strategies to limit the remodelling process 
are available, including achieving patency of the infarct related artery and 
inhibition of the renin-angiotensin-aldosterone and sympathetic nervous systems 
(ISIS-1 (First International Study of Infarct Survival), 1988; Pfeffer MA et al. 
1992; AIRE study investigators, 1993; ISIS-4 Collaborative Group, 1995; 
Fibrinolytic Therapy Trialists, 1994; Grines et al. 1999b). The extent of benefit of 
these strategies is dependent on the absolute risk of the patient, with high-risk 
groups having potentially the most to gain. Selection of patients suitable for each 
intervention is therefore paramount and should be based on the risk;benefit ratio of 
the individual rather than on a population basis. At present this is difficult to 
achieve although historical, electrocardiographical and clinical features help in the 
early assessment of risk (Hammermeister KE et al. 1979; Fibrinolytic Therapy
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Trialists, 1994; Mahon et al. 1999). Echocardiography is a powerful predictor of 
both morbidity and mortality following infarction (Sutton et al. 1997; Migrino et 
al. 1997). However, echo identifies early remodelling when it has already begun, 
and therefore its use as an aid to risk stratification in the acute phase is limited.
In contrast, our studies support the potential use of biochemical markers of 
collagen turnover as an early identifier of those at risk of remodelling in the 
immediate period following infarction (Chapter 5). The measurement of plasma 
levels of CITP at admission provides additional prognostic information to clinical 
and other variables, identifying those most at risk of remodelling, and therefore at 
risk of a poor outcome. The early measurement of CITP may allow better targeting 
of therapy, reducing the risk of potentially serious side effects in those at low risk 
of an adverse outcome, and ensuring those liable to benefit from these 
interventions are identified early. For example, the level of plasma CITP at 
admission may influence the choice between tlirombolytic or mechanical based 
reperfusion strategies and perhaps help in the decision regarding acute 
administration of ACE inhibitors, aldosterone antagonists, beta-blockers or statins. 
Although the use of plasma CITP in the early identification of high-risk patients is 
an attractive prospect, further work is required to determine whether interventions 
based on levels confer a clinical benefit.
Serological markers of collagen turnover may also help in the risk stratification of 
patients presenting with non-ST elevation acute coronary syndromes. As 
previously discussed, ischaemia can cause alterations to the ECM in the absence 
of overt myocyte necrosis (Zhao M et al. 1987; Charney et al. 1992). We have
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demonstrated early elevation in plasma CITP in high-risk patients (Chapter 7), a 
feature not present in those subsequently deemed to be low risk. This divergence 
of plasma CITP between high and low risk groups apparent on admission 
sampling may allow very early identification of those at highest risk. Further work 
is required to determine whether measurement of CITP provides any additional 
prognostic information to routine investigations such as the 12 lead ECG and 
troponin measurement, and whether early measurement of plasma CITP could be 
used to guide interventions.
Finally, as early remodelling is characterised by collagen degradation, which is 
dependent on the activity of matrix metalloproteinases, there has been much 
interest in the potential use of synthetic inhibitors of matrix metalloproteinases as 
a method to attenuate the remodelling process. Manipulation of the MMP-TIMP 
system following MI is an attractive concept, and two animal studies have 
examined the use of synthetic MMP inhibitors in this setting (Rohde et al. 1999; 
Creemers et al. 1999). As previously discussed, although these studies 
demonstrated decreased LV dilatation and improved fractional shortening, one 
study also demonstrated delayed infarct healing (Creemers et al. 1999). It is 
important to remember that MMPs have diverse biological actions, being involved 
in the regulation of biologically active growth factors such as TNF-alpha, TGF- 
beta and IL-1 (Gearing et al. 1994; Schonbeck et al. 1998). Therefore, inhibition 
of MMPs may have potent adverse effects on other cellular and matrix 
components. Furthermore, MMP inhibition may also reduce fibroblast activation 
and paradoxically reduce collagen synthesis. Like all therapeutic interventions, the 
risk:benefit ratio of MMP inhibition following MI must be established. It is likely
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that biochemical assessment of collagen turnover will play a key role in the future 
when considering the use of MMP inhibitors. Further work in this field is required.
8.4 Conclusions
The series of studies in this thesis provide further insight into the pathophysiology 
of the remodelling process and support the use of plasma markers of collagen 
turnover in the non-invasive assessment of remodelling following acute ischaemic 
events.
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